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Abstract
Streptococcus pneumoniae is a global cause of mortality and morbidity. Its 
genetic plasticity renders it responsive to the selective pressures of the host 
environment and antimicrobial chemotherapy.
Hyaluronidase (hyaluronate lyase) is an important protein virulence determinant 
of this organism, which has previously been described as a spreading factor, 
facilitating invasion of host tissues during episodes of invasive disease by degrading 
the hyaluronic acid component of the host extracellular matrix.
The available protein sequence indicates that hyaluronate lyase is exposed to the 
extracellular environment. Selection to drive variation at the hyl locus by the host 
immune response was investigated using high-resolution restriction analysis (HRRA) 
and direct sequence analysis. This revealed that variation of hyl is low, however, 
there is statistically significant evidence that variation at hyl is mediated by 
homologous recombination. The low overall divergence suggests that recombination 
is restricted to the intra-species level.
Phenotypic analysis of hyaluronate lyase activity did not reveal statistically 
significant associations with site of isolation or genotype. Hyaluronate lyase was 
shown to be inducible by hyaluronate.
Mutagenesis of the hyl locus reveals that other pneumococcal enzymes do not 
functionally complement loss of the enzyme.
Hyaluronic acid (HA) is able to support growth of some strains of S. 
pneumoniae, and hyaluronate lyase has been shown to be required for growth. 
Pathways for the utilisation of HA derived metabolites are proposed in the light of 
available pneumococcal genome data, and published observations in other systems.
The previously published hyl gene sequence is thought to be incomplete. 
Elements upstream of hyl have been isolated and show putative strong promoter and 
cleavable N-terminal signal sequence.
xiii
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Chapter I -  General introduction
1.1 - The pneumococcus from a historical perspective
“No other disease kills from one fourth to one half o f all persons attacked...so 
fatal is it, that to die of pneumonia in this country is said to be the natural end of 
elderly people”.
Those were the words of Dr. William Osier circal900, one of the foremost 
American physicians o f his time (Golden, 1992). Streptococcus pneumoniae (or the 
pneumococcus) is an organism responsible for widespread global mortality and 
morbidity, yet investigations involving this pathogen have helped lay the foundation 
stones of molecular biology and immunology. When addressing the balance between 
man and disease, the place of S. pneumoniae is firmly rooted in scientific history.
In the nineteenth century, immediately prior to characterisation of the 
pneumococcus, the spread of infections by this organism was exacerbated by socio­
economic conditions prevailing over large sections o f society, both within Britain, and 
globally. To the ‘lower’ classes, high local population densities, poor housing and 
sanitation (and the lack of an understanding o f a need for such) and 
immunocompromisation imposed by dietary constraints all contributed to high 
mortality resulting from a plethora o f infectious diseases.
However, pneumococcal infection was by no means restricted to the socially or 
financially disadvantaged. Individuals could be struck down in any walk o f life. This 
was a key feature described at the beginning o f the nineteenth century by Laennec, 
who also noted ‘variable but significant mortality’ (Foster, 1970).
In terms of human suffering, it is now understood that & pneumoniae is the 
causative agent of the severest type o f pneumonia, meningitis, bacteraemia, 
septicaemia, and endocarditis, as well as the non-life threatening conditions otitis 
media and arthritis. The route to the isolation and characterisation of the 
pneumococcus was conducted through investigations o f the archetypal lower 
respiratory tract infection caused by this organism, known as lobar pneumonia.
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This was a condition whose prognosis was poor, onset generally followed (and indeed 
follows still) an episode of lesser illness, often viral. As the condition proceeds, rapid 
inflammation of the tissues of the lung takes place, followed by influx of fluids into the 
major lobes of the lung (or lobar consolidation), an extremely painful experience for the 
victim. The next stages of the disease include ‘red hepatisation’ where the lung tissues 
appear red in colour due to the influx of red blood cells from the distended vascular 
tissues. This is followed by ‘grey hepatisation’ caused by accumulation of fibrin 
associated with red and white blood cell degradation. Further outward symptoms vary 
depending on the severity of the illness, but include shaking chills, chattering teeth, and 
production of rust-coloured or greenish mucus. These symptoms are associated with high 
temperature, profuse sweating and mental perturbation. The blood may also become 
depleted of oxygen, leading to discolouration of the lips and nail beds.
Death can occur in a number of ways; anoxia brought about by compromised gaseous 
exchange at the respiratory mucosa, complications arising from secondary infections by 
other organisms, or spread of the pneumococcus to other sites via the circulatory system. 
This latter route can subsequently lead to pneumococcal meningitis and other invasive 
conditions.
Investigation into the causes of this disease were initiated most notably by Jurgensen 
in 1874 when he established the link between this condition and other diseases caused by 
infectious agents. He noted that “The assumption of a specific aetiologic agent is 
necessary, croupous (literally, coughing) pneumonia belongs, then, to the group of 
infectious diseases...” (Foster, 1970). This prophecy was borne out after the introduction 
of Robert Koch’s plate technique for the isolation of micro-organisms in pure culture, 
when a cascade of information regarding the agents of disease came about.
There is some variation in the early literature regarding exactly who was the first to 
isolate and identify the pneumococcus. In 1886 Albert Fraenkel, a disciple of Koch’s was 
credited for growing the pneumococcus in pure culture and noting its relationship to 
disease (Bulloch, 1960, Brock, 1988), however, the organism was almost certainly 
described before this. In 1882 C. Friedlander (working with the 31 year old Dane, H.C.J. 
Gram) described diplococci in lung sections taken post mortem. The same year Leyden
2
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and Gunther reiterated this observation, also noting that the cocci were capsulated (this 
time isolated from a living subject).
At around this time the work of Friedlander became confused by the accidental 
inclusion o f what is now known to be Klebsiella pneumoniae in his experimental 
samples. These capsulate organisms are found in the lung, grow in pairs, and crucially, 
more successfully than pneumococci on the medium used by Friedlander.
The final chapter o f this early work in S. pneumoniae was written by A. 
Weichselbaum, who extended the appreciation of the pathogenic ability o f the organism 
when he was able to implicate the pneumococcus in cases o f meningitis, endo- and 
pericarditis and arthritis.
1.2 - Pneumococcal infection in the twentieth century
The pneumococcus still presents us with very high levels of morbidity and mortality 
today. The UK Public Health Laboratory Service (PHLS) cites annual rates of invasive 
(meningitis and bacteraemic) pneumococcal infection at around 4000 to 5000 cases per 
year (data based on that available from the PHLS website at
http://www.phls.co.uk/facts/streppn.html). Data from the CDC in the USA cites half a 
million pneumonia cases, 3000 meningitis cases, 50,000 bacteremia cases, 100,GOO-
135,000 hospitalisations for pneumonia and 7 million otitis media cases annually 
(http://www.cdc.gov/ncidod/dbmd/diseaseinfo/streppneum t.html).
The ability o f this pathogen to remain such an important agent o f  disease (despite 
advances in the comprehension of the molecular basis of the interplay between host and 
pathogen) rests on two key elements o f the biology of the organism.
The production of virulence determinants in the form of the capsule, and protein 
virulence determinants enables the organism to evade host immune responses and bind to 
and invade the host tissues (Watson and Musher, 1990, Lee el a l, 1991, Frost el al.,
1996, Gray, 2000). This is complemented by the naturally transformable nature of the 
organism. The ability to take up exogenous DNA, and incorporate it into the genome 
affords the pneumococcus a high degree o f genetic, and subsequently, antigenic
3
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plasticity. This also renders the organism responsive to selective pressure, be it in the 
form of the attentions of the host immune system or antimicrobial chemotherapy.
1.3 -  Genetic plasticity in the Pneumococcus - Transformation
In 1928 Griffith established the link between pathogenicity and the capsule by noting 
that non-encapsulated (or ‘rough’) strains were avirulent in an intravenous mouse model 
of infection. He later conducted the classical experiment in which he co-inoculated mice 
with two different strains; a live rough strain derived from a serotype 2 strain which had 
lost its capsule, and a smooth (capsular) serotype 3 strain which had been heat killed. The 
result was that some of the mice succumbed to infection, and the strains isolated from the 
blood of these mice were characterised as serotype 3 (Griffith, 1928). Hence he had 
implicated the transfer of the capsular phenotype of the dead type 3 strain to the live 
genotype 2 strain. 16 years later (in the experiments of Avery, MacLeod and McCarty) 
DNA was identified as the substance mediating the transfer of this phenotype (Avery et 
al., 1944).
1.3.1 -  Regulation of competence for genetic transformation
Today there is a good deal understood about the molecular basis for genetic variation 
by transformation and recombination in the pneumococcus. In brief, the events 
surrounding this process involves binding exogenous dsDNA at the cell surface, 
degradation of one strand of the incoming molecule, followed by translocation of the 
ssDNA into the cytoplasm in the 5’ to 3’ direction. The translocated strand is methylated 
by DpnA and coated with Single Strand Binding protein (Ssb) (Morrison, 1978, Morrison 
and Marinelli, 1979, Lacks et al., 2000). These steps are followed by RecA mediated 
recombination into the genome. Key elements of these processes are described in more 
detail below and illustrated in figure 1.1.
The significance of natural transformation is illustrated in the context of target mediated 
resistance to the first described class of antimicrobial agents, the penicillins. Resistance to 
the penicillins has arisen by alterations to the genes encoding the Penicillin
4
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Binding Proteins (PBPs), the molecular targets for this class of drugs. The initial events 
surrounding the emergence of resistant clones seems to have involved development of 
low affinity forms of PBPs in related oral streptococci (presumably under chronic 
selective conditions over time), followed by horizontal gene transfer of these loci into 
pneumococci (Dowson et al., 1993, Coffey et al., 1993).
The nature of the selective pressure provided by antibiotic use and the opportunities 
for genetic transfer between related streptococci has rendered the pneumococcus 
frequently resistant to penicillin. Clonal groups of penicillin non-susceptible 
pneumococci have come to characterise the global distribution and impact of 
pneumococcal disease (described in more detail in section 1.4).
The onset of competence is tightly regulated in the growing population of 
pneumococci, and represents a classical two component regulatory system, with added 
layers of regulatory complexity which are under active investigation by a number of 
groups.
Pneumococci become competent during early log phase and only remain competent 
for around 40 minutes (Morrison, 1997, Ween and Haverstein, 1999), and competence 
was hypothesised to be under the control of an ‘activator’ substance (Tomasz, 1965).
This substance was later characterised as an oligopeptide produced and secreted by 
pneumococci during growth, and named CSP (for Competence Stimulating Peptide). The 
gene encoding this peptide, termed coinC was isolated using reverse genetics starting 
with the peptide sequence (Haverstein and Morrison, 1995).
comD and comE were found to encode the 2 component regulator/response apparatus 
of this system (Pestova et al., 1996, Cheng et al., 1997).
Subsequent studies have shown that there is more than one class of pheromone 
produced, complemented by structural modifications of the ComD protein associated 
with a given pherotype (Claverys et al., 2000).
The comA and coniB genes encode the CSP export proteins (Morisson, 1997). The ComA 
protein is a member of the ATP dependent transport proteins, and the comAB promoter is 
a target for the phosphorylated ComE response regulator (Cheng et al., 1997). When 
exogenous CSP reaches a threshold level in the growing culture, genes
5
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Multiple regulatory systems have been found that demonstrate specific metabolite 
requirements before competence for genetic transformation can develop. These include a 
requirement for O2, sensed via NADH oxidase (Auzat et al., 1999), cations such as Ca2+, 
Zn2+ and Mn2+ (Fox and Hotchkiss 1957, Dintilhac et al.,1997) and phosphate (Novak et 
al., 1999). The ciaH/R two component system is thought to be involved in regulation of 
competence in response to calcium and phosphate levels, repressing the early competence 
genes when these ions are at sub-optimal concentrations (Giammarinaro et al., 1999).
Another key element in the competence regulatory system is the SigH protein, an 
alternative sigma factor encoded by the comX gene. SigH and can be considered as the 
regulatory link between the early competence genes and those involved in the later stages 
of the process (Lee and Morrison, 1999). SigH functions by recognising and binding to 
the consensus sequence 5’-TACGAATA-3’ at position -10 with respect to the 
transcriptional start point. This sequence is termed the ‘cin-box’, and precedes genes 
encoding components of the DNA translocation complex, Ssb and the nuclease 
responsible for degrading the incoming 5’ to 3’ strand of DNA (EndA) (Lacks et al., 
2000).
A recent study by Rimini et al. has investigated the temporal distribution of gene 
expression during competence induction using cDNA hybridisation to high-density 
genomic microarrays. This approach enabled the authors to identify genes that are up 
regulated and down regulated during the development and shutdown of competence. Up 
regulated loci include the known competence genes (described above) plus others 
implicated in diverse processes including DNA modification and central metabolism. 
Down regulated genes notably include ribosomal proteins, indicating a transient 
shutdown of protein synthesis during competence (Rimini et al., 2000). Whilst of great 
interest, a further discussion of the implications of this work are beyond the scope of this 
chapter.
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1.3.2 -  DNA uptake and homologous recombination
Unlike other naturally transformable bacteria, such as Haemophilus influenzae, S. 
pneumoniae is promiscuous in that it does not require a species-specific sequence to 
identify DNA suitable for uptake, thus opening up the possibility of inter-species genetic 
exchange.
As the incoming strand enters the cell, it undergoes methylation at 5’-GATC-3’ 
motifs by the product of the dpnA gene, one of the late competence genes expressed 
under the control of SigH (Lacks et al., 2000). Claverys et al. suggest that this 
methylation is required to protect the inserted, single stranded donor DNA from 
restriction by Dpnll prior to resolution and replication of the double stranded 
recombinant DNA (Lefrancois et al., 1998, Claverys et al., 2000).
Integration into the host chromosome has been shown to be dependent upon RecA 
(MortierBarriere et al., 1998), which is transported to the inner face of the cell membrane 
by the product of the cinA gene (Masure et al., 1998).
The proposed mechanism of recombination is complex and involves a number of 
proteins, of which RecA is thought to play a principal role (Camerini-Otero and Hsieh, 
1995). A mismatch repair (MMR) system operates in S. pneumoniae in the form of 
HexAB (the hexAB genes in the pneumococcus are homologous to the mutSL genes of 
E.coli). While this system efficiently recognises and repairs single base mismatches, it is 
prone to saturation in the presence of large numbers of mismatches (Humbert et al.,
1995). So, when errors occur during normal chromosomal replication, they are efficiently 
repaired by Hex. However, when the cell takes up DNA during transformation, and the 
recombination process is underway, Hex does not present a significant barrier to 
integration and the establishment of novel sequences. This may represent an adaptation of 
the pneumococcus to its recombinogenic lifestyle, and the genetic plasticity that it affords 
(Majewski et al., 2000).
It is estimated that competent pneumococci can take up several DNA fragments per 
cell, accounting for up to 5% of the pnemococcal genome. Estimates suggest that the
9
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probability of recombination of such fragments into the genome is 0.1-0.5 for 2-20% 
divergent DNA, rising to 1 for homologous DNA (Claverys et al., 2000).
Observations from our laboratory and others indicate that inter-species recombination 
has been involved in the evolution of several pneumococcal genes (S. King -  
Unpublished data, Poulsen et al., 1998, Whatmore and Dowson 1999). This has 
implications for vaccine design, as protein based formulations will conceivably select for 
escape variants unless suitable precautions are taken. Current attentions are centred on 
searching for a stable pneumococcal protein for inclusion in the next generation of 
pneumococcal vaccines.
1.4 - Incidence of S. pneumoniae: Clones and serotype prevalence
Despite the pathogenic capacity of the pneumococcus, it is able to persist in the host 
population unnoticed. The organism can be carried in the nasopharynx of carriers in an 
asymptomatic state in many cases. It is often thought of as part of the normal flora of the 
human upper respiratory tract. Carriage rates are estimated to be 5-10% of a healthy adult 
population and 40-50% of infants under the age of 24 months (Gray, 2000), however 
these figures are subject to seasonal and geographic variation.
A key determinant of host susceptibility to pneumococcal infection is the immune 
status of the host. A minor episode of viral infection is often enough to enable the 
pneumococcus to take hold, indeed the activity of influenza virus neuraminidase has been 
implicated in the unveiling of host cell receptors for pneumococcal adhesion (Plotkowski 
et al., 1986, AlonsoDeVelasco et al., 1995). Alternatively, the sub-optimal immune 
responses of young children or elderly individuals may provide the pneumococcus with 
the opportunity to invade. Other paths to immunocompromisation include infection with 
HIV, impaired function or loss of the spleen, and suppression of the immune response by 
chemotherapeutic drug use. In this light, the pneumococcus can be regarded as an 
opportunistic pathogen.
In all, 90 serotypes are known to exist, some of which are particularly associated with 
invasive disease. Certain capsular polysaccharides are associated with invasive infections 
and delineated on the basis of the target population. For example, serotypes 1, 3 ,4 ,7 , 8
to
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and 12 are commonly isolated from invasive disease in adults, whereas serogroups 6, 14, 
19 and 23 are more common in young children (Gray, 2000).
A key feature of pneumococcal incidence is the occurrence of clonal population 
growth. The pneumococcus is able to undergo the usual processes of genetic drift by 
point mutation of its genes. It is also able to undergo genetic shift via horizontal transfer 
of genetic material with other bacteria.
Pneumococcal progeny which have acquired a particular combination o f genetic 
elements (which gives them a selective advantage over their competitors) are able to 
proliferate rapidly, leading to the appearance of pneumococcal clones. The development 
of antibiotic resistance (notably to penicillin) has driven the appearance of such clones.
Techniques used to describe clonal relatedness include antibiogram definition, 
chromosomal techniques such as pulsed-field gel electrophoresis and arbitrarily primed 
PCR, more sensitive techniques include Restriction Fragment Length Polymorphism 
(RFLP) analysis of particular genes, and more recently, Multi-Locus Sequence Typing 
(MLST) (Enright and Spratt, 1998).
Much of the classical work on the spread o f antibiotic resistant clones originated from 
the study of the Spanish serotype 23F, 6B clones and the 9V clone thought to have 
originated in France (Munoz et al., 1991, Enright et al., 1999). Subsequent studies 
revealed the existence o f another three multiply antibiotic resistant clones o f serotypes 
14 ,15F and 19F, also from Spain (Coffey et al., 1996). Molecular approaches have 
traced the spread of some of these clonal strains across the globe. Derivatives of the 
Spanish 23F clone (Spain23F-l) is known to have spread to the USA (Munoz et al., 1991), 
Hong Kong (Ip et al., 1999), continental South America (Castaneda et al., 1998), Mexico 
(EchanizAviles et al., 1998) and Korea (McGee et al., 1997). This clone also appears to 
have spread to Belgium, via France, undergoing some variation at the genome level as it 
has done so (Ferroni et al., 1996, HoefhagelsSchuermans et al., 1999). These 
observations have secured the pandemic status o f this clone.
Much emphasis is placed on the identification of a particular clone on the basis of the 
serotype of the members of that clone. The genetic (and hence phenotypic) plasticity of 
the pneumococcus has been hinted at in the case of the evolution of the PBPs. It is not 
surprising then, that the nature o f the capsule can alter by horizontal gene transfer also, a
11
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phenomenon known as Capsular Switching. The molecular techniques employed to 
identify the early emerging clones have also helped reveal instances where the genes 
encoding the capsule (and hence serotype, see below) have rearranged with those of other 
pneumococci. Certain instances have been studied in molecular detail (Coffey et a i,
1998, Coffey et a i,  1999, Ramirez and Tomasz, 1999a) and capsular switching is thought 
to be a common mechanism of phenotypic variation.
While the ability of successful pneumococcal clones enable the organism to evade 
certain forms o f antimicrobial therapy, initiation of invasive disease and the evasion of 
the attentions o f the host immune system are conferred by other attributes o f the 
pneumococcus.
1.5 - Virulence determinants o f £  pneumoniae
Before embarking on a description of the pneumococcal virulence determinants, it 
may be beneficial to briefly describe the architecture o f the pneumococcal cell.
The cell membrane is surrounded by the cell wall responsible for the Gram positive 
phenotype. This is in turn overlaid by the capsule in those cells expressing capsular 
polysaccharide (see below).
The cell wall consists of crosslinked peptidoglycan layers (GlcNac-pi-4-MurNac) 
linked to its cognate stem peptide (Gray, 2000). Imbedded in this matrix is the cell wall 
polysaccharide (CWPS) or C polysaccharide. This is a complex teichoic acid containing 
phosphorylcholine residues (AlonsoDeVelasco et a i ,  1995).
The breakdown products of the peptidoglycan complex are highly inflammatory 
(usually released after autolysin mediated autolysis -  see section 1.5.3.1), and are thought 
to be responsible for many of the toxic effects of pneumococcal infection (Gray, 2000). 
The cell wall is also the location o f many pneumococcal proteins such as the PBP’s and 
some of the protein virulence determinants to be described in detail below.
12
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1.5.1 -  The capsule
The capsule is sometimes considered to be the primary virulence determinant of the 
pneumococcus. It contributes to disease by inhibiting clearance by host phagocytes. This 
is reflected in the 10s fold difference in LD50 between encapsulated and acapsular strains 
in a murine challenge model (Watson and Musher, 1990).
The capsule is present overlaying the cell wall. Interspersed with its polysaccharide 
chains are proteins such as the pneumococcal surface proteins (Psp’s) and cell wall 
constituents such as teichoic acid (TA or C-polysaccharide), lipoteichoic acid (LTA) and 
phosphorylcholine. Most of these elements are potentially immunogenic. Antibody 
responses to the capsular polysaccharide are detected in immunocompetent individuals 
during the course of infection, however, such T-cell independent responses are poor in 
two key populations, namely the elderly, and the very young (less than 24 months).
The capsule is not ubiquitous and under some circumstances is lost. The amount of 
capsule produced can vary at any one time, and it has been suggested that an isolate of S. 
pneumoniae should be considered to contain a mixture of capsule phenotypes (Weiser 
and Kapoor, 1999). The presence or absence of the capsule bestows different phenotypes 
upon the organism in terms of its relationship with the host. Capsúlate pneumococci are 
resistant to phagocytosis, whereas acapsular cells are not. However, the presence of the 
capsule presents a barrier to cytoadherence with in the nasopharynx by the occlusion of 
structures on the pneumococcal cell surface responsible for binding to host 
macromolecules. Hence the balance between persistence in the host and clearance by 
immune surveillance, and that between colonisation of the host mucosa and loss by mass 
action from the respiratory tract is determined by the processes which regulate capsule 
production within the pneumococcus.
The biosynthetic genes required for capsule synthesis are closely linked and are 
arranged as opérons. The caspsular biosynthetic gene clusters of strains of different 
capsular serotypes are located in the same chromosomal locations (Claverys el al., 2000), 
and there has been much work investigating the nature of the capsular biosynthetic gene 
clusters. To date the loci encoding production of the type 23F (Morona et al., 1999b)
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Ramirez and Tomasz, 1999b), 2 (Iannelli et a i, 1999), 8 (Munoz el a i, 1999), 19 
(Morona el a i, 1999a), 37 (Llull el a i,  1999), 3 (Arrecubieta el a i, 1995, Arrecubieta el 
a i, 1996), 1 (Munoz el a i, 1997), 14 (Kolkman et a i,  1997) and 33F (Llull et al., 1998) 
have been described. The complexity o f individual capsular loci correlates approximately 
with the chemical complexity of the polysaccharide produced.
1.5.2 -  Immune responses to pneumococcal antigens
Host clearance o f pneumococci is thought to depend upon effective opsonisation 
(both by antibodies and complement components), followed by phagocytocis and 
subsequent killing in the phagolysosomal compartment (AlonsoDeVelasco et a i, 1995, 
Tu et a i, 1999).
Exogenous antigens capable o f eliciting a host antibody response can be broadly 
divided into two categories; the thymus dependent (TD) antigens, and the thymus 
independent (TI) antigens. The nature o f these antigens and that of the host response to 
them differ somewhat. The TD antigens are often proteinaceous, and the host response to 
them is anamnestic.
The TI antigens are generally high molecular weight macromolecules, which are 
poorly metabolised in the host. This class of antigens includes polysaccharides, 
polypeptides and polynucleotides. Responses to these antigens are not anamnestic, and 
importantly, are age dependent.
The available pneumococcal vaccines are multivalent polysaccharide preparations, 
which constitute TI antigens. While the host response to TI antigens in the healthy adult 
is effective, this is not the case in other groups of individuals, making them particularly 
vulnerable to pneumococcal disease. Asplenic patients, those who suffer frequent RTI’s 
(respiratory tract infections), HIV patients, the elderly, and the young comprise these 
high-risk groups. Geriatric production o f anti-polysaccharide (anti-PS) ab is seen to 
decline in individuals from the age of 50-60 onwards. Paediatric production of anti-PS ab 
is only observed after the age o f 4-5 years (as seen with the prevalent serotypes affecting 
children, 6A, 14, 19F and 23F) (Douglas et a i,  1983). Thus it is apparent that the 
available polysaccharide vaccines are not particularly useful to these groups of
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individuals. The current drive of vaccine research includes an investigation of the 
efficacy and antigenic stability o f pneumococcal proteins for inclusion in the next 
generation o f pneumococcal vaccines, consisting of PS antigens conjugated to protein 
carriers.
1.5.3 -  Protein virulence determinants
The work presented in this thesis is based around a specific field o f research into 
pneumococcal protein virulence determinants (PVD’s). These afford the pneumococcus 
the ability to invade the tissues o f the host and cause disease.
1.5.3.1 -  The Choline binding proteins and Autolysin
The pneumococcal cell wall, as mentioned above, is comprised o f a complex mixture 
of proteins, peptides and teichoic acids (Navarre and Schneewind, 1999). Many of the 
proteins found immobilised the pneumococcal cell wall can be broadly categorised as 
those which bear the classical gram positive cell wall anchor motif (LPXTG), and those 
which bear choline binding domains. Pneumococcal teichoic acids are rich in choline, 
however the pneumococcus is unable to synthesise this compound, for which it has an 
absolute requirement (Yother el al., 1998).
To date a number of pneumococcal choline binding proteins (Cbp’s) have been 
described. These include the major autolysin, LytA (Garcia el al., 1986, Lopez el al., 
1986, Whatmore and Dowson 1999), pneumococcal surface protein A (PspA) 
(Talkington el al., 1991), a murein hydrolase, LytB (Garcia el al., 1988), a lysozyme, 
LytC (Garcia el al., 1999), PcpA, which is thought to play a role in pneumococcal 
adhesion (Sanchez-Beato el al., 1998) and an adhesin, CbpA (Rosenow el al., 1997) also 
termed SpsA or PspC (Brooks-Walter el al., 1999).
Mutagenesis studies have shown that some o f the Cbp’s behave as adhesins. These 
include CbpA, which is thought to interact with GalNAc-P 1,4-Gal and GalNAc- 
P1,3-Gal receptors on host cells.
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The precise function of PspA is not known. Recent studies have implicated PspA in 
blocking the activation of the alternative complement pathway at the stage of Factor B 
mediated activation o f C3b. Tu et al. have shown that loss of PspA leads to rapid 
clearance of pneumococci from infected mice (Tu et al., 1999).
The first Cbp to be characterised was the major autolysin, LytA. This protein is an N- 
acetyl-muramoyl-L-alanine amidase, and is involved in degradation of peptidoglycan. 
Like many o f the Cbp’s, it has a modular organisation, with the (now well characterised) 
choline binding domain at the C-terminus o f the molecule and the catalytic portion at the 
N-terminus.
The nature o f the contribution of LytA to virulence is thought to vary depending upon 
the route of inoculation in animal models, reflecting different disease states in the human 
host (Berry et al., 1989, Sato et al., 1996, Whatmore and Dowson, 1999).
LytA is known to contribute to virulence in two ways, firstly by promoting 
inflammation by the release of cell wall breakdown products. Secondly, the key 
pneumococcal cytotoxin, pneumolysin (see section 1.5.3.2, below) is not actively 
exported, rather it accumulates in the pneumococcal cytoplasm and is released by 
autolysin mediated lysis of the cell.
1.5.3.2 -  Pneumolysin
Pneumolysin is one of the classical pneumococcal PVD’s, and has been the focus of a 
considerable amount of investigation. The pneumolysin monomer is a 53kDa haemolysin 
that targets and inserts into cholesterol-containing host cell membranes. Here the 
monomers polymerise, forming a transmembrane pore, leading to host cell lysis (Paton et 
al., 1993).
Pneumolysin belongs to the family of thiol-activated toxins, and is released from the 
pneumococcal cytoplasm following general cell lysis mediated by autolysin. It is the 
action of this class o f enzymes that is responsible for the haemolytic phenotype seen 
when pneumococci are grown on blood agar media.
At lower concentrations, pneumolysin is known to have numerous effects on the host, 
including impeding epithelial cilliary function (Steinfort et al., 1989) and enhanced
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inflammation due to the release of tumour necrosis factor-a and interleukin-ip from host 
monocytes (Houldsworth et al., 1994). Neutrophil migration and activity is affected as 
well as lymphocyte replication and antibody synthesis (Paton and Ferrante, 1983, 
Ferrante et al., 1984).
Pneumolysin also interacts with soluble components of the immune system, resulting 
in inappropriate activation of complement, leading to further inflammation. (Mitchell et 
al., 1991, AlonsoDeVelasco eta!., 1995, Benton et til.. 1997). This is thought to be a 
consequence of the structural similarity of domain 4 of the pneumolysin monomer to the 
Fc portion of IgG (Rossjohn et al., 1998).
The clinical features of pneumococcal pneumonia can be induced by the addition of 
purified pneumolysin to the rat lung (Mitchell et al., 1997). Similarly, when isogenic 
pneumolysin negative strains are used in a mouse lung infection model, wild type growth 
can be restored by the addition of exogenous pneumolysin. A similar effect was seen in 
the case of irreversible hearing loss after episodes of pneumococcal meningitis (Winter et 
al., 1997).
As a noteworthy aside, it is perhaps important to mention the finding that there 
appears to be more than one pneumococcal haemolysin. The locus encoding 
pneumolysin, ply, appears to be redundant to loci encoding at least two further 
haemolysins. The contribution of these alternative haemolysins to virulence is currently 
under investigation in our laboratory (S. Colby and D. Sturgeon -  unpublished data).
1.5.3.3 -  Neuraminidases
Neuraminidases are sialidases that cleave N-acetylneuraminic acid (NeuNAc) from 
glycoproteins, mucin and gangliosides. The physiological consequences of such an 
activity during pathogenesis involves reduction of mucus viscosity and the unveiling of 
potential receptors for bacterial attachment to host epithelia (Mitchell et al., 1997, Tong 
et al., 2 0 0 0 ).
S. pneumoniae is known to have at least two genes encoding neuraminidases, 
designated nanA and nanB (Berry et al., 1988, Camara et al., 1991, Camara et al., 1994).
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The first description of a pneumococcal neuraminidase involved screening a cosmid 
library for clones which were able to encode proteins able to degrade the fluorogenic 
neuraminic acid analogue, 2’-(4-methylumbeliferyl)-a-D-N-acetylneuraminic acid 
(MU AN).
NanA and NanB differ in terms of their pH optima, and the two proteins possess 
different sorting sequences. NanA has an N-terminal cleavable signal sequence, and a C- 
terminal cell wall anchor motif, whereas NanB has a cleavable N-terminal signal 
sequence but no cell wall anchor at its C-terminus. This suggests the differential use of 
cell associated and secreted neuraminidases with different enzymatic properties.
The contribution of neuraminidase to virulence has been assessed in some animal 
models by insertion-duplication mutagenesis at the nanA locus (Winter et al., 1997). This 
mutant, named ANA1 was shown to be deficient in nasopharyngeal colonisation and 
induction of otitis media in the chinchilla model (Tong et al., 2000). A similar attenuation 
of virulence was observed in a murine pneumonia model (Mitchell et al., 1997), but not 
the guinea pig meningitis model (Winter et al., 1997). A role for other neuraminidase(s) 
in these systems was ruled out on the basis of negligible degradation of MU AN by the 
ANA1 strain.
1.5.3.4 -  IgAl Protease
The IgAl proteases contribute to virulence by interfering with the opsonisation 
process of mucosal IgAl, the predominant immunoglobulin of the upper respiratory tract. 
By cleaving the dimeric molecule at the hinge region, the IgAl proteases uncouple 
antigenic recognition from the effector responses of the immune system.
Such proteases represent a diverse group of enzymes, found in a wide variety of 
organisms including H. influenzae. Neisseria meningitidis, N. gonorrlweae, 
Streptococcus sanguis, S. mitis, S. oralis and S. pneumoniae.
The IgAl protease from the pneumococcus is thought to act in concert with 
neuraminidase, with the latter enzyme disrupting the glycosylated regions of the IgAl 
molecule, making it more susceptible to proteolysis by IgAl protease (Reinholdt and 
Kilian, 1996).
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The structure of the pneumococcal iga gene contains some interesting features; a cleavable 
signal sequence is evident at the N-terminus (Poulsen et al., 1996, Wani et al., 1996). 
Downstream from this there are a number o f  tandem repeats. The nature and extent of reiteration 
o f these repeats is variable among the IgA 1 proteases. The C-terminal portion of the gene, 
thought to contain the catalytic centre, harbours the zinc-binding motif, HEMTH(X>2oE (Poulsen 
et al., 1996, Poulsen et al., 1998).
The novel location of a cell wall anchor motif at the N-terminal region of the protein is an 
interesting feature, and the distribution o f hydrophobic regions around the anchor motif, and the 
position of a proline-rich region (often associated with surface proteins) suggests an alternative 
topology of the protein at the cell surface, with three transmembrane spanning regions (Poulsen et 
al., 1998).
Sequence analysis revealed that the streptococcal iga loci display mosaic structures, and are 
evolving by transformation-mediated homologous recombination between the species S. oralis, S. 
m itis  and S. pneumoniae, but not S. sanguis.
A phenotypic analysis o f IgAl protease activity in a wide range o f strains was undertaken by 
Reinholdt and Kilian (Reinholdt and Kilian, 1997). They found that activity o f this enzyme varied 
w idely throughout the streptococci tested, with no specific association of IgAl protease activity, 
w ith either commensal or pathogenic organisms.
1.6 -  in vivo studies of pneumococcal protein virulence determinants
The purpose of studying PVD’s in vivo is twofold; firstly to assess the contribution of 
individual virulence determinants to pathogenesis in different modes of infection. The second 
interest is evaluation of pneumococcal proteins as immunogens. The currently available vaccines 
belong to the Pneumovax class. These compositions consist of polyvalent arrays o f capsular 
polysaccharides. As mentioned in section 1.5.2, such vaccines are only efficacious in 
immunocompetent individuals. Their applicability in other populations is restricted by the 
inability of those individuals to mount an appropriate and long-term immune response to 
polysaccharide antigens.
To take these issues in turn, the individual contribution of the principal virulence 
determinants in particular model systems has been mentioned in the relevant sections above. It is 
perhaps noteworthy to mention the in-vivo approach to identification of
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virulence determinants taken by Polissi et al. (Polissi et al., 1998). This approach 
involved a powerful signature tagged mutagenesis (STM) technique to isolate mutants 
with attenuated virulence. A population of mutagenised pneumococci was generated by 
recombination after suicide vectors were introduced by transformation, containing 
random pneumococcal genome fragments, plus a unique oligomeric ‘tag’.
Virulence attenuated mutants from either pneumonia or septicaemia models were 
identified after Southern based screening of the bacteria recovered from the mouse lung 
or bloodstream respectively against individual mutants generated at the start of the 
experiment (the regions containing the unique tags were used in the hybridisation steps). 
Mutants which were present in the in-vitro pools, but not the in-vivo pools were 
characterised by Inverse PCR (iPCR -  see Chapter 2, section 2.2.1 for a description of the 
technique).
The genes identified by this approach were numerous, and some differences were 
noted between those genes isolated from the pneumonia and septicaemia models. The 
genes identified after the first round (intranasally inoculated) of selection were grouped 
into 4 classes. The first included the known virulence determinants hyaluronate lyase, 
neuraminidase, autolysin and IgAl protease. Interestingly, pneumolysin was not 
identified as a requirement in this screen, unlike other pneumonia models using 
pneumolysin negative mutants (Mitchell et al., 1997). The authors suggest that this may 
be a consequence of trans complementation by wild type expression of Ply from other 
strains in the pool. This would still reflect a requirement for LytA (which remains cell 
associated), as was the case in this experiment. The inclusion of IgAl protease in this 
group is also interesting. It is understood that this enzyme has no activity against murine 
IgAl (Proctor and Manning 1990), therefore IgAl protease must play an alternative role 
in this system.
The second class of genes identified as required were those involved in various 
metabolic functions. These included genes involved in purine biosynthesis, glutamine 
biosynthesis, phosphate fixation and anaerobic metabolism. This suggests that 
pneumococcal genes involved in survival under nutrient limiting conditions are required 
in this model. The final 2 classes of genes included proteases, transport systems and 
genes involved in DNA recombination and repair.
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When these mutants were tested in the septicaemia model it was found that there was 
no longer a specific requirement for hyaluronate lyase, neuraminidase or autolysin. 
Therefore it appears that these enzymes play a role in colonisation and persistence at the 
mouse respiratory epithelial mucosa, but are not required after the transition across the 
lung-blood barrier, as reflected in the mouse septicaemia model. The strengths o f  this 
experimental approach lie in the inclusion of the multitude of factors present in the in- 
vivo selection system, which are not present under in-vitro culture conditions. Thus the 
interplay between host and pathogen is represented in this model.
Berry and Paton examined double mutants o f nanA, hyl, pspA, lytA and cbpA in a 
pneumolysin negative background (Berry and Paton, 2000). They found that in the mouse 
septicaemia model, the pneumolysin knockout (APly), was significantly less virulent than 
the wild type strain (D39 serotype 3 isolate), whereas Hyl" and NanA' single knockouts 
were not. The PspA' mutation resulted in moderate attenuation of virulence. Interestingly, 
when the double mutants APly-Hyl'and APly-PspA' were tested, they found that these 
strains were significantly less virulent than the APly strain alone. This observation leads 
to the interpretation that the combined influence o f  pneumococcal PVD’s constitutes a 
system where the whole is greater than the sum o f  the parts.
The second central aim o f in-vivo studies is to assess the immunogenicity o f  
pneumococcal protein antigens, and their potential efficacy for inclusion in the next 
generation o f conjugate vaccine preparations that include both proteinaceous and 
polysaccharide components.
As mentioned in section 1.5.2, individuals who are at high risk from pneumococcal 
infection do not possess the ability to respond well to TI antigens, including 
polysaccharides. This renders the Pneumovax class of vaccines ineffective in these 
groups. In order to address this problem, the phenomenon o f enhanced recognition of PS 
antigens in the context o f a protein carrier molecule has been exploited. This approach 
has been highly successful in protection against H. influenzae type b (Mitchell et al., 
1997), where anamnestic responses to polysaccharide antigens has been achieved.
Primary work in this field involved conjugation of streptococcal polysaccharides to 
the heterologous diptheria and tetanus toxoids. These were selected on the basis of their 
Th cell activating ability, and were effective in animal models immunised with GBS type
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3 and serotype type 4 pneumococci (Peeters el al., 1991, Paoletti el al., 1992). Drawbacks 
associated with this approach include sequestration of the antibody response by excessive 
anti-carrier antibody production. This has been shown to result in suppression o f immune 
responses to subsequent formulations using the same carrier in mice (AlonsoDeVelasco 
el al., 1995).
In this light it can be seen that pneumococcal carrier proteins would provide attractive 
alternatives to non-pneumococcal carriers. If carrier proteins or peptides can be identified 
which confer appropriate T-helper and B cell stimulation, and confer antibody mediated 
responses to the hapten polysaccharide moieties, the potential advantages are twofold; 
early-onset antibody mediated opsonisation against PS epitopes, followed by protein 
mediated opsonisation, and/or abrogation of function of pneumococcal toxins.
An obvious limitation to the use of conjugation of PS to carrier peptides or proteins is 
the number of haptens attached per preparation. This could be simply addressed using a 
knowledge of serotype prevalence within the given target population (segregated on the 
basis of geography or target group).
Another potential drawback is the emergence o f carrier-escape variants within the 
population. Where the TD anti-carrier ab response is able to exert selective pressure on 
the population o f pneumococci as a whole, transformation/homologous recombination 
mediated antigenic escape becomes a possibility.
To this end, knowledge o f the population diversity o f carrier candidates is required. 
Pneumococcal genes including lylA, pspA and nanA are all thought to have evolved by 
homologous recombination between divergent alleles (Swaitlo et al., 1997, Garcia el al.,
1999, Whatmore and Dowson, 1999 and S. King -  unpublished data). In this study the 
diversity at the hyl locus is examined to establish the extent and nature of variation in 
order to examine the potential use of the protein (or derivatives of it) in new conjugate 
pneumococcal vaccines.
1.7 -  Hyaluronatc lyase
The remainder of this introductory chapter will focus on the pneumococcal 
hyaluronidase, more accurately termed hyaluronate lyase. This will begin with an
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introduction to the substrate, followed by a discussion of the class of enzymes responsible 
for its degradation. This will be followed by a description of the pneumococcal enzyme. 
An outline of the aims and perspectives of the work presented here will follow an 
introduction to the available assays for hyaluronic acid degradation.
1.7.1 -  Occurrence of hyaluronic acid in the host
Hyaluronic acid (HA) is a member of the glycosaminoglycan (GAG) family o f 
carbohydrates. This class of polysaccharide is characterised by disaccharide repeat units, 
one component o f which is always an amino sugar. In many cases the amino sugar is 
sulphated at the C4 position, although this is not the case for HA. The remaining 
component of the disaccharide is an uronic acid. The GAG’s fall into 3 distinct classes, 
characterised by their disaccharide composition and linkage pattern. The polymaltose 
group contains heparan sulphate, the polylactose group includes the chondroitin and 
keratan sulphates and the cellobiose class includes HA.
The GAG’s are often associated with a core protein, forming the proteoglycan 
component of the extracellular matrix. The other major components of the extracellular 
matrix are proteins such as collagen and elastin. Together these major components form a 
tight mesh that accounts for the structural stability of the extracellular matrix. One o f  the 
better-characterised GAG/proteoglycan structures is that of the proteoglycan aggregates 
found in mammalian cartilage. An example of this is shown in the electron micrograph in 
figure 1.2, along with a schematic representation of the components of the aggregate.
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Core Protein
Figure 1.2 -  GAG/proteoglycan aggregates found in mammalian cartilage. A:
Electron micrograph with platinum shadowing. B: Schematic diagram showing key 
features of the macromolecule. Both the micrograph and the diagram are taken or adapted 
from Alberts el al. Edition 2, p.807 (Alberts el al., 1989).
As can be seen, the aggregate is composed o f proteoglycans bound to a core HA 
molecule by link proteins. HA differs from the other GAG’s in several respects. There are 
no sulphated residues, the chain length can be very long at around 2-3,000 residues, often 
reaching molecular weights of several million Daltons. It is not found associated with a 
core protein and it is not found in branched chains.
The relatively simple structure of HA (as shown in figure 1.3) has lead to the 
suggestion that this molecule represents an early evolutionary form of GAG (Alberts el 
al., 1989), whereas the more structurally elaborate species o f GAG have evolved as a 
result of the selective pressure provided by the microbial pathogens which degrade them 
(L ie /al., 2000).
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Figure 1.3 -  Repeat unit of hyaluronic acid (HA). All substituents are shown.
As can be seen from figure 1.3, HA consists of alternating N-acetylglucosamine 
(GlcNAc) and glucuronic acid (GlcUA) residues linked by alternating P-1,3 and P-1,4 
glucosidic bonds. The repeat unit is termed N-acetylhyalobiuronic acid.
Aqueous solutions containing HA are highly viscous, and increased concentrations of 
HA can lead to the formation o f HA gels. HA-rich fluids act as lubricants and facilitate 
shock absorption in vertebrate joints. These properties are largely steric in nature; mutual 
repulsion o f the carboxyl groups on the glucuronic acid moieties results in the co­
ordination o f  large numbers o f water molecules.
Understanding the roles o f HA in the host has advanced over the years from the early 
appreciation o f  its importance in tissue structure to implications for tissue differentiation, 
angiogenesis, metastasis, embryogenesis and tissue repair.
HA is recognised as a major component of the extracellular matrix (West et al., 1985, 
Reed et al., 1990b, Stamnekovic and Arrufo, 1994, Frost et al., 1996). The distribution of 
HA varies between tissues and around 50% of total HA is thought to reside in the skin. 
The turnover o f  this material is rapid, with 50-75% of tritiated HA injected into rabbit 
skin metabolised over 24 hours (Reed et al., 1990a)
Several studies have implicated HA in the organisation of tissues undergoing rapid 
migration and proliferation. These effects are mediated by physical and biochemical 
factors: The influx of water into HA-rich regions (due to the hygroscopic nature of the 
molecule) results in host cells being forced apart, allowing for the migration o f other cell
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types around the region (Toole, 1981). The effects of HA on the cellular environment are 
also regulated by HA receptors on host cells, including CD44 and RHAMM (Receptor 
for Hyaluronic Acid Mediated Motility) (Stamnekovic and Arrufo, 1994).
High levels o f HA appear to inhibit cellular differentiation in some systems (Kujawa 
and Tepperman, 1983, Kujawa et al., 1986) including that o f the developing chick 
embryo cornea (Toole, 1981).
HA also plays a complex role in angiogenesis. High molecular mass HA is seen to 
inhibit formation of vascular tissue, while low mass HA stimulates the process (Feinberg 
and Beebe, 1983, West et al., 1985). Thus interplay between hyaluronate synthases and 
hyaluronidases potentiates angiogenesis. This has further implications for various 
processes ranging from embryogenesis to metastasis.
While the diverse roles played by HA in the host are of evident interest, it is the 
contribution o f HA to ECM structural integrity which is of primary concern when 
addressing the case of pneumococcal hyaluronate lyase. However, the range of enzymes 
capable of degrading HA is broad and diverse, as will be discussed below.
1.7.2 -  Hyaluronidases degrade HA
As mentioned above, HA is broken down by hyaluronidases and hyaluronate lyases. 
Together these enzymes form a large and diverse group of proteins from the eukaryotic 
and prokaryotic kingdoms. The common biochemical function shared by these enzymes 
is their ability to degrade hyaluronic acid, and as such they are believed to act as 
spreading factors, albeit in different biological systems. Their genetic and structural 
diversity is reflected in the way in which these enzymes perform this degradation.
1.7.3 -  Mammalian and insect hyaluronidases -  PH-20
The mammalian hyaluronidase is an endo-P-N-acetyl-D-hexosaminidase that cleaves 
between GlcNAc and GlcUA residues to yield primarily tetrasaccharides. The ability of 
the enzyme to perform transglycosylation reactions then leads to the secondary
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production of di- and octa-saccharides. This enzyme is marked by its relatively broad 
substrate specificity, also being able to degrade chondroitin sulphates (Frost el al., 1996).
This class of hyaluronidase is termed the PH-20 type on the reactivity of one of the 
earliest examples of this class (from Guinea Pig sperm acrosome) with a particular 
monoclonal antibody raised against a protein previously termed PH-20 (Primakoff and 
Myles, 1983). The enzyme from mammalian sperm contributes to the fertilisation process 
by enabling the sperm to traverse the layer of HA-rich cumulus cells surrounding the egg.
Other PH-20 type hyaluronidases have subsequently been described in insect venom. 
The enzyme from honey-bee venom was identified on the basis of homology to the PH- 
20 prototype, and is related to venom hyaluronidases from other hymenopterans. This has 
lead to the interesting suggestion that the venom spreading factor in these organisms has 
evolved from the mammalian reproductive system (Frost et al., 1996).
Antibody binding studies suggests that the PH-20 structural class o f hyaluronidase 
may be more widely distributed than has been previously thought. Antibodies raised 
against the hyaluronidase of Apis melifera were shown to be cross reactive with surface 
proteins shown to be able to bind HA from the spirochaete Treponema denticola (Scott et 
al., 1996).
Homology studies have indicated that the active site of the PH-20 type hyaluronidases 
lies in the amino terminal portion of the protein. This active site is thought to consist of 
two conserved acidic residues (glutamic or aspartic acid) and the substrate binding pocket 
is thought to be lined with hydrophobic residues such as tryptophan and tyrosine (Kreil, 
1995).
1.7.4-Othervenom hyaluronidases
Hyaluronidase activities in other venom samples were studied by Cevallos et al. 
(Cevallos et al., 1992) using an in-gel technique which involves PAGE through gels 
containing HA, renaturation, incubation and visualisation of zones of HA degradation 
using a modification o f the dye-binding technique o f Benchetrit et al. (Benchetrit et al., 
1977) -  see section 1.8.2.1, below. Using this technique they were able to identify 
hyaluronidase activity from the venom of Dolichovespula maculata (White faced hornet),
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Vespula gennanica (Yellow jacket wasp), Pogonomyrmex rugosus (Harvester ant), 
Heloderma horridum horridum (Mexican bearded lizard), Heloderma suspectum 
suspectum (Gila monster), Lachesis muta (Bushmaster snake), Crotalus basil ¡sens 
(Mexican west-coast rattle snake), Bothrops asper (Central American pit viper), Micrurus 
nigrocinctus (Central American coral snake) and Centruroides limpidus limpidus (a 
scorpion of Mexican origin. In many cases the low intrinsic toxicity of the purified 
hyaluronidase supports the view that the enzymes contribute to toxicity by facilitating the 
spread of other venom components (Frost et al., 1996)
1.7.5 -  Leech hyaluronidase
The enzyme from the leech (Hirudo medicinalis) is an endo-P-D-glucuronidase, 
which cleaves between GlcUA and GIcNAc residues to yield primarily tetrasaccharides 
(Yuki and Fishman 1963). It differs from the mammalian enzyme in its absolute substrate 
specificity, and is of passing interest as a glucuronidase rather than a glucosaminidase, 
however it has not been extensively characterised and will not be considered further here.
1.7.6 -  Bacterial Hyaluronate lyases
The bacterial enzymes comprise another class of HA degrading enzyme. The most 
extensively characterised are endo-N-acetyl-D-hexosaminidases. Whereas the PH-20 
class of enzymes are hydrolases, the bacterial enzymes are lyases, progressively 
degrading the HA chain by a 3-elimination reaction leading to the production of 
unsaturated disaccharides containing an -ene moiety in the uronic acid component of the 
molecule. This reaction is illustrated in figure 1.4, below.
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HA Lyase
COOH CHlOH COOH CHjOH COOH CH2OH i  COOH CH.OH
COOH CH2O H  COOH CHjOH COOH CHjOH COOH CH2OH
+ 0" < >
n-1
Figure 1.4 -  The reaction catalysed by bacterial hyaluronate lyase. Only the key 
substituents are shown, with the hydroxyl groups simplified to short vertical bars. Note 
the introduction of a n bond between C4 and C5 of the GleUA moiety.
The mode of action illustrated in figure 1.4 was first described for the pneumococcal 
hyaluronate lyase (Linker and Meyer, 1954), and a large number of bacterial 
polysaccharide lyases have been described, although few in detail. For a review see 
Sutherland (Sutherland, 1995).
The prokaryotic HA lyases are often cited for their high substrate specificity, 
although this is not universally true. The HA lyase o f the group B Streptococcus, S. 
agalactiae has also been shown to be active against chondroitin sulphate, cleaving at the 
unsulphated regions o f the molecule (Baker et al., 1997, Lin el al., 1997). This wider 
substrate specificity may reduce trophic restrictions on this organism, of facilitate more 
effective invasion o f host tissues.
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1.7.7 -  The special case of the hyaluronidases of Streptococcus pyogenes
S. pyogenes, the group A streptococcus (or GAS) is one o f the limited number of 
streptococci which produces a capsule containing HA. In S. pyogenes HA capsule 
production has been shown to be directed by the has operon (Albertini et al., 1998).
Other members of the HA capsule producing group include streptococcal species from 
Lancefield group C (including isolates S. dysgalactiae, S. equi and S. equi subspecies 
zooepidemicus) (Gunther et al., 1996).
Interestingly, the authors of this study found that the incidence of production o f the 
HA capsule was very low in clinical human and animal samples. One possible suggestion 
for this observation is that the HA capsule occludes cell surface adhesins required of 
adhesion to the host epithelia, however the observation runs counter to the findings of 
murine infection studies which have associated HA production with virulence (Leonard 
et al., 1988, Moses et al., 1997). This apparent discrepancy is not easy to resolve, as the 
sites of isolation of these organisms are not given in the former citation. It is possible that 
the same play-off between adhesion versus resistance to phagocytosis, modulated by the 
capsule in pneumococci may operate in the GBS system.
Another suggestion is that the HA capsule may actually contribute to adhesion by 
attachment to host cells through HA binding to CD44 (Schrager et al., 1998). 
Furthermore, the notion that co-ordinated expression of the HA capsule contributes to 
virulence was supported by the identification o f a two-component system capable of 
modulating the expression of the has operon (Levin and Wessels, 1998), however the 
exogenous signal for this system has not yet been identified.
S. pyogenes has been shown to possess a chromosomally located hyaluronidase gene, 
and is host to at least 2 types o f bacteriophage that encode their own hyaluronidase.
Given the nature of the GAS HA capsule there is a patent requirement for phage encoded 
hyaluronidase during the viral infection cycle. The first nucleotide and amino acid 
sequence o f such an enzyme was described by Hynes and Ferretti (Hynes and Ferretti, 
1989). This was cloned from the bacteriophage H4489A, and termed HylP. The authors 
also noted the prior description o f an apparently different
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hyaluronidase by Benchetrit (Benchetrit et al,. 1978) from bacteriophage GT8760. While 
the restriction fragment profiles o f the two viral genomes were identical, the enzymes 
differed on the basis o f their electrophoretic mobility. The authors were unable to 
conclusively explain the apparent differences between these two hyaluronidases.
The Hynes/Ferretti collaboration then went on to describe another phage-associated 
hyaluronidase, this time from a T-type 22 strain (Hynes et al,. 1995). This was termed 
HylP2, and was nearly identical to HylP other than the loss o f a series of collagen-like G- 
X-Y repeats. Subsequent analysis o f  a population of hylP type genes demonstrated that 
these phage encoded enzymes evolve by homologous recombination between strains, not 
unlike the mechanism of variation driving the evolution of various streptococcal genes 
(see section 1.3.2- above) (Marciel et al,. 1997).
S. pyogenes also encodes its ‘own’ hyaluronate lyase, which is distinct from the 
phage-encoded proteins. This shows homology to other bacterial hyaluronate lyases, 
notably that o f the pneumococcus (53% identity over a 500 residue region). It is notably 
different from the phage enzyme as it harbours the string o f conserved residues which is 
thought to comprise the active site o f  the bacterial hyaluronate lyases (see section 1.7.9, 
below) (Lin et al,. 1997).
In their description of the gene encoding HylP2, Hynes et al. noted the activity of a 
‘third hyaluronidase’ detected in the extracellular milieu (Hynes et al,. 1995). It is 
suggested here that this secreted enzyme is in fact that encoded by the ‘genomic’ rather 
than phage associated locus.
1.7.8 -  Phylogenetic associations between known HA degrading enzymes
Some examples of the hyaluronate degrading enzyme classes described above are 
grouped according to amino acid sequence similarity in the dendrogram shown in figure 
1.5. The illustrative purpose of such a dendrogram is twofold: It serves to highlight the 
genuine relationships between proteins within the same class, and demonstrates the 
distinction between the classes o f HA degrading enzymes.
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Homo sapiens
Macaca fasciularis (Monkey)
---------  Oryclolagus cuniculus (Rabbit)
Cavia porcellus (Guinea pig)
Mus musculus (Mouse)
---------------  Rati us norvegicus (Rat)
------  Xenopus laevis (Frog)
Apis melifera (Honey bee)
I--------  Dolichovespula maculata (Hornet)
-----------  Vespula vulgaris (Wasp)
Propionibacterium acnes
Enterococcus faecalis
------------S. pyogenes phage H4489A (hlyp)
--------------  S. py phage H4489A (hlyp2)
— Staphylococcus aureus
—  Streptococcus agalactiae
— Streptococcus pneumoniae 
Streptococcus pyogenes
0 1 
Genetic Distance
Figure 1.5 - Phylogeny of examples of the major classes of HA degrading enzymes.
Alignments of amino acid sequences were made using the Neighbour-Joining method. 
Bootstraps were calculated on the basis of 500 replicates. The dendrogram was generated 
using the MEGA suite of programs (Molecular Evolutionary Genetics Analysis, version 
1.01, The Pennsylvania State University, University Park, PA 16802).
Several features described in the preceding sections are reflected in the phylogenic 
tree shown in figure 1.5. The individual clustering of the groups of mammalian and insect 
hyaluronidases and the prokaryotic hyaluronate lyases is evident, as is the derivation of 
the insect venom hyaluronidases from the eukaryotic group of enzymes. Some of the 
bootstrap values are notably low, indicating that the assignment of a given breakpoint at a 
particular node are less certain than others.
1.7.9 -  Conserved features of prokaryotic hyaluronate lyases
The sequences of the bacterial and bacteriophage encoded proteins reveals that a 
number of residues remain well conserved. These are indicated in the alignment shown in
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figure 1.6, as are the absolutely conserved residues thought be the catalytic residues 
(described in more detail in section 1.7.11).
S.py N -  (X)<o - G F Y Q D G S L I D H  V V T N A Q S  P L Y K K G I A Y T G A V G N V L I D G L
S.pn  N - ( X ) « - G F Y Q D G S Y I D H T -----------------------------  N V A Y T G  A Y G N V L I D G  L
S. ag N -  (X)4o- G F Y A D G S Y I D H T - ----------------------------- N V A Y T G A Y G N V L I D G L
S. au N -(X )45- G F Y K D G S Y I D H -------------Q -----------------D V P Y T G  A Y G V V L L E G I
P.ac N - ( X ) « - G F R A D G G F I Q H ---------------- S -------------- HI  P Y T  G G Y G D V L F S G L
E.faec n  -  (X)«- G L Y P D  G S L I Q H G --------------------- Y -----------F P Y N G S Y G  N E L L K G F
Figure 1.6 -  Alignment of the cluster of residues believed to from the active site of 
the bacterial hyaluronate lyases. Conserved residues are shown bold typeface, catalytic 
residues are shown in red typeface. Abbreviations, accession numbers (or other 
reference) and residue positions are as follows; S. py -  Streptococcus pyogenes (23-101) 
residues 6003-7715, contig. 265, WIT database sequence (http://www.mcs.anl.gov/wit2), 
S. p n -S . pneumoniae (349-416) L20670, S. a g -  S. agalactiae (517-584) E l308674, S. 
au -  Staphylococcus aureus (241-314) Q59801, P. ac -  Propionibacterium acnes (222- 
289) Q59634, E.faec — Enterococcus faecalis (437-504) residues 6882-3895, contig. 
6165, WIT database sequence.
As can be seen from figure 1.6, 12/28 residues are absolutely conserved within all of 
the sequences shown. 19/28 (68%) residues are conserved in most of the sequences, with 
the divergence in the active site region highest for the proteins from Propionibacterium 
acnes and Enterococcus faecalis. This reflects the trend shown in the dendrogram in 
figure 1.5. A clustal alignment of these sequences reveals percentage identity ranging 
from 47.8% (S. pneumoniae/S. pyogenes) to 14.6% (S. agalactiae/E. faecalis). As can 
also be seen, some residues are absolutely conserved among these proteins, three such 
residues, N349, H399 and Y408 (pneumococcal sequence annotation) will be shown to 
be critical for enzyme function in section 1.7.11, below. This section describes how 
structural studies of pneumococcal hyaluronate lyase have helped elucidate the roles of 
certain residues in the catalytic mechanism o f these enzymes.
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1.7.10 -  First characterisation of hyaluronate lyase from the pneumococcus
The locus encoding the pneumococcal hyaluronate lyase was initially described by 
Berry et al.. (Berry et al,. 1994). Using a crude hyaluronate lyase preparation they 
generated polyclonal mouse antisera, with which they isolated the region harbouring the 
hyl locus from a cosmid library expressing in E. coli. Using a combination of restriction 
digestion and hyaluronate lyase assays (a description o f commonly used assays for 
hyaluronate degradation is given in section 1.8.2.1, below), the region purported to 
contain the hyl locus was subcloned and its sequence derived. This was deposited in the 
Genbank database under the accession number L20670.
Their open reading frame o f 2849 bp encodes a 949 amino acid protein. A strong 
candidate for a rho-independent transcription terminator was defined about 100 bp 3’ to 
the suggested stop codon. However, poor -35, -10 and ribosome binding elements 
suggested that the transcriptional start point of the gene was ill defined. This issue will be 
returned to in section 1.8.6, below.
Expression of the subcloned region in E. coli, and subsequent Western analysis 
indicated that the protein was subject to proteolytic cleavage in the E. coli host system, as 
well as translation from an alternative start codon 489 bp 3’ to the predicted start codon. 
This was not seen in S. pneumoniae.
Leaving the nature of the N-terminus of the protein due to the uncertain nature of the 
assigned promoter elements, the C-terminus contains an excellent candidate for a Gram 
positive cell surface anchor motif. This motif consists o f  a hexapeptide with the 
consensus LPXTG(E) (in this case, LPQTGE) which becomes covalently attached to the 
stem peptide moiety o f cell wall peptidoglycan. This is followed by a stretch of 
hydrophobic amino acids, which traverse the cell membrane. The terminal structure is a 
cluster of basic residues which remains associated with the cytoplasm (Navarre and 
Schneewind, 1999). This strongly suggests that the pneumococcal hyaluronate lyase is 
associated with the cell-wall.
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1.7.11 — Pneumococcal hyaluronate lyase-crystal structure and catalytic 
mechanism
The earliest indications o f which residues might be employed at the catalytic centre of 
bacterial hyaluronate lyases came from the work of Lin, Averett and Pritchard. Using site 
directed mutagenesis techniques in S. agalactiae, they demonstrated that a key histidine 
residue is vital for enzymatic activity (Lin et al,. 1997). This residue corresponds to the 
histidine shown in red in figure 1.6.
During the past 2-3 years the structural biology group o f  Mark Jedrzejas have been 
interested in elucidating the crystal structure and catalytic mechanism of pneumococcal 
hyaluronate lyase. These efforts have culminated in detailed crystal structures, resolved 
to 1.56A in the absence of substrate, and 1.7 A in the presence HA disaccharide repeat 
units (Jedrzejas et al,. 1988, Li et al,. 2000, Ponnuraj and Jedrzejas, 2000). Their 
proposed catalytic mechanism is supported circumstantially by the conservation of key 
residues within this class of enzyme (as described above) and by site-directed 
mutagenesis studies. Their work is summarised as follows:
Their earliest attempts at crystallising the protein resulted in stability problems, and 
lead them to adopt a strategy where the expressed protein was truncated, lacking the N- 
terminal 163 residues (from the sequence deposited under the accession number L20670) 
(Berry et al,. 1994, Jedrzejas et al,. 1988). Subsequent work with this truncated construct 
resulted in the derivation o f stable crystals, and high resolution analysis o f the structure. 
The protein was shown to consist of 2 structural domains, an N-terminal a-helical region 
and a C-terminal P-sheet rich domain, with a prominent cleft between them. The overall 
dimensions of the protein are 59 X 59 X 88 A. These features are shown in figure 1.7.
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Figure 1.7 -  Domain structure of pneumococcal hyaluronate lyase. A: Ribbon 
diagram o f the a-domain, B: Ribbon diagram o f the P-domain, C: Surface electrostatic 
map o f the complete crystal structure. Positive charges are indicated in blue, negative in 
red. Both images are taken from the paper of Li et al. (Li et al,. 2000).
The structure revealed in this analysis shows several key features; The P-domain 
consists of a 4-layered sandwich, and is not thought to contribute significantly to 
catalysis. The function of this domain is suggested to be the modulation o f catalytic 
activity upon binding small molecules or cations, such as Ca2+ (Li et al,. 2000).
The a-domain contains the catalytic residues and has the conformation of a twisted 
aJa barrel. There are also some structures which partially occlude the cleft between the 
domains in the region of the linker peptide. This feature will be returned to below.
The cleft itself binds the HA molecule and contains 4 key features; a positively 
charged region, responsible for primary interaction with its polyanionic substrate. A
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patch of aromatic residues interacts with a stretch of C-H features on the substrate 
molecule (distributed over three successive sugar rings). Modelling of the substrate into 
the cleft suggests that this patch is required for accurately positioning the substrate such 
that the glycosidic bond to be cleaved is selected and held in the appropriate position at 
the active site. The third key region is the active site itself, and is described below. The 
fourth region is a small negatively charged region, which lies at the ‘post-catalytic’ end 
of the cleft. This may be required for electrostatic repulsion of the disaccharide product 
after it is cleaved from the rest of the HA chain.
The mechanism of catalysis is thought to involve a number of residues, and 
interactions between the enzyme and substrate, however this description will be limited 
to the roles of three key residues, N349, H399 and Y408. Their term for the type of 
reaction shown is ‘Proton Acceptance and Donation’ or PAD.
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A: The HA molecule is immobilised in the 
active site by interaction with the positive 
and hydrophobic elements of the cleft. 
Interaction of N349 with the carboxyl moiety 
of the glucuronic acid residue renders the C5 
proton of this sugar more acidic. This 
facilitates abstraction of the CS proton by 
H399. The hydroxyl component of Y408 
hydrogen bonds with the glycosidic oxygen.
B: Loss of the GlcUA C5 proton liberates an 
electron pair, which form a n bond over the 
C4-C5 a  bond. Y408 acts as a proton pump, 
losing its hydrogen atom to the glycosidic 
bond, which is broken as the proton is 
accepted by the glycosidic oxygen atom.
c
N 349
D
N 344
A
o o
— -u*
> A  .
H Ç
H 3*»
C: Cleavage is complete, leaving the GlcUA- 
R' species as a leaving group. Removal of 
this product from the cleavage centre may be 
facilitated by the negative patch of the cleft.
D: The catalytic H399 and Y408 residues re­
equilibrate with their micro-environment, 
ready for the next round of catalysis.
Figure 1.8 -  Reaction catalysed at the catalytic centre of pneumococcal hyaluronate 
lyase. This figure is adapted from et al. (Li et al,. 2000), with some elaborations. Key 
electron pair transitions are indicated by double headed red arrows.
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Figure 1.8 describes the catalytic mechanism proposed by Li el al. The stabilisation 
of the substrate by N349 is brought about by hydrogen bonding via environmental water 
molecules. This has an electron withdrawing effect on the GlcUA C5 atom. Not unlike 
the ruse o f a pickpocket, while the ‘attention’ o f the C5 atom is diverted by N349, H399 
is able to remove the proton from the other plane of the molecule. This unusual 
mechanism neatly explains the sequence of events which take place thereafter, leaving 
the novel unsaturated disaccharide product.
The absolute conservation o f N349, H399 and Y408 across this group of enzymes 
supports their hypothesis, however, site directed mutagenesis approaches were taken to 
confirm and evaluate catalytic attenuation. N349A, H399A and Y408F mutants showed 
6, 12 and 0% of wild type activity. The residual activity o f the H399A mutation was 
attributed to the remaining function of N349 in making the GlcUA C5 carbon more 
acidic, allowing its proton to be lost without having a specific residue being reduced.
One or two implications for the evolution of these enzymes have also arisen from the 
structural work described above; The ability o f bacteria to degrade GAG’s of higher 
organisms clearly affords them a toehold towards pathogenesis, and both groups of 
organisms degrade HA via quite different means. The striking difference in the 
mechanism of HA degradation between these classes o f organisms may reflect the 
evolutionary pressure o f such competition, and the higher specific activity o f the bacterial 
enzymes may indicate their ‘response’ to the barrier functions of mammalian HA 
turnover (Li el al,. 2000).
Another interesting point concerns the relationship of the pneumococcal hyaluronate 
lyase fold structure to other degradative enzymes. The barrel structure of the a-domain 
resembles structures seen in glycoamylase and alginate lyase, and the complete structure 
(as determined by the authors) bears striking resemblance to that o f  chondroitin AC lyase 
from Flavobaclerium heparinum (although the latter enzyme has a wider opening to the 
cleft, which almost certainly accounts for its wider substrate specificity (Fethiere el al., 
1999)). The implication being that the structure and function of the pneumococcal 
enzyme may provide a paradigm for those o f other proteins involved in the degradation 
of simple and complex polysaccharide substrates. It will be interesting to see whether the 
PAD mechanism o f catalysis manifests itself in other degradative systems.
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1.8 -  The work presented in this thesis -  brief rationale and methodology
An outline of the aims and approaches taken in this body of work are briefly 
described below. A broader explanation o f the basis of each area of investigation is given 
at the beginning of each major section within chapter 3.
1.8.1 -  Variation at the locus encoding hyaluronate lyase, hyl
As described in section 1.3.2, numerous pneumococcal genes are known to evolve by 
recombination between homologous stretches of DNA. This will be of interest in 
addressing the nature of the evolution of pneumococcal hyaluronate lyase. Also, 
consideration of Hyl as a candidate for inclusion in next generation polysaccharide 
conjugate vaccines must necessarily include an appraisal o f  the genetic, and potentially 
antigenic variation at the hyl locus.
As such it is necessary to analyse the hyl locus from a wide range of strains, which 
differ in geographic and clinical sites o f isolation, serotype and year of isolation, to 
ensure that a sample is taken which is representative of the population as a whole.
The approach taken in our laboratory to conduct sequence variation analyses using a 
large number of strains is that of High Resolution Restriction Analysis (HRRA), 
sometimes referred to as Restriction Fragment Length Polymorphism analysis (RFLP).
This technique is described in detail in chapter 2, section 2.2.1. In brief, it enables the 
identification of distinct allelic variants and the analysis o f  large numbers of individual 
loci without the economic burden of sequencing the entire locus. The ‘window’ of the 
restriction endonuclease recognition footprint along with a statistical inference algorithm 
can be used to estimate the overall percentage divergence between loci with different 
restriction digest profiles. Representative alleles of key restriction profiles are then 
characterised by direct sequence analysis.
Previous studies have focused on the distribution of genes within members o f clonal 
groups o f pneumococci specifically associated with disease (Coffey el al,. 1991, Sibold el 
al,. 1992, Enright and Spratt, 1998). A recent study has addressed the occurrence of 
strains with identical genetic backgrounds in invasive disease and carriage,
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and shown that members o f clones frequently associated with invasive disease are also 
found in the carried state (Muller-Graf et al,. 1999). A similar analysis was undertaken in 
the work described here to investigate the potential association of particular hyl allelic 
variants with carriage, incidence of pneumonia, meningitis, septicaemia and otitis media. 
This section also describes screening for homologous genes in other streptococci.
1.8.2 -  Phenotypic analysis of hyaluronate lyase production
In 1995 Kostyukova et al. published work which implied that hyaluronate lyase 
activity from strains isolated from the cerebrospinal fluid (CSF) of meningitis patients 
was significantly higher than that of strains isolated from asymptomatic carriers of S. 
pneumoniae, indicating a relationship between hyaluronate lyase phenotype and site of 
isolation (Kostyukova et al,. 1995). However, it was not clear from this work whether 
any rigorous attempts had been made to exclude large numbers of clonally derived 
isolates from their sample. Indeed, the invasive isolates were collected from a paediatric 
clinical environment, just the sort of setting one might be expected to find predominant 
pneumococcal clones (see section 1.4). It was therefore decided to re-investigate the 
relative activity of hyaluronate lyase using strains from a wide range of disease types and 
carriage, with an emphasis placed on avoiding multiple samples of clonal isolates during 
collection of the strains to be assayed.
The analysis o f phenotype requires the use o f the appropriate assay(s). The section 
below describes the methods that are commonly available.
1.8.2.1 -Hyaluronate lyase assays
These measure either a decrease in the concentration of substrate, or an increase in 
the concentration digest products. The key assays available are described below.
One of the earliest assays used to determine the concentration o f hyaluronic acid is based 
on the highly viscous nature of hyaluronic acid solutions (Hass, 1946). Changes in the 
viscosity of such solutions is indicative of the conversion o f high molecular weight 
hyaluronic acid polymers to the shorter oligosaccahrides, tetrasaccharides and
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disaccharides which result from the action of the various hyaluronidases. This assay was 
successfully used for a time, but has been described as a process which is ‘tedious, time 
consuming, and requires large amounts of hyaluronic acid’ (Dorfman and Ott, 1947).
Another early assay is the mucin clot formation prevention assay. It was shown by 
(McClean and Hale, 1941) that, in the presence of albumin, hyaluronic acid precipitates 
out of solution upon acidification forming a visible clot. The enzymatic degradation of 
hyaluronic acid prior to performing this reaction prevents the formation of this clot, and 
was used as a method for the estimation of hyaluronate lyase activity.
This method was modified in the turbidimetric method o f Seastone and Kass 
(Seastone, 1939, Kass and Seastone, 1944), who found the viscosity measurement assay 
‘inconvenient’. They demonstrated that clot formation was preceded by the formation of 
a turbid suspension upon addition of a limiting amount of hyaluronate lyase to 
albumin/hyaluronate solutions prior to acidification. However this method has a number 
of drawbacks; it is not highly quantitative between experiments, it is effective over a 
limited concentration range, and the observation that some hyaluronate preparations 
require pre-digestion with bovine testicular hyaluronidase in order to form the desired 
characteristic turbid suspension.
The hyaluronic acid determination assays described above were originally used in the 
investigation of mammalian hyaluronic acid and hyaluronidases. Precipitation of 
acidified hyaluronate was also used as the basis of the plate assay of Smith and Willet 
(Smith and Willet, 1968), who were specifically interested in the production o f bacterial 
glycosidases. In their assay, hyaluronic acid and bovine serum albumin (BSA) were 
incorporated into agar plates, on which various cultures of micro-organisms were grown. 
After growth and expression of the bacterial hyaluronate lyases, the plates were flooded 
with acetic acid. The high molecular hyaluronic acid/albumin complexes were 
precipitated, leading to an opaque or cloudy appearance. Around some colonies, clear 
zones were seen. This was taken to indicate that the hyaluronic acid was degraded by 
soluble bacterial hyaluronate lyases. The relative sizes of the zones of clearance could be 
taken as a measure o f the relative amount of enzyme produced, although it could also 
reflect the different solubility characteristics of different hyaluronate lyases.
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During the early stages of this work, this assay was considered. However, after 
discussion with collaborators working in a related field (K. Homer and D. Beighton, 
personal communication), it was decided that this assay would not be appropriate. The 
work done by Homer and Beighton with S. intermedius showed the assay to have a 
number of drawbacks, of which two were seen to be significant: Strains which were 
hyaluronate lyase positive in the ‘Stains-alP assay (described below) were only weakly 
positive in the plate assay. Also, as the technique requires co-precipitation of hyaluronic 
acid with BSA, the degradation o f  the latter by proteases would also lead to a positive 
result. Hence hyaluronate lyase activity could be masked by the activity of other bacterial 
enzymes. This lack of assay specificity was considered to be undesirable.
Levy and McAUan demonstrated that it was possible to measure the concentration of 
acetylated hexosamines in a colourimetric reaction with 4-(N,N-dimethylamino)- 
benzaldehyde (Levy and Me Allan, 1959). This assay has been used to measure the 
activity o f streptococcal glycosidases by measuring the accumulation of digest products 
(Homer et al., 1994) and was shortlisted as a suitable assay for use in the work described 
here.
Benchetrit and co workers described a quite different type of assay (Benehetrit et al., 
1977). Theirs was a colourimetric assay based on thiazolium compound l-ethyl-2-[3-(l- 
ethylnaptho[ 1,2c/]thiazolin-2-ylidine)-2-methylpropenyl]naptho[ 1,2c/]thiazolium bromide 
(marketed by Sigma-Aldrich Chemicals as ‘Stains-all’).
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Figure 1.9 -  Chemical structure of l-ethyl-2-[3-(l-ethylnaptho[l,2</|thiazolin-2- 
ylidine)-2-methylpropenyl]naptho|l,2</lthiazolium bromide (‘Stains-all’).
This is a carbocyanine dye, which interacts specifically with hyaluronic acid to give 
rise to a characteristic absorbance peak in the visible spectrum (650nm). This is seen as a 
change in colour o f the solution from deep purple to blue, and can be measured 
spectrophotometricaly. This interaction is specific for high molecular weight hyaluronic 
acid, and not the products of digestion by hyaluronate lyase, making it possible to 
monitor the degradation of substrate in hyaluronate lyase assays.
Another assay for hyaluronate lyase activity was described by Pritchard and co­
workers (Pritchard et al., 1994). This assay is based on the formation of an unsaturated 
disaccharide as a major product of hyaluronate digestion by the bacterial hyaluronate 
lyases (see section 1.7.9). The jr bond at the 4-5 position o f the glucuronic acid moiety of 
the disaccharide leads to detectable absorbance in the U.V/vis spectrum. The assay 
described here is based on increased absorbance at 232nm as the hyaluronate lyase 
reaction proceeds. This is depicted in figure 1.10.
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Figure 1.10- Structure of the disaccharide produced by pneumococcal 
hyaluronidase, a derivative of N-acetylhyalobiuronic acid. Note the presence of the pi 
bond in the glucuronic acid moiety.
This assay has the advantage that it is straightforward to perform, on readily 
available equipment, and it can be performed without the introduction of costly reagents.
1.8.3 -  Hyaluronate lyase knockout mutagenesis
The aim of this area of work is to establish that hyaluronate degradation by the 
pneumococcus is solely attributable to the action of hyaluronate lyase, and that there is no 
functional redundancy with regard to this activity.
The analysis o f a naturally occurring deletion mutant is undertaken, as well as the 
construction of a defined mutant by interposon mutagenesis.
This feeds into the next section, which is specifically concerned with the ability of 
pneumococci to grow on HA as a sole carbon source.
1.8.4 -  HA utilisation by £  pneumoniae
Hyaluronidases and hyaluronate lyases are traditionally considered to act as spreading 
factors, and thus contribute to pathogenesis. Since HA is a potentially rich carbon source 
and is in abundance in those sites at which the pneumococcus is found, it is tempting to
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speculate that hyaluronate lyase might contribute to pathogenesis by providing the 
pneumococcus with a valuable source of metabolisable carbon.
This is analysed using chemically defined media, to which various carbon sources 
have been added. The results of these enquiries are given in chapter 3, section 3.4.
1.8.5 -  Effect of capsule on hyaluronate lyase phenotype
As mentioned in section 1.5.1, variation in the amount of capsule produced by the 
pneumococcus potentiates its response to the host in different environments (being 
inhibitory to both adhesion and phagocytosis). The manner in which hyaluronate lyase 
production fits into this process of variation. Selection o f acapsular mutants was achieved 
using a bio film growth model.
1.8.6 -  Hyaluronate lyase -  upstream sequence elements
As indicated in section 1.7.10, the hyaluronate lyase sequence as described by Berry 
et al. is very likely to be incomplete at its 5’ extremity (Berry el al., 1994). At least three 
lines o f evidence support this. The first is the unsatisfactory nature of the ascribed 
promoter elements, the -35 and -10 sequences are divergent from the consensus 
sequences of these elements, and the Shine-Dalgamo sequence consists of a single pair of 
guanine residues. On the other hand, there is a C-terminal anchor motif in the hyl 
translation product which matches the consensus for this motif perfectly. The strong 
indication that this is a protein which is cell surface expressed, for at least some of the 
time, then requires that the protein possess some means of trafficking to this location. 
This would normally be in the form of a Gram positive N-terminal signal sequence. Such 
a feature is not present in the sequence as given.
The third indication that the Berry sequence is incomplete comes from the discovery 
by Gase et al. that the related enzyme, from S. agalacliae is indeed longer than was 
previously thought, and shows the features of a classical N-terminal cleaveable signal 
sequence (Gase et al., 1998).
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2.1 -  Materials
2.1.1 - Growth Media
Liquid cultures of S. pneumoniae were grown in either BHI (brain heart infusion) 
broth or pneumococcal C-Medium. BHI (Difco) was made up in dH20  at 37g l'1.
C-medium is derived from the original formulation of Lacks el al. (Lacks and 
Hotchkiss 1960). Cultures were grown at 37°C without shaking.
C-Medium
Pre-C; 160ml
Supplement; 5.2ml
Glutamine [5mgmr']; 0.8ml
AdamsIII; 4ml
Pyruvate (2%w/v); 2ml
Phosphate buffer [1M]; 6ml
Yeast Extract (5%w/v); 3.6ml
Filter sterilised prior to storage at 4°C.
Composition o f the individual components;
ElfcC
Sodium acetate (anhydrous); 1.23 g l'1
Casamino Acids (Difco -  Vitamin free, acid hydrolysed); 5 g l'1
L-Tryptophan; 5 g l'1
L-Cysteine 50 mg l'1
pH titrated to 7.4-7.6 with 10M NaOH
Supplement
3 in 1 Salts; 15ml 
Glucose (20% w/v); 30ml 
Sucrose (50% w/v); 1.5ml 
Adenosine [2mgmr']; 15ml 
Uridine [2 mgml'1]; 15ml
3 in 1 Salts
MgCl2.6H20 ;  100 g f ‘
CaCl2 (anhydrous); 500 mg l'1 
CaCl2.2H20 ;  660 mg f 1 
MnS04.4H20  [0.1M]; 0.2 ml l'1
Phosphate Buffer (gives final pH = 8.0)
KH2P04 [1M]; 26.5ml 
K2HP04 [1M]; 473.5ml
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Adams III 
Adams I; 48ml 
Adams II; 12ml 
Asparagine; 600mg 
Choline chloride; 60mg 
CaCl2 [0.1M]; 480pl
Adams II
FeS04.7H20 ; 500mg l*1 
CuS04.5H20 ; 500mg 11 
ZnSQ*.7H20 ; 500mg l 1 
MnCl2.4H20 ; 200mg l 1
Adams I
Biotin [2mg ml'1]; 7.5pl 
Nicotinic acid; ISmg 
Pyridoxine hydrochloride; 17.5mg 
Calcium pantothenate; 60mg 
Thiamine hydrochloride; 16mg 
Riboflavin; 7mg
All solutions were filter sterilised and stored at 4°C.
Modified C-Medium
The experiments described in chapter 3, section 3.4 involve the use of C-medium 
containing defined carbohydrates. For this, the components were used as described 
above, with the exception that supplement was made without glucose or sucrose, but 
contained either no additional carbohydrate, or HA, GlcNAc, GlcUA or glucose added 
to 0.5mg ml'1 (molar equivalents were not used as the experiments were qualitative 
rather than quantitative).
E.coli was cultured in LB (Luria-Bertani) medium. Liquid cultures were incubated 
at 37°C with shaking at 220rpm.
LB Medium
Tryptone; lOg l'1 
Yeast extract; 5g f'
NaCl; lOgT'
pH adjusted to 7 with 5N NaOH 
Solid media
S. pneumoniae was grown on BHl/blood agar (14.8g agar (Becton-Dickinson 
Microbiology Systems) per 1BHI) supplemented with 20ml sterile defibrinated sheep 
blood (TCS Microbiology). E.coli was cultured on LB agar (14.8g agar per 1 LB). 
Plates were incubated at 37°C under 5%C02/95% atmospheric air.
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Antibiotic selection
Selection was made on chloramphenicol (crm) at a concentration of 30|ig ml'1 for 
E. coli and 5pg ml'1 for S. pneumoniae.
2.1.2 Pneumococcal Strains
The pneumococcal strains used in these studies are listed in table 2.1, with 
information given where available. All strains are stored in BHl/Glycerol (15%v/v) at 
-80°C. Temporal distibution, country/site of isolation and serotype were varied to 
select against the inclusion of multiple clonal isolates. REP PCR was employed to 
confirm that strains were genotypically distinct, giving rise to diverse band patterns
(data not shown).
Strain Strain ID Serotype Country Year Site of 
Isolation
R6 359 ns* USA Ca. 1930 CSF
141928 885 1 Kenya 1991 Throat
12B-13E 922 3 (UK)Oxford 1994 Throat
12B-24G 948 4 (UK)Oxford 1994 Throat
142144 889 5 Kenya 1990 Throat
I2B-10E 914 6A (UK)Oxford 1994 Throat
13B-I6K 949 6A (UK)Oxford 1995 Throat
12B-I8G 954 6B (UK)Oxford 1994 Throat
I2B-IIF 956 6B (UK)Oxford 1994 Throat
86013 873 8 Kenya 1990 Throat
86033 877 9L Kenya 1990 Throat
12B-4D 965 9N (UK)Oxford 1994 Throat
2248 864 9V Kenya 1990 Throat
141926 884 10A Kenya 1991 Throat
12B-7C 902 I0A (UKKbtford 1994 Throat
86034 878 10F Kenya 1990 Throat
132209 882 10F Kenya 1990 Throat
13B-27J 903 11A (UK)Oxford 1995 Throat
85999 869 12F Kenya 1990 Throat
100497 880 13 Kenya 1990 Throat
55610 862 14 Kenya 1991 Throat
I3B-22J 904 14 (UK)Oxford 1995 Throat
86003 872 I5A Kenya 1990 Throat
I2B-28G 905 I5A (UKXJxford 1995 Throat
I2B-2IE 901 I5B (UK)Oxford 1994 Throat
12B-4F 906 I5C (UK)Oxford 1994 Throat
86029 875 16F Kenya 1990 Throat
I3B-23C 907 16F (UK)Oxford 1995 Throat
55616 863 17F Kenya 1991 Throat
12B-34C 908 17F (UK)Oxford 1995 Throat
86030 876 I8A Kenya 1990 Throat
86002 871 18C Kenya 1990 Throat
12B-33B 909 I8C (UK)Oxford 1995 Throat
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I2B-33B 909 18C (UK)Oxford 1995 Throat
I3B-15F 910 19A (UK)Oxford 1995 Throat
I3B-I2L 911 I9F (UK)Oxford 1995 Throat
I2B-I0D 913 19F (UK)Oxford 1994 Throat
13B-8K 916 20 (UK)Oxford 1995 Throat
I2B-111 917 21 (UK)Oxford 1994 Throat
12B-I1H 957 21 (UK)Oxford 1994 Throat
13B-7I 918 22F (UK)Oxford 1995 Throat
I2B-25C 952 22F (UK)Oxford 1994 Throat
I3B-9C 943 23A (UK)Oxford 1995 Throat
29636 861 23B Kenya 1991 Throat
I2B-23I 919 23F (UK)Oxford 1994 Throat
12B-I4C 921 23F (UK)Oxford 1994 Throat
I2B-8J 923 23F (UK)Oxford 1994 Throat
85991 866 25 Kenya 1990 Throat
85994 867 29 Kenya 1990 Throat
100493 879 32A Kenya 1990 Throat
I3B-1IJ 945 33F (UK)Oxford 1995 Throat
I2B-5L 967 35F (UK)Oxford 1994 Throat
12B-21H 946 37 (UK)Oxford 1994 Throat
I2B-28J 947 38 (UK)Oxford 1995 Throat
E/226 355 14 Uruguay 1995 Blood
619 53 1 Spain 1987 Vagina
141950 322 3 Kenya 1991/92 Sputum
102 393 4 - - -
964 39 4 Spain 1988/89 Blood
NSM2 187 - Spain 1989 Sputum
GMI33 168 6 Spain 1989 Wound
GM134 169 6 Spain 1989 Wound
4880/89 194 6B Spain 1989 Eye
132206 312 7 Kenya 1991/92 Sputum
142145 339 7 Kenya 1991/92 Sputum
GM62 123 7 Spain 1988/89 LRT
555 31 8 Spain 1988/89 Blood
GM21 91 8 Spain 1988/89 Blood
85983 310 9 Kenya 1991/92 Pemasal
181 3 9V Poland 1994/95 Throat
142163 324 10 Kenya 1991/92 Blood
GMI4 87 10 Spain 1988/89 Blood
142162 329 10 Kenya 1991/92 Blood
86007 303 11 Kenya 1991/92 Blood
GM39 103 11 Spain 1988/89 LRT
142154 326 12 Kenya 1991/92 Blood
132217 340 12 Kenya 1991/92 Blood
549 30 13 Spain 1988/89 Blood
651 59 13 Spain 1988 Ear
4473/90 200 - Spain 1990 Blood
7447/90 201 - Spain 1990 Blood
9058/90 213 - Spain 1990 Ear
8547/93 231 - Spain 1993 Peritoneal
Fluid
544 28 15 Spain 1988/89 Sputum
1677/94 237 . Spain 1994 Eye
100494 308 16 Kenya 1991/92 Sputum
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631 56 16 Spain 1987 Vagina
100496 319 16 Kenya 1991/92 Sputum
GMI23 162 17 Spain 1988/89 LRT
100522 321 18 Kenya 1991/92 Blood
GMI 75 18 Spain 1988/89 Blood
132224 327 18 Kenya 1991/92 Blood
86012 307 19 Kenya 1991/92 Throat
521 26 19 Spain 1988/89 Sputum
85997 315 19 Kenya 1991/92 Sputum
141954 333 20 Kenya 1991/92 Blood
GM122 161 20 Spain 1988/89 Blood
4875/89 256 “ Spain 1989 Peritoneal
Fluid
GM66 125 21 Spain 1988/89 Other
100520 318 23 Kenya 1991/92 Blood
GM67 126 23 Spain 1988/89 Blood
E/208 352 23F Uruguay 1994 Pleural
Fluid
18/10/71 379 24 Papua 1971 -
GMI 20 159 34 Spain 1988/89 Other
7026/70 392 35 - - -
GM92 145 3 Spain 1988/89 Blood
II0K/70 381 42 Papua 1970
PN TY P E 45 398 45 UK - -
WU2 470 3 UK 1995 -
she 15 485 3 UK 1995 -
shelO 483 3 UK 1995 Ear
too6 481 3 UK 1995 Ear
gbo5 476 3 UK 1995 -
pn3 472 3 UK 1995 -
SPOI 471 3 UK 1995 -
ply ' 9 492 3 UK 1995 Ear
ply 12 490 3 UK 1995 Ear
newl 489 3 UK 1995 -
wollO 487 3 UK 1995 -
sto8 482 3 UK 1995 Ear
por4 480 3 UK 1995 Ear
nor 16 479 3 UK 1995 Ear
lei 17 478 3 UK 1995 Ear
Iei29 477 3 UK 1995 Ear
lei 17 475 3 UK 1995 Ear
she23 473 3 UK 1995 -
mid2 466 3 UK 1995 Ear
D39 1001 3 UK 1995 -
Ply22 474 3 UK 1995 Ear
0100993 860 3 UK 1995 -
gui5 491 3 UK 1995 Ear
141950 322 3 Kenya 1991 Blood
Iivl4 494 3 UK 1995 -
409 495 3 UK 1993 Horse
7731 496 3 UK 1992 Horse
600142 497 3 UK 1996 Horse
3307 498 3 UK 1992 Horse
4826 499 3 UK 1992 Horse
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5530 501 3 UK 1992 Horse
21.2 502 3 UK 1992 Horse
5 503 3 Ireland 1987 Horse
15 504 3 Ireland 1987 Horse
17 505 3 Ireland 1987 Horse
Table 2.1 -  Strains used in genetic analysis.
*ns = non-serotypable (acapsular).
Strain Strain ID Serotype Country Year Site of 
Isolation
792 36 - Spain 1989 Blood
GM5 77 - Spain 1989 Blood
GM8 81 15 Spain 1989 Blood
GM43 107 16 Spain 1989 Blood
GM47 n o 13 Spain 1989 Blood
GM57 116 14 Spain 1989 Blood
GM58 117 II Spain 1989 Blood
85997 314 14 Kenya 1992 Blood
E206 342 14 Uruguay 1994 Blood
E213 353 6B Uruguay 1994 Blood
E228 354 6B Uruguay 1994 Blood
Table 2.2 - Additional blood isolates used in phenotypic analysis.
Strain Strain ID Serotype Country Year Site of 
Isolation
GM131 166 4 Spain 1989 LRT
GM132 167 13 Spain 1989 LRT
159 432 16 - 1994 Sputum
85990 304 19 Kenya 1992 Sputum
GMI08 154 3 Spain 1989 LRT
GM145 176 23 Spain 1989 LRT
100509 301 14 Kenya 1992 Sputum
100506 317 14 Kenya 1992 Sputum
norl 467 3 UK 1995 Sputum
ash 468 3 UK 1995 Sputum
484 27 6 Spain 1989 Sputum
1177 44 9 Spain 1989 Sputum
1182 45 14 Spain 1989 Sputum
1183 46 6 Spain 1989 Sputum
GM42 106 9 Spain 1989 Sputum
GM84 139 6 Spain 1989 Sputum
GMI24 163 14 Spain 1989 Sputum
Table 2.3 - Additional lung isolates used in phenotypic analysis.
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Strain Strain ID Serotype Country Year Site of 
isolation
664 63 6B Spain 1986 Ear
48/90 197 - Spain 1990 Ear
1139/89 192 - Spain 1989 Ear
273 10 14 Poland 1995 Ear
667 65 23 Spain 1988 Ear
630 55 r i6 Spain 1987 Ear
El 59 347 14 Uruguay 1994 Ear
ply 19 492 - UK 1995 Ear
7597 425 - - 1994 Ear
68961 430 - - 1994 Ear
5408 428 - - 1994 Ear
Table 2.4 - Additional otitis isolates used in phenotypic analysis.
Strain Strain ID Serotype Country Year Site of 
Isolation
- 1795 23F Poland - CSF
- 1796 14 Poland - CSF
- 1797 38 Poland - CSF
- 1798 31 Poland - CSF
- 1799 I8B Poland - CSF
- 1800 4 Poland - CSF
- 1801 1 Poland - CSF
- 1802 14 Poland - CSF
- 1803 35B Poland - CSF
- 1804 9N Poland - CSF
- 1805 I9F Poland - CSF
- 1806 11A Poland - CSF
- 1807 12F Poland - CSF
- 1808 A Poland - CSF
- 1809 16F Poland - CSF
- 1810 2 Poland 1996 CSF
. 1811 1 Poland 1996 CSF
- 1812 2 Poland 1996 CSF
- 1813 I8C Poland 1996 CSF
- 1814 9V Poland 1996 CSF
- 1815 19A Poland 1996 CSF
- 1816 3 Poland 1996 CSF
- 1817 7F Poland 1996 CSF
- 1818 1 Poland 1996 CSF
- 1819 3 Poland 1996 CSF
- 1820 9N Poland 1996 CSF
- 1821 4 Poland 1996 CSF
- 1822 1 Poland 1996 CSF
- 1823 14 Poland 1996 CSF
- 1824 7F Poland 1996 CSF
- 1825 12F Poland 1996 CSF
. 1826 1 Poland 1996 CSF
. 1827 22F Poland 1996 CSF
- 1828 I2F Poland 1996 CSF
- 1829 9 V Poland 1996 CSF
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- 1830 6B Poland 1997 CSF
- 1831 I5C Poland 1997 CSF
- 1832 1 Poland 1997 CSF
- 1833 8 Poland 1997 CSF
- 1834 23 F Poland 1997 CSF
- 1835 6B Poland 1997 CSF
- 1836 7F Poland 1997 CSF
- 1837 33F Poland 1997 CSF
- 1838 8 Poland 1997 CSF
- 1839 8 Poland 1997 CSF
- 1840 22 F Poland 1997 CSF
- 1841 34 Poland 1997 CSF
- 1842 3 Poland 1997 CSF
- 1843 I8C Poland 1997 CSF
- 1844 23F Poland 1997 CSF
- 1845 23F Poland 1997 CSF
- 1846 - Poland 1997 CSF
- 1847 - Poland 1997 CSF
- 1848 - Poland 1997 CSF
- 1849 - Poland 1997 CSF
- 1850 - Poland 1997 CSF
- 1851 - Poland 1997 CSF
- 1852 - Poland 1997 CSF
- 1853 - Poland 1998 CSF
- 1854 - Poland 1998 CSF
- 1856 - Poland 1998 CSF
- 1857 - Poland 1998 CSF
- 1858 - Poland 1998 CSF
- 1859 - Poland 1998 CSF
- I860 - Poland 1998 CSF
- 1861 - Poland 1998 CSF
- 1862 - Poland 1998 CSF
- 1863 - Poland 1998 CSF
- 1864 - Poland 1998 CSF
- 1865 - Poland 1998 CSF
- 1866 - Poland 1998 CSF
- 1867 - Poland 1998 CSF
- 1868 - Poland 1998 CSF
Table 2.5 - Additional meningitis isolates used in phenotypic analysis.
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Strain Strain ID Other Name Species Group* Site of Isolation
Col 1 667 PN92/1207 S. pneumoniae na
Col 3 668 PN92/944 S. pneumoniae A Eye
Col 5 669 PN93/832 S. pneumoniae Blood
Col 6 670 PN93/779 S. pneumoniae A Blood
Col 7 671 PN93/356 S. pneumoniae A URT1
Col 8 672 PN93/707 S. pneumoniae A Sputum
Col 9 673 PN93/904 S. pneumoniae A Blood
Col 11 674 PN93/688 S. pneumoniae A CSF3
Col 12 675 PN93/950 S. pneumoniae A Blood
Col 13 676 na na na
Col 14 677 PN93/789 S. pneumoniae A Blood
Col 15 678 PN92/1139 S. mitis B Sputum
Col 16 679 PN93/952 Streptococcus sp. B LRT3
Col 17 680 PN91/2745 Streptococcus sp. na
Col 18 681 PN93/454 Streptococcus sp. B Sputum
Col 19 682 PN93/800 S. oralis B Blood
Col 20 683 PN93/776 Streptococcus sp. B na
Col 21 684 PN93/447 Streptococcus sp. C Eye
Col 22 685 PN93/1264 Streptococcus sp. B na
Col 24 686 PN93/656 Streptococcus sp. Sputum
Col 25 687 PN93/1003 S. oralis C Blood
Col 26 688 PN93/403 Streptococcus sp. Synovial fluid
Col 27 689 PN93/I35 Streptococcus sp. Sputum
Col 28 690 PN93/918 Streptococcus sp. B Sputum
Table 2.6 -  Additional streptococci used. * as defined in Whatmore et al. 
(Whatmore et al., 2000), 1; URT -upper respiratory tract, 2; CSF -  cerebrospinal 
fluid, 3; LRT -  lower respiratory tract, na = data not available.
2.1.3 - EL coli Strains
Recombinant plasmids were maintained in E. coli JM109 (Yanisch-Perron et al., 
1985). This strain has the genotype endAl, recAl, gyrA96, thi, hsdR17, (rk\ n O , 
relAl, supE44, A(Iac-proAB), [F\ traD36, proAB, lacf*ZAM15].
2.1.4 -  Plasmids used
Molecular cloning was routinely carried out using either the pGEM-T™ TA 
cloning vector (Promega Corp.) or pUC18 (Yanisch-Perron et al., 1985). Further 
plasmid constructs used in the generation of a HyTrCrm* mutant (see chapter 3, 
section 3.4.1) were derived from hyl maintained in pUC18.
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Blue/white selection using the pGEM-T™ system was carried out according to the 
manufacturers recommendations.
During pneumococcal transformation experiments a control plasmid generated by 
Sue Colby was used. This plasmid (p683CAT) contains the pneumolysin gene 
interrupted by the chloramphenicol resistance cassette marker.
2.1.5 -  Commonly used buffers and solutions
TE ; Tris-HCl [lOmM], EDTA [lmM], pH 7.5-8.
5 X TAE; Tris-base [2M], Acetic acid [1M], EDTA [500mM].
5 X TBE; Tris-base [0.44M], Boric acid[0.44M], EDTA [lOmM].
Stains-all solution; ‘Stains-all’ (l-ethyl-2-(3-[l-ethylnaptho(l,2-d)thiazolin-2- 
ylidine]-2-methylpropenyl)naptho-(l,2-d)thiazolium Bromide [0.1 mM], Acetic acid 
[lmM], Ascorbic acid [0.5mM] in 50:50 (w/v) dHjO 1,4-dioxan. Solutions were 
prepared prior to each assay, as prolonged storage was found to be detrimental to 
assay specificity.
Pneumococcal resuspension buffer; Tris-HCl [50mM], pH 7.5.
Pneumococcal hyaluronate digest buffer; Na2HPC>4 [200mM], pH6.5, HA [2mgmr‘]. 
Ammonium acetate hyaluronate lyase assay buffer; Ammonium acetate [50mM], 
CaCl2 [3mM], pH 6.5.
Gel loading buffer; Sucrose (50% w/v), EDTA [5mM], Bromophenol Blue (0.1% 
w/v), Xylene Cyanol FF (0.1% w/v), SDS (0.01% w/v).
2.1.6 - Kits routinely used
OIAPrep Spin Miniprep Kit (Cat. No. 27104) -  Qiagen Ltd.
QIAQuick Gel Extraction Kit (Cat. No. 28704) - Qiagen Ltd.
QIAQuick PCR Purification Kit (Cat. No. 28106) - Qiagen Ltd. 
pGEM®-T Easy Vector System II (Cat. No. A1380) -  Promega Ltd.
Dig Hi-Prime (Cat. No. 1585606) -  Boehringer-Mannheim Biochemica.
Dig Easy-Hyb (Cat. No. 1603558) -  Boehringer-Mannheim Biochemica.
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2.1.7 - Primers used
Primer
Name
Gene accession no. 
and base at 5’ 
extremity of 
annealing site
Sequence (5'-3’) Annealing 
Temp (°C)
whp.for L20670/20 GGCCCCGCGGAGTC ATTGAGGCT AAGGAT 55
whp.rev L206703004 GGCCCCGCGGTTGGCCTTCTTCGGATTTT 55
hyl.for L20670/213 TGCAACGACGTCAGGAACAAAG 58
hyl.rev L20670/2922 ACGGAATAAATAAAACGCCCCAAGTA 58
hspFl L20670/285 AATCAAGCTGGAGTTATTC 55
hspFIB L20670/623 GGATGACTGGAATGGCATCATCGC 55
hspF2 L20670/806 TGCCACTT ATCGGAAATTG 55
hspF3 L20670/1078 CAGATCCCGAACATTTCCGAAAGA 55
hyl3.mid L20670/1505 CGT GGCCGC AGT AG A AGT ACT A AG A 58
hspF4 L20670/1877 ACT AT AGCGATGGCTACTGGCCAA 55
hspF5 L20670/2232 G AAGCCTCCCTT AC AG AAC AAG AA 55
hspF6 L20670/2613 ATTCTGTCTCTACTATTTCCAACC 55
hspRl L20670/2736 CT GG AGCT G ATTCCT GGGT 55
hspRlb L20670/2453 TT GCTT AT G AGCCTG ACT A ATCGT 55
hspR2 L20670/2167 GC AGC AGT ATCTGTTGAA 55
hyl5.mid L20670/1811 CAAGGT ACG ACTGGAAAAG AGTGAC 58
hspR4 L20670/1199 AATTTCTTGATCATCCTTACGCAG 55
hspR5 L20670/961 CAGTTCCCAACAATGCTCTTTTC 55
hspR6 L20670/533 GGTTGTCCCTTCCTTAAGAGGTTC 55
hipS.out L20670/158 CCCGACTTT ATT ATCTGT 50
hip3.out L20670/3738 CGTGAAGAAATCATCCAC 52
hyp2.for L20670/1270 GGATCCTATATCGACCACACCAATGTTG 48
hyp2.rev L20670/2131 CCT AAAAAGGC AATCTT ATC 48
gpx.for Ctg4l54*/13555 CCCTT GC AATC AGTTT AT G 55
gpx.rev Ctg4154*/13224 TTCAAAGACTTGCCCATCT 55
gpx5.out Ctg4154*13496 CAGAAGGCGTTGATTTCC 52
cat. for K01998/128 T AGTTC AAC AAACG AAAATTGG AT AA 53
cat.rev K01998/1000 ACGGGGC AGGTT AGTGAC AT 53
hexA.for Ctg4241*/173 CCG AC AATCCGATCCCT ATGG 50
hexA.rev Ctg424l*/2270 TATCAGCTGGTCCCGGTTCAATC 50
recP.for Ctg4268*/228 ACCGCG ACCGCTTT ATTCTTTC 58
recP.rev Ctg4269*/351 ATGCTG ACT ACGCGGG ATTTTTC 58
TA.5 pOEM-Tn-#*/l 58 TG ACCATGATTACGCCAAGCT 58
TA.3 pGEM-T™**/2948 TCCCAGTCACGACGTTGTA 58
PEI This Study/348 CCTTCTGGCTTTGCTGAATGGT AT 60
Table 2.7 -  Primers used in this study
*Ctg denotes the contig upon which the gene lies at
** From the pGEM®-T Easy Vector System II - Pro mega Ltd.
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2.1.8 - Other chemicals used
Sodium hyaluronate (from human umbilical chord) (Cat.No. 53740) -  Fluka 
Chemicals.
CSP1 -  Amino acid sequence N -  EMRLSKFFRDFRQRKK -  C 
CSP2 -  Amino acid sequence N -  EMRISRIILDFLFLRKK -  C
2.2 - Methods
2.2.1 — DNA manipulations
Pneumococcal genomic DNA extraction
Cells from 2X BHI/blood agar plates were harvested in a final volume o f  * 500pl 
TE using a cotton swab. 10pl lysozyme [10 mg ml'1] was added and suspensions were 
incubated at 37°C for 15-30 minutes. 30|il proteinase K [10 mg ml'1] was added and 
suspensions were incubated at 37°C for a further 30 minutes. Following this, 40pl 
sodium sarkosyl (20%w/v) was added and suspensions were incubated at 37°C for 10 
minutes. Lysates were mixed with 500pl phenol-chloroform (50:50 v/v) and spun at 
13000 r.p.m. in a benchtop microcetrifuge. The supernatant was removed, and the 
remainder o f the lysate was re-extracted with 200pl phenol-chloroform. The 
combined supernatants were again extracted with an equal volume of phenol- 
chloroform, then chloroform alone. DNA precipitation was performed by the addition 
of a 10% volume of sodium acetate ([3M], pH6.5) and 250% volume ice-cold ethanol. 
After incubation at -20°C for 15 minutes, the precipitate was collected by 
centrifugation at 13000 r.p.m. for 15 minutes. The pellet was washed with 70% ice- 
cold ethanol and centrifugation was repeated. The DNA pellet was dried for 40 
minutes in a vacuum dessicator, and resuspended in 50-100pl dH20. This was 
followed by RNAse treatment at 65°C for 10 minutes. DNA was stored at -20°C.
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PCR
PCR amplification was performed using Taq DNA polymerase supplied by Life 
Technologies Inc. according to the manufacturers instructions. Primer annealing 
temperatures were approximated using the Walace rule, where Td (°C) * 
[2X(A+T)]+[4X(G+C)] (Wallace etal., 1979).
Each reaction was conducted using MgCb at 1.5pM for 35 cycles. Primer 
annealing temperatures are given in table 2.7. In reactions where two primers with 
different annealing temperatures were used, the lower temperature was included in the 
annealing step.
Inverse PCR (iPCRl
This technique is used to identify sequences 5’ or 3’ to a given, known DNA 
sequence.
Restriction digests are selected which do not cut, or cut in a defined portion of the 
known sequence. Endonuclease treatment was carried out for 2 hours at the 
recommended temperature, then heat inactivated by incubation at 80°C for 10 
minutes. Digest fragments are then treated with T4 DNA ligase for 4 hours at room 
temperature. Theoretically, a circularised product which contains the known DNA 
sequence, plus an indeterminate portion o f the flanking sequence, defined by the 
position at which the chosen enzyme cuts outside the known sequence. The outward 
facing primers are then used to amplify this region from the lariat molecule formed in 
the ligation. This approach is outlined diagrammatically in figure 2.1, below.
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Enzyme X cuts an 
unknown distance 
upstream
5'
HIP3.out
Enzyme X cuts at a 
defined point 3' to 
MP3.out
-----► ^
1-------------- 3'
MPS.out
^  Chromosomal digest
^  Ligate
o
° o
o
PCR amplify backbone region ^
MP5.out 
--------- ►
I .
>—
Flanking region
Enzyme X religated 
crossover region
—I —
◄---------
MP3.out
Figure 2.1 -  Diagrammatic representation of the iPCR technique.
Restriction endonuclease treatment
Restriction digests were performed according to the suppliers recommendations. 
During the MIRA experiments it was found that the addition o f BSA to a final 
concentration o f lOOpgml'1 improved the quality of digest patterns after PAGE.
DNA electrophoresis
DNA was routinely visualised by electrophoresis through either 0.8-1% agarose in 
TAE buffer, or 4% and 8% polyacrylamide in TBE buffer. Polyacrylamide gels were
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stained post-electrophoresis in 1XTBE containing ethidium bromide at 60p.gr'. 
Agarose gels were cast containing ethidium bromide at 35pgl'\ and the running 
buffer contained ethidium bromide at 60pgf'. Stained DNA was visualised on an 
ultraviolet light source at 300nm (UVP Inc.).
High Resolution Restriction Analysis (HRRA)
In previous studies HRRA has been used to estimate the diversity between alleles 
of a particular gene from large numbers of strains. This is followed by a statistical 
analysis of the data generated. (Muller-Graf el ai, 1999, Whatmore and Dowson, 
1999, Doherty et al., 2000). The method is illustrated diagrammatically in figure 2.2.
Briefly, aliquots of a given PCR product are independently subjected to restriction 
digestion with a range of frequently cutting enzymes (normally with 4 base 
specificities). Products are separated by PAGE through 4% and 8% polyacrylamide 
gels. Differences in the nucleotide sequences of distinct alleles results in the loss or 
gain of restriction sites, and hence alters the band pattern of a given allele when 
digested with a given enzyme. Different band patterns arising from digestion with a 
common enzyme are referred to as restriction types. The restriction types are 
combined to give alleles. Alleles are differentiated on the basis of different combined 
restriction types. Comparisons are then made between strains by looking at the 
distribution of common and divergent bands against the total number of digest 
products in all restriction types. Comparisons were made by eye and variations in 
electrophoretic mobility were controlled by the inclusion of multiple reference lanes 
containing DNA mass ladder. Poor staining and visualisation of smaller digest 
fragments complicated the analysis. As such, fragments of <50bp were not included 
in the band matching procedure.
Statistical analysis of the results was conducted using the algorithm of Nei and Li 
(Nei and Li, 1979).
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A Strain Collection
Strain X Strain Y
/ A \
Enz. Enz. Enz. Enz.
A B C D d  * • *;Restriction
I I I  Digests
//V.
Enz. Enz. Enz.
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i
B
I
C
I
Enz.
D
!
A
Compare like digests and combine all band patterns
l
Band matching algorithm
1
Estimated Percentage divergence
B
Figure 2.2 -  A; Diagrammatic representation of the HRRA technique. B; 
Example of a typical HRRA PAGE image (8% acrylamide gel), individual 
restriction types are numbered.
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DNA ligations
Ligations were performed using T4 DNA ligase supplied by Life Technologies 
Inc. according to the manufacturers recommendations.
Construction of T-vectors
5|ig pUC18 was digested with a blunt cutting restriction endonuclease (Bst\ 1071), 
which cleaves pUC18 once. The linearised vector was electrophoresed through 
agarose and recovered using the QIAgen Gel Extraction Kit. 5.5pl 10X Taq buffer 
was added to the eluate volume o f 50pl, and 2pl dTTP [lOOmM], 10 units o f Taq 
polymerase was added to the mixture, which was mixed and incubated at 72°C for 2 
hours. Once again, the linearised-tagged vector was purified by agarose gel 
electrophoresis and recovered with the QIAgen kit. Untagged vector was re­
circularised with 2 units T4 DNA ligase, in the appropriate ligase buffer. The entire 
volume was electrophoresed once more, and the linear plasmid excised and purified. 
Ligations were performed immediately at vectoninsert ratios ranging from 0.1:1 to 
1:0. 1.
Southern blotting
Southern analysis was performed according to the directions provided by 
Boehringer-Mannheim Biochemica in their guide to Southern blotting. Amendments 
made due to the use of alternative reagents, such as EasyHyb™ are detailed in the 
instructions provided with the reagents.
DNA Sequencing
Two methods of DNA sequencing were used during the course of the work 
described here; the CEQ2000 DNA Analysis System -  Beckman Instruments Inc. and 
the ABI Prism 377 DNA Sequencing System -  Applied Biosystems. Reactions were 
carried out using materials and procedures provided by the manufacturers.
Sequence analysis was performed using the DNAStar suite of programs (DNAStar 
Inc.), and programs within the MEGA suite of programs (Kumar el al., 1993).
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2.2.2 - Bacterial transformation
E.coli
Competent E.coli (JM109) were prepared by the CaCl2 method described in 
Sambrook el al. (Sambrook el a i, 1989). The heat shock method of transformation 
included within the same reference was also used.
S. pneumoniae
Section 1.3 of chapter 1 describes the growth-phase dependent nature of 
pneumococcal competence for genetic transformation. In our lab it is common 
practice to define a growth/competence curve for each given strain. This involves C- 
medium adapting cells prior to starting the experiment. S. pneumoniae were harvested 
in 5ml C-medium after overnight growth on BHl/blood agar. This was incubated at 
37°C for 2-4 hours, or until the suspension acquires a slightly turbid appearance. 
Aliquots were then frozen at -80°C after the addition of 15% (v/v) glycerol. These 
were used as starting inocula in experiments to define the point at which the cultures 
became competent.
1 OOpl of C-medium adapted cells were inoculated in 7ml C-medium and 
incubated at 37°C until the OD550 reached 0.2 from this point onwards the culture was 
sampled every 15 minutes and frozen in 15% (v/v) glycerol.
p683CAT was used as a positive control plasmid to test the aliquots from each 
time point for competence. This was carried out by transformation as follows; 25|il 
frozen stocks were added to 500pl C-medium. 8pl BSA (10% w/v), 500ng test 
plasmid, 0.5pl CaCl2 [1M] and 2pl o f either CSP1 or CSP2 was then added. This was 
incubated at 37°C for 3 hours, and then spread on selective BHl/blood agar. Positive 
transformants were identified after incubation at 37°C for 12-20 hours.
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2.2.3 -  HA digests and hyaluronate lyase assays
Hvaluronate digests
The method of hyaluronate digests is taken from the method of Homer et al. (Homer el 
al., 1996, and personal communication). Briefly, cells were harvested from an overnight 
culture of S. pneumoniae grown on BHI/blood agar in 500pl pneumococcal resuspension 
buffer (see section 2.1.5). The OD62o of the suspension was adjusted to 0.1 (7- 15%) when 
read in an iEMS microtitre plate reader (Labsystems). This crude enzyme preparation was 
then used in hyaluronate digests, which were prepared as follows; lOOp.1 cell suspension was 
added to 350pl pneumococcal hyaluronate digest buffer (section 2.1.5) and 200pl aqueous 
HA [2mg/ml]. Digestion was allowed to proceed for 24 hours at 37°C. Negative controls 
were performed using resuspension buffer as an inoculum.
Induction with hvaluronate
Induction of hyaluronate lyase was achieved by incubation of cells harvested from 
overnight growth on solid media in 1ml C-medium (made without glucose or sucrose) to 
which HA had been added to a final concentration of O.Smgmr1. This was incubated at 37°C 
for 3 hours. Inclusion of glucose in this media had no effect on induction phenotype.
Induction mixtures were monitored at OD620, which indicated that growth was not observed 
during this time.
At the end of this incubation, cells were harvested by cenrifiigation at 3000 r.p.m. for 5 
minutes. The cell pellet was washed once with pneumococcal resuspension buffer, and 
resuspended in 500pl of the same. As for non-induced cells, the O.D620 was adjusted to 0.1 
(7- 15%), and the digests performed as described above. Induction was defined as an increase 
in titre by ¿20% using either assay.
‘Stains-all’ assay
5pl of the digest mix was added to 45pl ‘Stains-all’ solution [0.1 mM], 50pl dH20  was 
added and A«» was recorded using the iEMS microtitre plate reader (Labsystems). Assays 
were performed in quadruplicate, with a standard HA curve defined during each set of assays 
(over the range 0.5-0.05 rngml'1).
The standard deviation and 95% confidence limits for each set of quadruplicate results 
were defined as shown in the equation below. Mean values were compared to the mean value 
obtained for the digest negative control. One unit of activity was defined as a decrease in 10% 
of the assay sample as compared to the negative control value, after Benchetrit el al. 
(Benchetrit et al., 1977).
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95%CL foru = x ±  —=  where s =
J n
Where p. = population mean 
x = sample mean 
n = sample size 
t = 1 statistic for 95% confidence internal at N = 3 
s = standard deviation of each quadruplicate sample 
N = degrees of freedom (= sample size -1)
Unsaturated disacharride assay
This was adapted from the method of Lin, Averett and Pritchard (Lin el al., 1997). 
Briefly, 30pl of digest mix was added to 60pl ammonium acetate hyaluronate lyase 
assay buffer. The absorbance was recorded at 232nm using a 0.1ml quartz cuvette, 
path length 0.5ml. The amount of 2-acetamido-2-deoxy-3-0-(P-D-gluco-4- 
enepyranosyluronic acid released was quantified according to the Beer-Lambert 
equation with the appropriate corrections for dilution and path length. The millimolar 
extinction coefficient (e) used was 5.5 (Yamagata et al., 1968).
2.2.4 -  Statistical treatment of hyaluronate lyase activity data
Mean values of hyaluronidase activity as measures by the ‘Stains-all’ assay, and 
released digest product were calculated for the strains within the groups tested. 
Variation of hyaluronate lyase activity between the groups was analysed using the 
analysis of variance, or Anova technique.
This treatment provides an output based on the ratio of inter- and intra-group 
variance, termed the F value (Fs). This statistic is used in the F-test in order to prove 
or disprove the null-hypothesis. The initial calculations of are outlined below, 
followed by a description of the F-test.
Each data set was treated in the following manner (x or*  denotes value or reading, 
y o ry  denotes variance from mean);
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Blood Carried Lung CSF Ear
Xbl Xcl X,, Xcsfl Xcl
xw X«2 X« Xcrf2 Xc2
Xb3 Xc3 X,3 Xc.O Xc3
Xta Xcn Xta Xcsfh Xen
** *c */ *c
nb nc ni ricjf n.
I * - / z *  -V I *
I  y ta I * 2 > 2 I>.2
Where jf = ^  X —
'  Hn,
n, = Group sample size (blood = 20, carried = 49 etc).
£  X ' i-» = Sum o f  values for that group sample.
2 y,1 -x ,Y  - i , Y  -x ,Y . . . . . . . J k ,  - i , ) 2 ]
Subscripts denote the group of origin, b = blood, c = carried etc.
1. The sample mean ( f  b_,) across the groups is calculated;
2. The inter-group variance ( T,, weighted by group size, n,) is given by;
— /  _  v2
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3. The intra-group variance ( Y2) is given as the sum of variances within each group;
n = I 2 > , 2
4. The total sum of the squares (SSt, intra+inter) is given by;
s s t = Z " , ( i . - X b - . y + z z > - 2
The next stage of the anova is to tabulate these values as follows;
Source of Variation DF SS MS f.
x, (Inter) a - 1
*  = Ft 
a - \
F>
f2
x, -  x, (intra) y2 V> = F  
Fl
x, -  (total) 7c
:w Yt + Y2
Where DF = Degrees o f Freedom 
SS = Sum of Squares 
MS = Mean o f Squares 
a = Number of groups (in this case a=5)
At this stage it is possible to carry out the final F-test. The basis of the F-test is the 
comparison of the F, output of the anova with a previously determined value, Font- 
This latter value is based on a theoretical probability distribution whose derivation is 
beyond the scope of the work described here. F^, can be defined as the value below 
which the null-hypothesis is obeyed at a given level of confidence. When F,<FCnt, the 
null-hypothesis is deemed true, and the groups are said not to vary significantly from 
one another. When F,>Fcrii then the null-hypothesis is disproved, indicating that there 
is an added element o f variation, ie; a true difference between the groups studied.
In order to determine Fen«, certain experimental parameters must be defined. Firstly, 
the experimental degrees of freedom are considered (outlined in the anova table 
above). Secondly, the expected level o f confidence (a) is set. It is standard
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practice to take a=0.05. Taking these values, and consulting tables of the F- 
distribution enables the user to define the Fcnt values for those given parameters, that 
is, the F value below which the null-hypothesis is obeyed at a given level of 
confidence. The majority of the calculations in the work described here were 
performed using the readily available Microsoft Excel data analysis add-in, which 
precisely calculates Fcni, and also gives a probability value.
2.2.4.1 - Other statistical methods
The Tukey-Kramer method was used to perform post-hoc analysis of the Anova 
results. This test enables us to make pairwise comparisons of group means, and asks 
the question ‘Is the variation seen higher than that expected from a predetermined 
value?’. This value is derived from the studentised Q distribution, and is called the 
Most Significant Difference’ o f MSD. It is calculated as follows;
MSD = Q/k, v] X Standard Error[A,Bj
Where Standard Error[A,B] = ^
( 1 1 (  1 ^M S ( w i t h i r t ) X \ +  _
\ n A ) \ n B )
Q[k.vj is derived from statistical distribution of the Q value for degrees o f freedom 
[K,V], where K = number of groups used and V = Degrees o f freedom of MS( within). 
Suffixes A and B denote individual groups (e.g.; Carried and Blood isolates). When 
the observed value o f the differences between the means of two individual groups 
exceeds the value derived for MSD, the difference is said to be significant.
Various statistical analyses were performed using the chi-squared (x2) test. This 
test is based on a comparison o f the observed and expected frequencies o f a particular 
value. This is compared against the x2 distribution to determine whether the 
difference of the distribution o f values is significant. The value for x2 is determined 
according to the following equation;
X’ = Z( O - E ) 2O
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Where O = observed value 
E = expected value
High values for indicate that a particular distribution has a low probability of 
occurring by chance.
The Maximum x2 test of Maynard-Smith was used in the detection of 
recombination between allelic variants (Maynard-Smith, 1992). This technique 
compares the distribution of polymorphisms along donor and recipient sequences with 
those expected to occur by chance. The test looks at every position along aligned 
sequences and generates a contingency matrix of the number of polymorphisms either 
side of a given position. The value of %2 is determined for this matrix, and the position 
at which the maximum value of x2 is obtained is identified as the putative 
recombination point.
The significance of this result is tested by running trials where random sequences 
of the same length (and polymorphic sites) are created. The significance level is 
determined as the proportion of trial pairs with greater maximum x2 values than the 
observed data.
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2.2.5 -  Biofilm growth model
Bio films were generated using the Sorbarod filter model o f  Gilbert et al. (Gilbert 
et al., 1989, Hodgson et al., 1995). This model establishes a biofilm culture on the 
parallel cellulose acetate fibres of the Sorbarod filter. A diagram o f the Sorbarod 
biofilm system is shown in figure 2.3.
To collection 
vessel
Figure 2.3 -  Diagrammatic representation of the Sorbarod model
The experiment was set up by inoculating the Sorbarod filter with the planktonic 
culture of choice, and supplying fresh liquid media at a constant rate. As the biofilm 
became established, acapsular variants arose. This was shown by either sacrificing the 
filter at a given time point and culturing the organisms on solid media, or by culturing 
the cells which were shed in the effluent.
Fresh media 
supplied by 
peristaltic pump
Syringe barrel
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3.1 Occurrence and variation of the hyl locus
3.1.1.1 - Introduction
Previous studies have addressed the question of genetic diversity at loci encoding 
virulence determinants of pathogenic streptococci. This has shown that in some 
instances variation can be high, and that the evolution of these virulence determinants 
is in some cases mediated by homologous recombination between related genes 
(Poulsen et al., 1998, Whatmore and Dowson, 1999, S. King, unpublished data).
The first question addressed in this study was that of genetic diversity at the hyl 
locus. In previous studies this has been achieved using high resolution restriction 
analysis (HRRA), also known as restriction fragment length polymorphism (RFLP) 
(Muller-Graf et al., 1999, Whatmore and Dowson, 1999, Doherty et a i, 2000), 
followed by a statistical analysis of the data generated. This is a technique suited to 
high throughput analysis of loci from large numbers of strains, and is a cost effective 
alternative to direct sequencing of loci from all isolates in the first instance. The 
technique is described in chapter 2. The band comparisons are quantified using the 
band matching algorithm described by Nei and Li (Nei and Li, 1979). The output of 
this procedure is presented as percentage divergence between alleles found.
Table 2.1 shows the strains used in this study, which includes 52 strains isolated 
from asymptomatic carriers, 54 invasive disease isolated and 35 serotype 3 strains, a 
serotype often associated with invasive disease (Gray, 2000).
In this study two other loci were studied by HRRA. These were recP (Accession 
No. M31296) and hexA (Accession No. M 18729), encoding proteins involved in 
recombination and mismatch repair respectively (see Chapter 1, section 1.3). This was 
in order to enable a direct comparison between allelic variation in hyl, encoding a 
virulence determinant, and two loci encoding genes with housekeeping functions.
The hyl fragment used in this study was amplified using the hyl.for/rev primer 
pair, described in Chapter 2, section 2.1.7. The predicted size of this
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product is 2695 bp. Amplification was successful from 133/141 strains (94.3%). PCR 
failure was assumed to be as a result of polymorphism at one or both of the primer 
binding sites on the target sequence. The presence of hyl was confirmed by Southern 
analysis (see section 3.1.2). The recP amplicon is calculated to be 1568 bp in length, 
and was successfully amplified from 141/141 (100%) of the strains. The hexA 
amplicon is 2097 bp long, and was amplified from 138/141 (98.5%) of the strains. 
This ratio of PCR success was taken as indicative of higher variation at the hyl locus 
over those of hexA or recP. This was found to be statistically significant by yj 
analysis, with y 2 = 9.416, P < 0.025 (where y 2cm = 3.84).
A series of trial digests was performed on the hyl, hexA and recP PCR products, 
and the enzymes finally chosen on the basis of the most clearly discernible digest 
patterns with the strains used. These are listed in table 3.1.1.
recP hexA hyl
Hinfl Alul Dde I
Hsp92U Hhal Hae III
Maelll Hinfl Hinfl
Mnl\ Hsp92U Msel
7iP509I 7sp509I Rsal
Table 3.1.1 - Restriction enzymes used in HRRA of the loci used in this study.
The overall restriction endonuclease footprints of the database gene sequences of 
each locus were 8.4% for recP, 8.5% for hexA, and 7.71 % for hyl.
3.1.1.2 - HRRA of recP
The restriction patterns seen with the recP digests were assigned restriction types, 
which were compiled as ET’s. These were deemed synonymous with alleles. These 
data are summarised in table 3.1.12 in appendix 3.1.
The estimated percent divergence between each allele was calculated as follows: 
The total number of bands for each allele type were established by adding together the 
number of bands from each RT. Pairwise comparisons between each RT for all alleles 
(1 versus2, 1 versus 3, 1 versus 4 and so on) were made.
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These data were tabulated, and are presented in table 3.1.2. The allele numbers are 
shown in bold, with the total number of bands for that allele displayed either above 
(on the upper X axis), or to the left (on the Y axis) of the allele number. The upper 
right triangular matrix gives the number of common bands between alleles. These 
data were used to compute the estimated percent divergence data using the Nei 3 
program (Nei and Li, 1979). The individual pairwise values of this calculation are 
shown in the lower left triangular matrix.
74
Original
Contains
Pullouts
o g s
Table 3.1.2 - Band matching data and estimated percentage divergence of 
recP.
75A
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3.1.1.3 - HRRA of hex A
The different hexA alleles were assigned on the basis of overall restriction 
and ET’s, allele assignments are shown in table 3.1.13 in appendix 3.1.
These data were treated in the same way as those obtained in the recP study, 
and the data matrix is shown in table 3.1.3.
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Table 3.1.3 - Band matching data and estimated percentage divergence of
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3.1.1.4 - HRRA of hyl
The different hyl alleles were assigned on the distribution of restriction types 
and are summarised in table 3.1.14 in appendix 3.1.
Once again, these data were treated in the same way as those obtained in the 
recP study, and the data matrix is shown in table 3.1.4.
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Table 3.1.4 • Band matching data and estimated percent divergence of hyl.
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3.1.2 -  Southern analysis of hyl PCR Negative Mutants
Several of the strains included in the study were PCR negative for hyaluronate 
lyase, but PCR positive for hexA / recP. Given the PCR controls used, and the 
successful amplification of other genes from the DNA of these strains, it was decided 
to screen them for hyl by Southern analysis, using the digoxygenin labeling and 
detection protocols (see chapter 2).
hyl allele 2 was amplified from strain 916, and as it was the most commonly 
represented allele. This was used to probe Kpnl and Mspl chromosomal digests of the 
PCR negative strains, along with R6 and strain 471 (also allele 2 positive).
The results of the Kpnl blot are shown in figure 3.1.1 (the Mspl blot also proved 
positive for the isolates used).
Figure 3.1.1 -  Southern blot of PCR negative strains probed with the hyl PCR 
product. Markers in lefthand lane = Dig labelled SPP1 cut with £coRI. Strain ID 
numbers are used. Strains 359 and 949 were included as positive controls.
As can be seen, all strains were positive for hyl by Southern analysis. Five of these 
strains were included in the phenotypic analyses described in chapter 3.2, and proved 
to be Hyl+.
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3.1.3 -  Comparison and interpretation of HRRA results 
3 .0 .1  - recP
Figure 3.1.2 shows the number of strains that possess each of the 17 recP 
alleles. As can be seen, the most common allele is allele 1, followed by allele 6, 
then allele 5. These groups of alleles represent the three major allele types seen 
with this locus.
1 2 3 4 5 6 7 8 9  10 11 12 13 14 15 16 17
Allele
Figure 3.1.2 - recP allele occurrence.
Within this group, the maximum estimated percentage divergence was 
2.607% between alleles 2 and 15. Both of these alleles occur once, in strains 18B 
(ID922) and 142163 (ID324) respectively. The maximum estimated percentage 
divergence from the three major allele representatives is given in table 3.1.5.
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Common
Allele
Diverged
Allele
Max. % 
Divergence
Strain
1 14 1.893 619 (ID53)
5 14 2.232 619 (ID53)
6 13 2.007 54 (ID967)
Table 3.1.5 - Maximum estimated percentage divergence from the three most 
common recP alleles found.
Of the 17 pneumococcal alleles found the distribution of allele types within each 
isolate group (carried, invasive and serotype 3 isolates) varies as follows:
The carried strains were found to possess 13 different allele types, of which alleles 
2, 7, and 13 are unique to that group. In this study efforts have been made to exclude 
the possibility of studying a number of clonal isolates (such as varying serotype, site 
and date of isolation and geographical origin). Where the number of alleles unique to 
a specific group of isolates is large, it is arguable that there is some selective pressure 
to maintain those alleles within that group. The actual number of carried strains which 
contain unique alleles represents a small proportion of the total number of strains 
studied (5/140 or 3.57%), as such this cluster of unique alleles is not thought to 
suggest any such selection. %2 tests were used to analyse the distribution of unique 
and shared alleles for the genes examined across the groups of carried, invasive and 
serotype 3 strains. In all cases the number of strains bearing unique alleles was not 
found to vary significantly, with y? < x2cni (X2cni = 5.99).
The invasive isolates contain 13 different alleles, of which alleles 14, 15, 16 and 
17 are unique to the group. These represent 4.28% of the total number of strains 
(6/140), and again, are not thought to represent allele selection.
The serotype 3 isolates all possess recP alleles seen in either the carried or 
invasive isolates.
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3 .0 .2  -  hex A
Figure 3.1.3 shows the distribution of hexA allele frequencies.
Allele
Figure 3.1.3 - hex A allele occurrence.
The hexA alleles found in this study number 15 in all. Of these, 107/138 
(77.5%) strains possess one of two major representative alleles (allele 2 or 4). 
The estimated percent divergence between these two alleles is 0.389%. The 
maximum estimated percent divergence from these alleles is shown in Table 
3.1.6.
Common
Allele
Diverged
Allele
Max. % 
Divergence
Strain
2 12 2.592 142154 (ID326)
4 12 1.994 142154 (ID326)
Table 3.1.6 - Maximum estimated percent divergence from the two 
predominant hexA alleles.
Thus allele 12, from strain 142154 (ID326) is the most divergent from the 
majority of other strains. It is a serotype 12 Kenyan isolate, taken from a patient 
suffering from invasive pneumococcal septicaemia. The other loci in this strain 
(recP and hyl) contain non-unique alleles.
The carried isolates contain 11 different alleles, of which 6,7, 8 and 10 are 
unique to that group. These represent 3.62% (5/138) of the total number of
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The carried isolates contain 11 different alleles, of which 6, 7, 8 and 10 are unique 
to that group. These represent 3.62% (5/138) of the total number of strains from 
which hexA was amplified. Using the argument outlined above, it is not thought that 
this represents underlying biological selection.
Of the alleles found in the group of invasive strains, alleles 12, 13, 14 and 15 were 
unique to the group. The relative percentage of strains in this ‘unique’ set of alleles is 
2.89% (4/138).
The serotype 3 collection all possessed either allele 2 or 4, the predominant alleles 
over all the strains included. Examination of the distribution of housekeeping genes 
within the type 3 group, and the relatively restricted number of hexA alleles indicates 
that this group is not highly diverged, and probably consists of a discrete number of 
clonal elements.
This distribution of unique allele representation across the 3 groups studied was 
not significant by the x2 test (x2 = 3.32, x2crit = 5.99).
3 .1 3 3  -  Hyaluronate lyase - hyl
133 strains were PCR positive for hyl, and found to posses 28 different alleles as 
determined by HRRA. Figure 3.1.4 shows the relative frequencies of these alleles.
U
1 2 3 4 3 6 7 8 9 10 I I  12 13 14 13 16 17 18 19 20 21 22 23 24 23 26 27 28
Allele
Figure 3.1.4 - hyl allele occurrence.
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Four of the predominant hyl alleles (1,2, 5 and 8) are found distributed throughout 
the groups of isolates from nasopharyngeal carriage or invasive disease, and alleles 1, 
5 and 8 show no association with one group or another as determined by the yj test.
Allele 2 is the most frequently represented. This representation may contain a bias 
from the inclusion of 10 serotype 3 isolates from the UK (some of which were 
isolated from the same town) that contain common hexA and recP alleles along with 
hyl allele 2. This is supported by the x2 test, which gives a value of x2 = 11.162 (x2Cnt 
= 5.99).
Muller-Graf et al. described a nationally distributed serotype 3 clone on the basis 
of HRRA data obtained from HRRA data from 9 housekeeping genes (Muller-Graf et 
al., 1999). It is possible that these isolates may be part of this clone, although the 
power of resolution of the HRRA data obtained here (ie; the ability to clearly identify 
distinct clonal relationships) is not high enough to clearly identify clonal groups 
(using 3 loci, as opposed to 9). The association of allele 2 with what may be a 
successful national clone, and its global distribution across a number of strains of S. 
pneumoniae of different serotypes and genotypes {hyl allele 2 is found in the context 
of 16 discrete combinations of hexA and recP alleles in this study) suggests that allele 
2 is itself a successful allele.
Strains with hyl allele 28 (n = 10) are the equine isolates derived from a recent 
study carried out in our laboratory (Whatmore et al., 1999). These strains also possess 
common recP and hexA alleles, supporting their clonal relationship.
During the PCR amplification of the hyl products, one strain (619, ID53) gave rise 
to an amplicon approximately 400bp smaller than those from all of the other PCR 
positive strains. It was assumed that this size difference was as a result of a naturally 
occurring deletion event. This strain was kept in the study, and was further 
characterised as described in section 3.3.2.
The maximum estimated percentage divergence between the predominant alleles 
is shown in table 3.1.7 (allele 19, assigned to the deletion mutant was excluded from 
this analysis).
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Common
Allele
Diverged
Allele
Max. % 
Divergence
Strain
1 22 2.214 86012 (ID307)
2 22 1.759 86012 (ID307)
5 22 1.848 86012 (ID307)
8 22 2.073 86012 (ID307)
28 22 2.214 86012 (ID307)
Table 3.1.7 - Maximum estimated percent divergence between the five 
predominant hyl alleles.
It is clear from table 3.1.7 that of the most common alleles the most highly 
diverged is allele 22, followed by 7, 14 and 20.
3.1.3.4 -  Discussion
The results of the HRRA approach presented here indicate that variation at the hyl 
locus is not notably higher than that observed for loci encoding two housekeeping 
genes, recP and hexA. This was shown using the x2 test comparing the hyl maximum 
estimated percentage divergence (%max) and the variation of the maximum and 
minimum estimated percentage divergence (%max -%mm) with the values obtained for 
hexA and recP alone, or and average percentage divergence value obtained for the two 
housekeeping genes taken together. In all cases x2 «  X2cni-
Despite the fact that hyaluronate lyase is likely to be located at the cell surface (see 
section 1.7.10, chapter 1), the hyl locus does not appear to have been under strong 
selective pressure to diverge, as might be expected. However, it is interesting that 
there are a higher number of distinct hyl alleles than for the housekeeping genes. This 
difference in allele numbers was shown to be statistically significant by the x2 test (x2 
= 10.9, x2crii = 5.99). This feature will be returned to in section 3.1.6.1.
The estimated percentage divergence at the hyl locus is lower than that of other 
extracellular virulence determinants, including nanA (36% - S.King, unpublished 
data), lytA (3.2% - Whatmore and Dowson, 1999) and iga (12% - Poulsen et al.,
1998).
The HRRA/Nei technique relies upon the detection of polymorphisms within a 
defined restriction endonuclease ‘window' to obtain an estimate of the overall
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variation at a given locus. As a result of which there will be background variation at 
the nucleotide level which remains undetected (i.e; polymorphisms that do not result 
in restriction site alterations). One element of the Nei and Li treatment is to account 
for this ‘silent’ variation.
Representative hyl alleles were sequenced to complement the HRRA data, and to 
determine the nature of nucleotide variation at this locus.
3.1.4 - Sequence analysis of selected hyl alleles
The HRRA technique is designed to obtain an estimate of the percentage 
divergence values expected at the nucleotide level. Since it relies upon the restriction 
recognition footprint of the enzymes used to generate the raw data, it can be regarded 
as a form of low-resolution sequence analysis.
In order to verify the validity of the HRRA technique, and to examine the nature 
of the variation at the nucleotide level, nine of the alleles were selected for direct 
sequence analysis over the hyaluronate lyase ORF. These were the predominant 
4alleles (1, 2, 5, 8 and 28) and those which were most highly diverged from them 
(alleles 7, 14, 20 and 22). Alleles were sequenced from the following strains; allele 1; 
strain ID 885, allele 2; strain ID 922, allele 5; strain ID 903, allele 7; strain ID 873, 
allele 8; strain ID 877, allele 14; strain ID 863, allele 20; strain ID 303, allele 22; 
strain ID 307, allele 28; strain ID 498.
The region selected for sequence analysis corresponds to nucleotides 113-2978 of 
the published hyl sequence (accession no. L20670) (Berry et al., 1994), corresponding 
to amino acids 9-stop codon, plus 12 codons downstream of this.
Sequencing was carried out using the Beckman CEQ-2000 system and ABI Prism 
system as described in chapter 2.
3.1.4.1 - Observed alterations to the published sequence
Sequences were aligned using the Clustal alignment algorithm contained within 
the Megalign program of the DNAStar suite. Alterations to the published
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nucleotide sequence were confirmed from data obtained by sequencing the 
complementary DNA strand.
The occurrence of restriction sites used in the HRRA study within the sequences of 
the nine alleles selected confirmed the polymorphisms leading to the observed 
restriction types and hence alleles derived in section 3.1.1.4.
The observed nucleotide alterations are summarised in figure 3.1.5, below.
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1111111  1111111111  1112222222  22222222222  222222
1112333334 4555666677 7790001111 2223346779 9990001111 12224455566 677799
4568678894 7269014734 5932681578 2482709561 2692220227 88898938915 727901
8480511395 6411775820 8172239545 5575385198 6660199148 42354550471 016774
all ....CT .GT .G--- ATC...T...
al2 ..G... .GT G . ..G. .AT. CT. .G........ ATC..GT.A. .C.. ..
al5 C.G..T .GT ....GC .AT. CT. ...TA.. ..T..T.... .A.C.. ATCACGT... .C.. ..
al7 C..A..CAGT ATC...T...
al8 C ___ T .GT .G..G. .A. . C.C ...TA.. ....G..... .A...C .TC...TT..
all4 C .....CAGT ___ G. .ATT CT.
al20 .....T .GT ...GG. .A. . C. ..ACT... .G.CG..... ...C.. .TC.C.T... ............ c
al22 .A ..CT . .C. .A G C .C .T C .C G T ... .C. . V . .
al28 C.G... . .A. . ..A. . ...T.AA A.T.G..... CGC. . .GC.. . T C . C . T T . A . C . T AC
L20670 AGAGACTCAC AAGAAACCCC TCAAGTCGTG CCCTACCCAC TATAGGATCT GGGGTACCGT TTCC GT
P.type CGAGATTCGT AAGAGACACC CCAAGTTGTG CCCTGCCCAC TATAGAACCT GTCGTATCGT TTCC GT
Figure 3.1.5 -  Summary of nucleotide alterations found in the 9 alleles studied. The published 
sequence (accession number L20670) is shown in blue, and the prototype sequence derived from this 
study in black (P. type). The numbers running vertically indicate positions of polymorphic sites with 
respect to L20670. Bases shown in red are variant with respect to L20670 in all the cases studied. 
Bases indicated in purple are variant in over 50% of cases. V represents a 24 bp duplication found in 
allele 22. This is discussed in the text below.
The nucleotide sequences of the alleles studied were translated into their respective 
proteins, and an alignment of these protein sequences was also made. Non- 
synonymous mutations leading to amino acid alterations are shown in figure 3.1.6, 
below.
111 111 22 2 233 334 4 45 5 66 667 888 8 8 9 9
22 6 999 124 7 7 9 123 816 78 1 24 5 61 2 443 034 59 0 0
02 4 248 995 36 6 734 312 95 2 804 0 0 6 471 253 46 3 4
a l l AL. S .G . .E . T . s . . VNV
a l 2 S S . A. E .TM . E . .NV G*.
a l 5 H. . . L . s . . AA!-: .TM .NV G. .
a l 7 H . I . .Y s . . .NV Duplicated
a l 8 H. . . L . S .G A .E . T . R . . s . . .NV Region
a l l 4 H. . . .Y S .  . A .  E LTM .NV
a l 2 0 . L . S .  . A .E . T . .ES s . .
a l 2 2 . 1 . AL. S .  . A .E . T . .V . . E . s.v RS. .NV G. . . . RNLKRKKK
a l 2 8 H. . • S
L 2 0 6 7 0 N W DPS PNE TDD S IT SEL QDL NHA KPK SDG DWS L P - ---------- ---
P r o t o t y p e H W DLS SNE ADE STT SEL
JQO SHA KPK SNV DWS LP
Figure 3.1.6 -  Summary of amino acid alterations found in the 9 alleles studied. The translated 
published sequence (accession number L20670) is shown in blue and the prototype derived from this 
study in black. The numbers running vertically indicate positions of polymorphism with respect to 
L20670. Residues indicated in red are variable with respect to L20670 in all the cases studied. Residues 
indicated in purple are variable in over 50% of cases. The 8 amino acid duplication found in the 
translation product of allele 22 is shown. This is discussed in section 3.1.6. * indicates amber stop 
codon.
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Table 3.1.8 summarises the observed nucleotide and predicted amino acid 
alterations, and includes the ratios of synonymous to non-synonymous changes. It 
also includes the number of nucleotide alterations that result in changes to the 
restriction type of each given allele.
Allele No. nt changes No. aa substi­
tutions
S/NS ratio % nt changes 
that lie within a 
restriction site 
with respect to 
P.type
w.r.t
L20670
w.r.t
P.type
w.r.t
L20670
w.r.t
P.type
1 24 14 10 5 1:0.41 14.2
2 20 15 12 8 1:0.6 6.6
5 25 13 12 5 1:0.48 0
7 12 10 7 6 1:0.58 16.6
8 18 6 11 2 1:0.6 0
14 20 12 10 5 1:0.5 16.6
20 19 9 9 4 1:0.47 11.1
22* 26 16 16 9 1:0.61 12.5
28 27 21 10 9 1:0.37 9.5
Table 3.1.8 -  Statistics relating to the alterations of the nine alleles studied.
Alterations were scored with respect to the prototype sequence given in figure 3.1.6. 
nt = nucleotide, aa = amino acid, s/ns = synonymous / non-synonymous, w.r.t = with 
respect to..., P. type = prototype sequence. *Note that allele also contains a 24bp 
imperfect duplication as well as the other observed alterations.
The observed nucleotide divergence is shown in table 3.1.9, below. The values 
estimated by the Nei and Li algorithm are also included. The table also includes 
amino acid identity/similarity data for the transcribed protein.
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Allele 1 2 5 7 8 14 20 22 28
1 X 0.907 0.803 0.698 0.558 0.837 0.733 0.768 1.012
0.714 0.257 1.241 0.433 1.33 1.3 2.214 0.529
2 98.935 X 0.523 0.558 0.628 0.558 0.733 0.698 1.082
99.255 0.433 0.836 0.257 1.124 1.1 1.759 0.714
5 98.937 99.361 X 0.663 0.593 0.523 0.698 0.803 0.907
99.256 99.574 1.124 0.168 1.213 1.594 1.848 0.257
7 99.044 99.042 99.044 X 0.488 0.419 0.663 0.837 0.872
99.362 99.468 99.256 0.924 0.462 ! .669 2.674 1.452
8 99.469 99.042 99.256 99.150 X 0349 0.523 0.698 0.872
99.575 99.468 99.469 99.362 1.012 1.387 2.073 0.433
14 98.937 99.361 99.362 99.469 99.469 X 0.733 0.907 0.942
99.150 99.681 99.469 99.575 99.362 2.214 3.301 1.3.3
20 99.256 99.255 99.044 98.937 99.362 99.044 X 0393 0.837
99.575 99.468 99.469 99.362 99.787 99.362 1.541 1.937
22 98.937 98.935 98.725 98.406 98.831 98.512 99.044 X 1.012
99.469 99.148 99.150 99.044 99.469 99.044 99.469 0.817
28 98.725 98.509 98.512 99.044 98.831 98.725 98.831 98.087 X
99.150 99.042 98.831 99.362 99.150 98.937 99.150 98.831
Table 3.1.9 -  Percentage divergence of selected hyl alleles at the nucleotide level.
The upper right part of the matrix shows percentage nucleotide divergence in bold, as 
calculated by the Needleman and Wunsch algorithm from direct sequence data. The 
values in grey are those derived from the algorithm of Nei and Li using the data 
generated by HRRA. The lower left part of the matrix shows the amino acid 
percentage identity (green) and similarity (red) as derived from the translated 
nucleotide data.
As can be seen from the table above, the overall divergence at the nucleotide, and 
hence amino acid level, is low. The estimated percentage divergence as calculated by 
the Nei and Li algorithm is in some cases, broadly accurate. However, in many cases 
the estimates prove to be either higher or lower than that observed from direct 
sequence analysis. Analysis of the mean divergence data obtained by each method 
(DNA sequencing and HRRA) were compared using a paired t-test. This indicated 
that the data sets were significantly different (t = 4.33, tern = 2.03, P<0.001). Possible 
reasons for this difference are discussed in section 3.1.4.3, below.
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Phylogenetic analysis of the sequence data was carried out in order to 
generate dendrograms from both the nucleotide and amino acid sequences. 
These are presented in figure 3.1.7, below.
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Figure 3.1.7 -  Phylogenetic relationships between the hyl alleles sequenced 
and predicted translation products. Analysis was made using the Neighbour- 
Joining method. Bootstrap values were calculated on the basis of 500 replicates. 
Analysis was carried out using nucleotide (A) and amino acid (B) sequence 
alignments.
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As can be seen from dendrogram A shown above, the relationships between the 
sequenced alleles reflect the nucleotide divergence shown in the data matrix given in 
table 3.1.9. The difference between the trees indicates the differing occurrence of non- 
synonymous changes between the alleles sequenced. Since the overall number of 
alterations is low, and the nucleotide/amino acid stretch is large, the reliability is such 
analysis is open to question, as is reflected by the low bootstrap values at all of the 
assigned breakpoints. As such, limited emphasis can be placed on the associations 
drawn from such analysis.
It is noteworthy that there is no obvious clustering of either common or diverged 
alleles. This suggests that there has been no partition of particular alleles on the basis 
of the phenotype conferred upon the respective isolates from which they originate.
3.1.4.2 -  Distribution of observed alterations
An interesting feature of the sequence data obtained relates to the distribution of 
alterations over the length of the gene studied. Analysis of the distribution of 
nucleotide and amino acid alterations indicates that there is more amino acid variation 
in the a-domain of the protein (which includes 55% of the amino acids). Table 3.1.10 
shows the percentage of nucleotide alterations and amino acid substitutions in the 
region encoding the a- domain of the protein, and the percentage of amino acid 
alterations in these domains.
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Allele % nt changes in a* 
domain
% aa changes in a- 
domain
1 50 80
2 60 75
5 61 80
7 80 100
8 50 100
14 75 100
20 66 75
22 43 55
28 43 55
Table 3.1.10 -  Distribution of nucleotide and amino acid alterations in the nine 
alleles examined. Alterations were scored with respect to the prototype sequence 
given in figure 3.1.6. nt = nucleotide, aa = amino acid.
Although the a-domain comprises slightly more (55%) of the molecule than the 13- 
domain in terms of amino acids, in all cases there appears to be a bias in the 
distribution of amino acid alterations toward the a-domain. This is interesting as it 
contains the catalytic residues. This feature will be returned to in section 3.1.5.2
3.1.4.3 -  Discussion
Table 3.1.9 shows that in some cases the percentage nucleotide divergence 
predicted by the algorithm of Nei and Li is either higher or lower than that observed 
from direct sequence analysis. The extent of disagreement between these values 
reaches significance as determined using a paired T-test (t = 4.33, tent = 2.03, 
P<0.001).
The Nei algorithm was developed with various starting assumptions, including the 
stochastic principle of molecular evolution; that nucleotide variation is distributed 
randomly over the length of DNA studied. As a result, the observed restriction site 
changes might also be expected to vary randomly. When variation occurs in a fashion, 
which differs from such an equal distribution, such analysis begins to break down.
While the overall extent of variation is low, such that phenomena such as 
homologous recombination between divergent alleles is not immediately apparent, 
other sources of error must be sought to explain the disparity between the predicted 
(by HRRA) and observed nucleotide divergence.
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It is suggested here that these differences can be understood by looking at the 
distribution of nucleotide changes over the alleles sequenced in the following manner:
Table 3.1.8 shows the relative percentage of polymorphisms that fall within the 
overall restriction footprint of the restriction endonucleases used in the HRRA 
procedure. In many cases where the Nei and Li algorithm has overestimated the 
percentage divergence, a relatively high proportion of the total number of 
polymorphisms for a given allele fall within the restriction endonuclease footprint.
This is the case with alleles 7 and 14 for example, in which 16.6% of all 
polymorphisms alter their restriction type with respect to the prototype sequence. The 
Nei and Li algorithm has overestimated the percentage nucleotide divergence in 8/8 
comparisons made with these alleles. A similar situation is seen with allele 22, where 
12.5% of polymorphisms fall within a restriction site, and divergence is overestimated 
in 8/8 comparisons. This interpretation does not hold for allele 1 however, where 
14.2% polymorphisms affect the restriction type, but the Nei and Li algorithm has 
overestimated divergence in only 4/8 comparisons.
The converse situation is less readily explained. Alleles 5 and 8 contain no 
polymorphisms that alter their restriction type, but the Nei and Li algorithm has 
underestimated the percentage divergence in only 4/8 comparisons. This is explained 
as follows; these alleles vary in such as way as to result in no changes to their 
restriction types, so no information is gained pertaining to their variation with respect 
to the prototype sequence. This renders the assessment of variation within these 
alleles as a function of the stochastic occurrence of restriction type ‘active’ 
polymorphisms within the alleles to which they are being compared.
This interpretation of the data suggests that while over-representation of 
polymorphisms in the restriction footprint can lead to a positive bias in the output of 
the Nei and Li algorithm, under-representation does not.
3.1.5 -  Searching for recombination between hyl alleles
Visual analysis of the distribution of nucleotide alterations between the alleles 
shown in figure 3.1.5 indicates that blocks of alterations are apparent across the 
sequences studied, however Sawyers Runs tests indicated that these putative 
recombination events are not statistically significant (Sawyer, 1989). It
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is suggested that this is due to the relatively low number of polymorphisms over a large 
surface of comparison.
Maximum Chi-squared tests were also performed (Maynard Smith, 1992). This technique 
has the advantage that individual putative points of recombination can be submitted for 
statistical analysis. In this case recombination was shown to occur between the alleles 
identified, and probability scores reached statistical significance (P<0.0100). Two examples 
of recombination events shown to be statistically significant are shown in figure 3.1.8, below.
C O T  GT G C A T  C T T A T T  AC ATC ACGT C
I I Allele 5
C A CAGT A____________________ A ATC T
^ ■ ■ ■ ■  Allele 7
C T G T G G A  C C T A G  A C  TC T T
C CAGT G A T T C T T A T  A C  TC T T
Or the more complicated example of allele 22, which bears polymorphic features similar to a 
number of other alleles;
Figure 3.1.8 -  Mosaic structures within hyl alleles as determined by the 
maximum g2 test. In all cases putative recombination points are statistically 
significant, with P<0.0100.
Thus, there is statistical evidence that the pneumococcal hyl locus is evolving by transfer 
of blocks of DNA of low overall divergence, leading to the formation of detectable mosaic 
gene structures.
Recombination at the hyl locus could be occurring in two ways. The accumulation of 
point mutations followed by intra-species recombination may lead to the structures observed. 
Alternatively, divergent DNA could be exchanged at the inter-species level.
The polymorphic regions of the pneumococcal hyl alleles identified by sequence analysis 
were compared with homologous regions from the hyaluronate lyase genes of other bacteria 
available in the public domain. This investigation did not indicate that there were any obvious
]  Allele 8
A1 1 Al 20 A I5
1 ACTCCQT I I Allele22
2121 2535
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potential donors for divergent DNA. This is unsurprising in the light of the low overall 
divergence observed within the pneumococcal hyl locus, and the relatively high divergence of 
other streptococcal hyaluronate lyase encoding genes available in the public domain (= 42% 
nucleotide divergence between the pneumococcal hyl locus and its homologues in both S. 
agalactiae and S. pyogenes). If genetic exchange with such donors were taking place, 
relatively highly divergent blocks of DNA would be apparent in the pneumococcal alleles 
sequenced. As such it was decided to conduct searches for potential homologues, and hence 
donors in more closely related streptococci.
Although S. constellatus and S. intermedius are hyaluronate lyase positive, Southern 
analysis of genomic DNA from these organisms proved either negative or only weakly 
positive when probed with hyl DNA from S. pneumoniae (S. Widdison - unpublished data).
Previous studies have shown that pneumococcal genes encoding PBP’s (Dowson et al., 
1993), LytA (Poulsen et al., 1998) and Nan A (S. King -  unpublished data) have been 
involved in recombination with loci from the oral streptococci Streptococcus oralis and S. 
mitis. Furthermore, a recent study by Whatmore et al. has revealed that certain groups of 
‘atypical’ isolates of S. mitis harbour the pneumococcal virulence determinant genes ply and 
lytA (Whatmore et al., 2000). Also, members of these groups of organisms were positive in 
Southern analyses of Widdison (Unpublished data).
As such it was thought that these closely related groups of isolates would be good 
candidates for donors of divergent DNA which might shed light on the polymorphisms seen 
at the pneumococcal hyl locus.
3.1.5.1 -  Screening other streptococci for hyl homologues
The approach taken here was based on specific and degenerate PCR methodology. The 
primer pairs used in this screen were the hyl and 2°hyl probe (hyp 2°) primers described in 
table 2.7, chapter 2. The latter primer pair contain degenerate sites, designed on the basis of 
homology to the group A and group B streptococcal hyl sequences. These primers 
successfully amplified products from representatives of the pneumococcal strains that were 
previously identified as PCR-negative in the HRRA study (section 3.1.2). The strains used in 
this experiment are listed in chapter 2, table 2.6.
Figure 3.1.9 (below) shows the relative annealing positions at the hyl locus, with the 
numbering of the available database sequence of the gene used throughout (accession number 
L20670). Also included in this figure is a photomontage
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some of the PCR positive and negative results obtained. Table 3.1.11 contains a 
full description o f the results obtained with the strains used.
A
I------------------------------------  2707bp -------------------------------------1
I--------------  861 bp ----------- 1
hyl.for hyp2*. for hyp2\ rev hyLrev
I
hyl (L20670)
B
2707bp
» n i t i  • » * • » * >
■ e Z ' S ^ ' S ' S ' S ' S ’S ' S  ‘S ' 8 3t f u u u u u o C u u  u u u
'e i- œ » —
TS TB S  •S -8
U U U U U
*8 *  u  *
m m  ft d«palmam
ftf <m m u *  V Mi
V
t V
861 bp
hyl primer pair hyp2° primer pair
Figure 3.1.9 -  PCR screen for hyl amongst typical and atypical 
pneumococci, and other oral streptococci. A; PCR rationale, B; Products 
separated through 1% agarose.
As can be seen, those strains that have given rise to amplification of a product 
of the expected size with the specific hyl primer pair have also done so with the 
degenerate hyp2° primer pair. Some templates gave rise to an amplification 
product that was smaller than expected (Col 5/hyl for example).
The results obtained from all strains tested are shown in table 3.1.11.
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Strain Strain
ID
Species Group* hyl primer 
pair
hyp2° 
primer pair
hyl
positive?
Col 1 667 S. pn (atypical) - - No
Col 3 668 5. pneumoniae A + + Yes
Col 5 669 S. pn (atypical) 800 . No
Col 6 670 S. pneumoniae A + + Yes
Col 7 671 S. pneumoniae A - - No
Col 8 672 S. pneumoniae A + + Yes
Col 9 673 S. pneumoniae A + + Yes
Col 11 674 S. pneumoniae A + + Yes
Col 12 675 S. pneumoniae A + + Yes
Col 13 676 na + + Yes
Col 14 677 S. pneumoniae A + + Yes
Col 15 678 S. mitis B 1000 - No
Col 16 679 S. mitis. B - + No
Col 17 680 S. mitis (atypical) - + No
Col 18 681 S. mitis B - - No
Col 19 682 S. mitis B 600 - No
Col 20 683 S. mitis B - - No
Col 21 684 S. oralis C 600 - No
Col 22 685 S. mitis B - - No
Col 24 686 S. pn (atypical) - - No
Col 25 687 S. oralis C 700 - No
Col 26 688 S. pn (atypical) - - No
Col 27 689 5. pn (atypical) - - No
Col 28 690 S. mitis B - - No
Table 3.1.11 — PCR screen for hyl in related streptococci. Where bands were 
observed, but not of the expected molecular weight, approximate sizes are given. 
Species designations of typical and atypical are based on the findings of 
Whatmore et al. (Whatmore et al., 2000). na - not available.
In this study, those strains that gave rise to a positive band of the expected 
size in both sets of PCR reactions were deemed hyl positive. Those that gave rise 
to only one band, or bands of spurious sizes were said to be hyl negative.
As can be seen, only those isolates determined to be typical pneumococci by 
Whatmore et al. proved to be hyl positive in this screen. One isolate (Col 7) 
belongs to an outgroup of the typical pneumococci, along with Col 11 and Col 
12. Interestingly, Col 7 was determined to be hyl negative, whereas Col 11 and 
Col 12 were hyl positive.
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Many of the strains examined in this study have previously been shown to 
harbour ply and lytA. Data presented here suggest that these strains do not contain 
hyl or loci bearing close similarity to hyl. This indicated a rather striking 
restriction of this locus to those strains identified as ‘typical’ pneumococci. This 
area is interest is under active investigation by another member of the group, 
following up these experiments with a Southern based screen for hyl 
homologues.
3.1.5.2 -  Discussion
The preceding sections show that the overall nucleotide divergence at the hyl 
locus is low, and that there is a bias for polymorphisms resulting in amino acid 
alterations to the translated protein to the a-domain. This may reflect either 
greater freedom of steric variation in the a-domain compared to the (}- domain, 
or may have implications in terms of the antigenicity of this part of the protein.
If the a-domain proved to harbour more immunodominant epitopes, then 
selective pressure from host immune surveillance might result in more alterations 
to this domain. If this were the case, we might expect to find the altered residues 
more frequently found in surface exposed loops, linking structural elements of 
this domain.
The crystal structure of pneumococcal hyaluronate lyase has recently been 
reported (Li et a l, 2000). Detailed information regarding the precise location of 
the individual a-helical components of the a-domain would enable us to 
precisely map the observed alterations to the protein, and further hypothesise on 
this issue. Representations have been made to the authors regarding this, however 
no additional information has been forthcoming.
Results described in section 3.1.S indicate that there is statistical evidence for 
recombination between pneumococcal hyl alleles. The inability to map correlate 
the polymorphisms observed with the homologous regions of other hyaluronate 
lyase sequences available in the public domain, or to locate homologous loci in 
related streptococci suggests that the variation observed is restricted to the intra­
species level. The occurrence of recombination between alleles of low overall 
nucleotide divergence, and the observation that polymorphisms are
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may have some bearing on the relatively high number of discrete hyl alleles found 
by HRRA, as compared to hexA and recP.
Another issue concerns the canonical pneumococcal sequence of hyl deposited 
by Berry et al. under the accession number L20670 (Berry el al., 1994). It is clear 
from the polymorphic sites represented in figure 3.1.5 that some modifications to 
the consensus sequence are required. These are given as follows, with amino acid 
alterations given in brackets. Numbering is shown with respect to L20670.
A399—>G, C445—>T (P119-»S), C*77^ A  (D196—>E), g 2281G2282—>TC (G731-W ). 
Alterations that occur in more than 50% of observed cases (5/8 or greater) are 
A147-»C (N20->H), C370->T (P94- ^ ) ,  A606- * !  (T173-»A), T757->C (I223->T), 
C1118—>T, A1372^ G  (N428—>S), G2028^ A  (D646—>N) and T2120->C.
3.1.6 -  Polynucleotide duplication in allele 22
Direct sequence data obtained in section 3.1.4 revealed that allele 22 
(sequenced from a serotype 19 carried isolate from Kenya -  ID 307) apparently 
contains a 24bp duplication near its 3’ end. Analysis of the region containing this 
duplication indicates that two independent duplication events seem to have 
occurred. This is illustrated in figure 3.1.10.
ttTiriniiTTrii»Ar.BS5a»»*rafc**A*TCTCAAr.A<MAAaAlAAAATCTCAAGAGGAAM^CCA'I"r
-------------------------------- * -------------------------------- + —  ------------------------- + -------------------------------- ♦  -  ----------------- - - -
CATGTCTTAAGTTTTCTTTTCC TTTTTAGACTTCTCCTTCT CTTGGTAA
V Q N S K E K E R K N L K R K K  K S E E E K N H
Figure 3.1.10 -  Duplicated region found in allele 22. The duplicated region is 
shown in red typeface, with the proposed duplications indicated.
As can be seen, the inserted sequence consists of two discrete elements, one 4 
bp in length and one of 20 bp. These lie in the region encompassing bases 2797- 
2821 of the L20670 sequence, with a single A —» G polymorphism in the 20 bp 
reiterated sequence. The structure observed seems to have arisen from two
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reiterated sequence. The structure observed seems to have arisen from two 
separate duplication events, either one alone would result in truncation of the 
translated protein. Taken together, these insertions restore the wild type protein 
sequence after the 20 bp insertion.
3.1.6.1 -  Discussion
The nature of this region is interesting, especially in the light that together, 
these sequences restore the reading frame of this mutant allele.
The duplication of the shorter of these sequences may have arisen as a result 
of slipped-strand mispairing (Levinson and Gutman, 1987) since there is a region 
of homology immediately 5' to this sequence.
The 20 bp insert is not preceded by any regions of notable homology, but may 
have arisen by a mechanism similar to the type proposed by Kless and Vermass, 
involving nicking of the nascent molecule, strand displacement, polymerisation 
of the new strand, and ligation of the displaced and newly formed strands to form 
the duplication. This is then resolved by replication of the entire molecule.
This system was demonstrated in the case of complementation of deletions in 
the Synechocystis D1 protein of photosystem II by the formation of tandem 
duplications under nutrient limited conditions (Kless and Vermass, 1995).
The observation that the penultimate residue of the reiterated sequence is 
different from the ‘parental’ sequence (G instead of A) is also interesting and 
may have arisen as a result of an error during replication.
The region including these elements falls outside the range of the structure 
given by Li et al. (Li et al., 2000), so it is not possible to speculate upon the 
structural implications of these insertions. However it is possible to determine 
whether hyaluronate lyase activity is affected in this strain. Assays with this 
mutant (described in the next section) revealed that enzyme activity is unaffected 
by these insertions, which occur close to the C-terminus of the protein.
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3.1.7 -  Truncation of the translation product of allele 2
Figure 3.1.5 shows that allele 2 (from strain 12B-13E, ID 922 - a carried 
serotype 3 isolate) contains an amber stop codon prior to the C-terminal cell wall 
anchor motif. This is another interesting feature that suggests that the translated 
protein would no longer be anchored to the cell wall. The strain from which this 
allele was sequenced belongs to a successful UK clone associated with invasive 
disease (Muller-Graf, 1999). Sequences of eight other allele 2-type strains were 
obtained, four from within this clone, and four strains not associated with the 
clone. The stop codon was found in the hyl loci from the clonally related strains, 
but not the unrelated strains. This will be returned to in Chapter 4, section 4.4.
The hyaluronate lyase phenotype of strain 12B-13E was examined, and is 
described in section 3.2.8.
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Appendix 3.1
Allele 7sp509I Mnll Hinfl Hsp91\\ Maelll
1 2 1 1 1 3
2 6 2 1 1 1
3 3 1 1 2 2
4 2 1 1 2 3
5 2 2 1 1 3
6 1 1 1 1 3
7 8 1 1 1 1
8 1 1 1 1 1 2
9 2 1 1 1 2
10 1 1 1 2 3
11 4 1 1 2 3
12 2 5 1 1 3
13 2 1 1 2 2
14 3 1 1 2 4
15 1 1 2 1 2
16 7 1 1 1 3
17 8 1 1 1 3
Table 3.1.12 - recP allele assignments.
Allele Alul Hhal Hinfl 7sp509I Hsp92U
1 1 1 1 2 1
2 1 1 2 2 2
3 2 1 1 2 2
4 1 1 1 2 2
5 3 1 1 2 2
6 5 1 1 2 3
7 6 1 1 2 2
8 1 2 1 2 2
9 1 1 1 3 2
10 9 1 2 2 2
11 4 1 1 2 2
12 1 1 1 1 3
13 1 1 1 2 3
14 7 1 1 2 2
15 10 1 1 2 2
Table 3.1.13 - hex A allele assignments.
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Allele Dde I Hae III Hinfl Msel Rsal
1 2 1 1 1 1
2 1 1 2 2 1
3 1 2 2 2 1
4 2 1 2 5 1
5 2 1 2 1 1
6 2 1 2 2 1
7 1 1 3 2 1
8 1 1 2 1 1
9 1 1 1 1 1
10 3 1 1 2 1
11 2 3 2 5 1
12 2 1 2 6 1
13 1 6 2 8 1
14 1 1 3 3 1
15 1 4 3 2 1
16 1 1 3 1 1
17 1 1 2 4 1
18 2 1 1 2 1
19 4 5 4 7 4
20 1 2 1 2 1
21 2 1 2 1 2
22 5 7 2 10 3
23 1 1 2 3 1
24 2 3 2 1 1
25 1 1 1 8 1
26 2 1 2 9 1
27 2 1 2 2 5
28 2 1 2 4 1
Table 3.1.14 - hyl allele assignments
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3.2 Assessment of phenotypic variation of hyaluronate lyase production
3.2.1 -  Introduction
As mentioned in the introduction (section 1.8.2), the phenotypes of pneumococci 
producing hyaluronate lyase are believed to vary (Kostyukova et til., 1995). As part of the 
work addressed in this project, it was decided that the analysis of genetic variation at the 
hyl locus should be complemented by a phenotypic analysis of hyaluronate lyase activity. 
In order to achieve this, a suitable assay (or assays) for hyaluronate lyase production 
needed to be found. It is evident from the literature that numerous hyaluronate lyase 
assays are available, as mentioned in section 1.8.2.1.
It was decided to proceed with the ‘Stains-all’ assay (to measure any decrease in 
substrate) alongside the spectroscopic method of Pritchard et al. (to monitor the 
accumulation of digest products). The final decision to proceed with these assays was 
based on practicability (with the intention to screen a large number of strains a rapid 
assay was required), cost effectiveness, and technical success in preliminary experiments.
3.2.2 Early experiments with ‘Stains-all’
Setting up the Stains-all assay was greatly helped by discussions with Dr.
Karen Homer. The assays were performed as described in section 2.2.3. Initially the 
Stains-all assay was tried using substrate supplied by Sigma-Aldrich Co. (sodium salt of 
hyaluronic acid derived from bovine trachea). When making aqueous solutions of the 
material supplied, it was seen that the viscosity of the solution was not high (as expected 
from the literature), and that the reaction with the ’Stains-all’ reagent was also not as 
expected. Rather than getting a shift from purple to blue colouration, the solution rapidly 
changed to a straw-yellow colour. This was indicative of some form of bleaching or 
collapse of the chromophore, similar to the effect of acidifying the ’Stains-all’ solution. 
Attempts to remedy this by making buffered hyaluronate solutions were unsuccessful.
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The next step was to switch to an alternative source of hyaluronic acid. The 
hyaluronic acid derived from human umbilical cord, supplied by ICN 
Pharmaceuticals, was tried next. This material gave rise to highly viscous aqueous 
solutions. It also gave the desired colouration upon interaction with ‘Stains-all’. 
This material was used in early experiments to derive standard curves from serial 
dilutions of hyaluronate solutions using a Dynex spectrophotometer. These curves 
are shown in figure 3.2.1. It was later noted that the material supplied by Fluka 
Chemicals was also appropriate for use in these experiments (also from human 
umbilical cord). It was concluded that differences in the source of hyaluronic acid 
(and possible differences in preparation at source) were at the source of the early 
problems encountered using this assay. Attempts to distinguish between the various 
sources of HA were made by MALDI MS. This indicated that qualitative 
differences existed between the material supplied by Sigma and those supplied by 
both ICN and Fluka. These experiments showed that with at least one matrix 
(dihydroxybenzoate), the distribution of dominant peaks was similar for both the 
ICN and Fluka material, but different for the Sigma material (data not shown).
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Stains-all Serial Dilution Curve
A
[HA](mg/ml)
Stains-all Linear Curve 1
B
0.8
0.6
0.4
0.2
0
c  Stains-all Linear Curve 2
0.5 
0.4 
0.3 
0.2 
0.1 
0
-0.1 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
[HA](mg/ml)
Figure 3.2.1 -  Early standard curves obtained using the ‘Stains-all’ assay. A) 
Over the range 5 -0mg/ml., B) Over the range 2-0.2mg/ml., and C) over the range 
1-0. lmg/ml. Note -  The wavelengths used differ by 20nm as these experiments 
were conducted using different spectrophotometers, equipped with different filters.
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Figure 3.2.1 shows the variation of optical density over three concentration ranges. As 
can be seen, two different wavelengths were used for these experiments (630nm and 
650nm). This reflects a change of instrumentation in the lab, the Dynex MRX 
spectrophotometer (with a 630nm filter) being replaced with the Labsystems iEMS plate 
reader (with a 650nm filter). Both wavelengths proved to be suitable for the assay. 
Reasonably good linear responses are seen over the range [2-0mg/ml]. However, it is also 
apparent that it is not possible to combine the curves. That is, the optical density at 
1 mg/ml for curve B is not equal to the optical density for the same concentration in curve 
C. Such variation was repeatedly found during the course of subsequent experiments. It 
was noted that solutions of ‘Stains-all’ were not suitable for storage, even at 4°C. Older 
batches of ‘Stains-all’ solution gave less coherent standard curves with greater errors 
between replicates (data not shown). From these observations the following protocols 
were adopted; for each set of assays, fresh ‘Stains-all’ solutions were made. For each 
batch made, standard curves were derived over the concentration range 0.5-0.05mg/ml to 
ensure that the reagents were performing reliably. An example of such a curve is shown 
in figure 3.2.2 (below).
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[HA](mg/ml)
HA/SA std curve
Figure 3.2.2 -  Standard curve obtained with the ‘Stains-ail’ assay.
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The 'Stains-all' assay gave good linear responses within a particular batch of reagent, 
but not from batch to batch, making direct comparisons of substrate concentration 
between sets of experiments difficult. To this end, the assay was conducted in the basis of 
an internal control comparison. Since the quantity o f HA (hyaluronic acid) used in each 
digest was fixed, negative controls where no cells or crude enzyme preparation were 
added to the HA were deemed to be comparable between experiments. Any kinetic 
degradation of substrate over the course of the digest was assumed to be similar over all 
experiments. Thus the internal negative control reaction gave the maximum expected OD 
(630nm/650nm) reading for each experiment. The ratio of the OD obtained for a given 
digest to this maximum value was taken as the basis for the assay.
3.2.3 - The UV/Vis. spectrophotometric assay of Pritchard et at.
This spectrophotometric assay described in section 1.8.2.1 proved to be easy to 
perform on digest mixtures, and was deemed to be a suitable secondary assay to use 
alongside the 'Stains-all' assay; where one measures the decrease in substrate, the other 
monitors the accumulation of specific reaction products.
This assay has been used to monitor the accumulation of the disaccharide liberated by 
hyaluronate lyase (AUA GlcNAc) by a number of independent investigators (Lineker and 
Meyer, 1954, Yamataga et at., 1968, Homer et at., 1994 and Lin et at., 1997).
Control experiments described below also indicated that the assay was a suitable one 
to use alongside the 'Stains-all' assay previously described. The concentration of the 
unsaturated N-acetylhyalobiuronic acid product of the reaction is calculated using a 
millimolar absorption coefficient (e) o f  5.5 (Lin et a l,  1997). A standard curve derived 
using this assay is shown in figure 3.2.2.1.
3.2.4 - Early digests -  Induction o f  hyaluronate lyase
Before hyaluronate lyase assays were conducted on a large range o f isolates, a
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Ate. 232 Assay Standard Qrve
Ee
CNm
<
4
[DG\](mM)
Figure 3.2.2.1 - Standard curve using the Abs. 232nm method. Measurements were 
obtained from serial dilutions of a hyaluronate digest by strain ID 161 after induction in
CMHA.
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number of experiments were carried out to qualify the methodology to be employed. 
These were conducted with a small number of isolates, including the laboratory strain, 
R6. Digests were set up according to the methodology of Homer et al. {personal 
communication.). Briefly, strains were grown overnight on blood-BHI agar plates, and 
cells harvested into Tris buffer. Cell suspensions were used as crude enzyme preparations 
on the basis of the LPXTG cell wall anchor motif described in section 1.7.10. The optical 
densities were adjusted to 0.1 (path-length = 1 cm). This was used as a crude enzyme 
preparation to inoculate buffered hyaluronate (HA). Degradation of the substrate was 
seen over time (some examples are shown in figure 3.2.3), as shown by the ’Stains-all’ 
assay (where a reduction in Abs.6so reflects depolymerisation of the HA substrate). As 
can be seen, different strains depolymerised the substrate at different rates.
1.8
1.6
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1.4
S 1.2</->
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1 0.8
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0.4
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0
0 5 24
Time (hours)
Figure 3.2.3 -  Depolymerisation of HA by hyaluronate lyase from pneumococci 
grown on BHI/blood agar.
The next issue addressed was that of the potential inducibility of hyaluronate lyase 
production in pneumococci. This has not been reported elsewhere, but such an effect 
seemed plausible given the nature of the enzyme function. Pneumococci were harvested 
from BHI-blood agar plates and then incubated in C medium made using no C6 sugars.
To this was added various sugars including glucose, HA, glucuronic acid and N-acetyl 
glucosamine. These were incubated for periods of time varying from 30 min. to 3 hours. 
Cells were recovered by centrifugation,
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washed and resuspended in Tris buffer as described above. ’Stains-all’ assays were 
conducted, and the results compared with those obtained for those obtained with the same 
strains taken straight from BHI-agar. The only conditions under which a difference was 
seen were those in which the cells were incubated in C-medium plus HA (CMHA) for 3 
hours (the difference in phenotype was not seen with shorter incubations). An example of 
such an effect is shown in figure 3.2.4.
Figure 3.2.4 -  Depolymerisation of HA by hyaluronate lyase from pneumococci 
after induction in CMHA.
As can be seen, for the strains used here, both the rate of depolymerisation, and the 
overall extent of depolymerisation have been increased by the treatment with CMHA. It 
was later found that growing the cells on BHI-blood agar, which had been overlaid with 
aqueous HA could reproduce this effect.
A number of experiments were conducted to determine whether this induction effect 
was subject to catabolite repression by glucose, by using CMHA containing various 
concentrations of glucose and N-acetyl glucosamine. In no case was there seen to be a 
loss of induction in inducible strains.
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3.2.5 -  Accumulation of hyaluronate lyase activity data
Hyaluronate digests were performed using whole cell suspensions of cells grown 
overnight on Blood-BHI agar at 37°C. The inducible phenotype of some strains 
indicated in section 3.2.4 was also further investigated by incubation of aliquots of 
the same strains in minimal C - medium supplemented with HA (described in detail 
in section 2.1.1) for 3h prior to inoculation of HA solutions. The ’Stains-all’ assays 
were performed in quadruplicate, and absorbance values of each digest were 
compared with that of the internal (no hyaluronate lyase) control. The unit of 
activity was defined as a reduction of the internal (no hyaluronate lyase) control 
value by 10%, after Benchetrit (Benchetrit el a i, 1978). The mean absorbance 
value and standard deviation was calculated for each set of readings. Units of 
activity were calculated on the basis of the mean values obtained, with 95% 
confidence limits (CL) based on the standard deviation of each set of quadruplicate 
readings.
In some cases, the Abs.oso for the sample was slightly higher than that for the 
negative control. For ease of computation these values were recorded as activity 
’not detected’. The higher absorption in these assays indicated that there was more 
HA in the sample after the digest than before. Since no HA synthetase has been 
reported in pneumococci, this was thought to be unlikely. The increase in Abs.65o 
has been attributed to one of two possible factors; The presumed presence of other 
complex polysaccharides in the solution, transferred with the whole cell fraction. It 
is arguable that if this is the case, carryover of interfering substances (which react 
with ’Stains-all’in the same way as HA) may mask hyaluronate lyase activity. 
Alternatively, the higher OD’s may simply reflect the variability of this assay 
system, and form part of the inherent error in the measurements.
The aim of these studies was to determine whether variation in hyaluronate lyase 
activity amongst a population of strains correlates with either site of isolation 
(disease state), or allelic variation at the hyl locus. Since some strains give a 
negative result with the 'Stains-all' assay, it is arguable that these results cannot be 
taken to be true measures of activity. However, since two assays have been used, it 
is suggested that independent treatment of these data sets will indicate correlations
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if there are any. That is to say, where a statistically significant result is missed 
using one assay, it is picked up in the second.
The tables in appendix 3.2 (tables 3.2.5 -  3.2.9) show the data obtained for the 
strains studied. They are divided into five groups representing the state from which 
each strain was isolated. These are blood (bacteraemia), carried (asymptomatic), 
lung (lower respiratory tract infection, or pneumonia), CSF (meningitis) and ear 
(otitis media). Activities under non-inducing (‘Normal’) and inducing conditions 
are given.
3.2.6 -  Statistical treatment of hyaluronate lyase activity data
In the first instance the average values of each set of titres, for each group were 
compared. These values are shown in table 3.2.1.
Normal SA 
Average Titre
Induced SA 
Average Titre
Normal [AUA 
GlcNAc]
Induced [AUA 
GlcNAc]
Blood 4.425 7.052 0.42 0.79
Carried 3.004 6.379 0.36 0.79
Lung 1.575 3.917 0.12 0.46
CSF 3.501 6.701 0.31 0.73
Ear 3.445 6.095 0.25 0.65
Table 3.2.1 -  Average hyaluronate lyase titres of the strains included in this 
study.
By observation, several points can be drawn from the data in this table: it is 
apparent that the activities of the groups of isolates are similar - with the exception 
of the lung isolates, which have lower average titres. Also it seems that induction of 
hyaluronate lyase occurred in all groups. However, the data analysed here are 
average values, taken from groups with high variability between individual strains. 
It was considered necessary to formalise the analysis of these observations.
When looking for variation between population samples such as these, the 
statistical method of ‘analysis of variance’ or anova is used. This technique 
compares the ratio of variation within a group (in this case groups are blood, CSF
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etc.), with variation between the groups (blood vs. CSF, vs. carried etc.), and is 
described in some detail in chapter 2, section 2.2.4.
Since the numbers of strains included in each group were not equal, a model II 
anova was used, which weights the intra group variance in accordance with the 
group sample size.
The output of the anova procedure (Fs) is compared with a predetermined value 
(Fcrit), derived from a theoretical probability distribution. This ratio of Fs to Fcnt is 
then used to either prove or disprove the null-hypothesis, which states that two 
populations vary in the same way, and therefore do not differ significantly from one 
another. The results of these calculations are given in table 3.2.2 below.
Stains-all [AUA GlcNAcl Assay
Fs Peril P N-H? Fs Fern P N-H?
Normal 2.862 2.421 0.024 No 3.302 2.424 0.012 No
Induced 3.193 2.421 0.004 No 2.554 2.424 0.040 No
Table 3.2.2 -  Results of F tests over all groups of isolates studied. N-H -  is the
null-hypothesis supported?
As can be seen, in all cases the null hypothesis has been rejected. That is to say 
Fs > Fcrii, and P<0.05. Thus in both the normal, and the induced data sets, using 
both assays, there is an added element (or elements) of variation, indicating a 
significant statistical difference between the groups.
In order to establish the source of this variation, the Tukey-Kramer method was 
used to make unplanned post-hoc comparisons of the data. This method is 
described in section 2.2.4.1. The results of this analysis show that it is the lung 
isolates that lead to the increased variance from the means during the Anova 
procedure. The activity of hyaluronate lyase in this group of strains is lower than 
that of the carried, CSF and blood isolates, but not of the otitis isolates. 
Combinations of other pairs of groups do not lead to significant differences beyond 
that expected by chance, and repetition of the Anova without the lung strains 
included leads to the acceptance of the null hypothesis in all cases. The data 
obtained from the Tukey-Kramer procedure are given in table 3.2.3.
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‘Stains-all’ Assay
Blood Carried CSF Lung Otits
Blood X 2.299 2.191 2.519 2.905
2.511 2.395 2.750 3.175
Carried 1.420 X 1.608 2.029 2.492
0.673 1.759 2.218 2.727
CSF 0.924 0.496 X 1.909 2.395
0.303 0.370 2.087 2.619
Lung 2.850 1.430 1.926 X 2.696
3.136 2.463 2.833 2.947
Otitis 0.980 0.440 0.056 1.870 X
0.957 0.284 0.654 2.179
[AUA GIcNAc] Assay
Blood Carried CSF Lung Otits
Blood X 0.231 0.219 0.262 0.293
0.358 0.316 0.370 0.146
Carried 0.059 X 0.162 0.212 0.250
0.008 0.235 0.304 0.354
CSF 0.114 0.055 X 0.204 0.243
0.069 0.077 0.289 0.347
Lung 0.304 0.245 0.190 X 0.277
0.329 0.337 0.260 0.397
Otitis 0.171 0.112 0.057 0.133 X
0.140 0.148 0.071 0.189
Table 3.2.3 -  O utput of the Tuke y-K ra m e r post-hoc analysis of the Anova results. The
upper right portion of each matrix gives MSD, the lower left gives actual difference 
between means. Blue denotes data obtained under non inducing conditions, red denotes 
induced activity data. Values that differ significantly are underlined.
Importantly, there is no evidence presented to support the findings of Kostoyukova et 
al. who associated high hyaluronate lyase titres with CSF isolates (Kostoyukova etal., 
1995).
This work does seem to indicate that there is an induction effect upon pre-incubation of 
isolates in media containing HA. This indication was investigated using the paired T-test. 
This was carried out for data from both assays and is presented in table 3.2.4 below.
Stains-all [A U A  GIcNAc] Assay
T , Tcrit P N-H? T . Tgrit p N-H?
Normal
vs
Induced
14.705 2.131 6.22 X 
Iff5
No 23.681 2.131 9.43 X 
10"6
No
Table 3.2.4 - Paired T-test results investigating the significance of the 
induction effect on mean titres.
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These results clearly show that there is a statistically significant effect of incubation of 
isolates in media containing HA prior to assay, by two independent assay data sets.
3.2.7 -  Can hyaluronate lyase phenotype be related to genotype?
The question of correlating phenotypic observations with the allele designations 
defined in the previous chapter was addressed next. The groups of isolates used for the 
allelic variation assessment and the phenotypic assessment were not identical, however 
there was a large group of isolates (64 in total) from the phenotypic study whose hyl 
alleles had been defined by HRRA. Once again, anova was used to investigate the 
variance within the individual groups (based on allele type this time) and across the 
groups. The null hypothesis in this case was ‘there is no correlation between hyaluronate 
lyase titre and representative allele’. Since the anova procedure requires that groups 
contain more than one value (some allele types were represented by only one strain), the 
total number of strains used in this study was reduced to 54. The alleles represented were 
1, 2, 5, 8, 10, 11, 16 and 17 (alleles 1, 2, 5, 8, and 17 were found to be the most common 
in the work outlined in section 3.1). As before, data sets from both assays were used. 
Data taken from assays of hyaluronate lyase activity under normal and inducing 
conditions were compared also. These are shown in table 3.2.4.1.
Non-induced Induced
Allele ‘Stains-all’ TAUA GlcNAcl ‘Stains-alT [AUA GlcNAc]
1 3.749 0.46 7.735 h 0.91
2 3.028 0.32 6.191 0.80
5 3.238 0.35 8.434 0.91
8 3.885 0.35 6.766 0.73
10 5.272 0.75 4.729 0.78
11 2.475 0.12 0.655 0.17
16 1.260 0.11 5.901 0.43
17 0.037 0.06 0.711 0.14
Table 3.2.4.1 -  Average hyaluronate lyase titres of allele representative strains.
As before, one way Anova was performed on the data to assess the extent of 
phenotypic variation between the strains studied. Using the criteria outlined in the
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previous section, the null hypothesis was accepted for the non-induced data set (‘Stains- 
all’ assay: Fs=0.818, Fcrj,=2.216, P=0.576, [AUA GlcNAc] Assay: Fs=1.066, Fcril=2.221, 
P=0.4). The situation for the induced data set was complicated by the rejection of the null 
hypothesis for the ‘Stains-all’ assay (Fs=3.064, FCni=2.216, P=0.0098), and the acceptance 
of the null hypothesis using the data from the [AUA GlcNAc] Assay (Fs= 1.593, 
FCnt=2.221, P=0.161).
The rejection of the null hypothesis for the ‘Stains-alf data was investigated using the 
Tukey-Kramer method as described previously. The results of this show that the strains 
bearing hyl alleles 11 and 17 showed less hyaluronate lyase activity than those bearing 
allele 1, and that the allele 11 strains were also significantly less active than the allele 8 
strains. The sample sizes of the allele 11 and 17 strain groups were low however (n = 2 
and 3 respectively), and so other representatives of these alleles would need to be 
analysed before any firm conclusions can be drawn from this result.
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3.2.8 -  Activity of the truncated hyaluronate lyase encoded by allele 2
As mentioned in section 3.1.7, allele 2 contains a stop codon in the hyaluronate lyase 
ORF at position 835 with respect to the 949 amino acid protein. The cell wall anchor 
motif lies C-terminal to this, so it was hypothesised that if an active protein were to be 
produced by this allele, activity might be found in the cell culture supernatant, rather than 
associated with the cell.
The strain from which allele 2 was sequenced (ID 922) was grown in C-medium until 
early exponential phase. Cells were removed by centrifugation and the pellet resuspended 
in tris buffer. Culture supernatant and resuspended cells were used in HA digests as 
previously described, and the production of AUA GlcNAc was measured at 232nm after 
incubation at 37°C for 24 hours. The results of this experiment are shown in figure 3.2.5, 
below.
C e l l  f r a c t i o n  S u p e r n a t a n t  N e g a t i v e  c o n t r o l
Figure 3.23 -  Production of AUA GlcNAc by hyaluronate lyase encoded by allele 2 
from strain ID 922.
As can be seen from figure 3.2.5, hyaluronate lyase activity is high in the supernatant 
fraction but negligible activity is associated with the cell. This is a clear indication that 
allele 2 from strain 922 is able to produce an active enzyme, which dissociates from the 
cell. It is unlikely that supernatant activity is seen due to autolysis of the growing cells, as 
the experiment was carried out using pneumococci growing at early exponential phase.
This observation runs counter to the assertion of Berry el al. (Berry et al., 1994) that 
hyaluronate lyase is released from the cytoplasm in a LytA dependent manner, and 
supports the hypothesis outlined in chapter 1 - section 1.8.6, that the hyl ORF as 
described is incomplete,
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and is likely to include a gram positive signal sequence. This question is returned to 
in section 3.6.
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Appendix 3.2
Hvaluronate lvase activity  data
The final column in each table indicates whether or not the given strain is inducible The total 
number of inducible strains is shown at the bottom of this column as a proportion of those strains 
studied in each group. N(C) denotes that induction was not seen as the strain produced high 
hyaluronate lyase titres under non- inducing conditions also. AUA GIcNAc is given as the 
abbreviation of the pneumococcal hyaluronate lyase reaction product, and concentration is 
expressed in mM. This crude value was taken as the titre in these assays. NA indicates that data 
were not available. Av denotes the average value of activities given, nd =activity not detected. 
Induction was scored as an increase in titre (using either assay) o f > 20%.
Blood Normal Induced Induction?
Strain Units
(SA)
95%CL [AUA
GIcNAc)
Units
(SA)
95%CL [AUA
GIcNAcl
36 nd - 0.06 2.463 0.725 0.12 Y
31 1.472 0.761 0.11 7.144 0.106 0.48 Y
75 1.530 1.508 0.05 1.231 0.762 0.06 N
77 0.627 0.957 0.13 9.099 0.084 1.15 Y
81 8.154 0.077 0.56 9.064 0.046 1.14 Y
87 9.270 0.055 1.02 9.071 0.089 1.00 N(C)
91 2.310 2.302 0.11 2.870 0.551 0.15 N
107 nd - 0.11 0.424 1.259 0.09 Y
110 9.280 0.045 0.82 9.117 0.029 1.14 N(C)
116 8.806 0.071 0.71 9.117 0.029 1.09 Y
117 0.528 0.385 0.10 3.037 0.794 0.20 Y
145 8.074 0.414 0.58 9.120 0.042 1.11 Y
161 9.155 0.058 1.14 9.103 0.029 1.09 N(C)
314 8.621 0.231 0.67 9.099 0.021 1.31 Y
324 6.832 0.035 0.44 9.099 0.038 1.07 Y
329 1.142 0.908 0.07 8.849 0.244 0.66 Y
342 1.373 1.053 0.29 9.078 0.028 1.02 Y
353 nd - 0.13 6.261 0.591 0.35 Y
354 4.614 3.116 0.58 8.762 0.164 1.79 Y
355 6.723 0.317 0.78 9.037 0.073 0.89 Y
Av 4.425 0.42 7.052 0.79 15/20
Table 3.2.5 -  Hyaluronate lyase activities of strains isolated from bacteraemic 
patients.
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Carried Normal Induced Induction?
Strain Units
(SA)
95%CL [AUA
GIcNAcl
Units
(SA)
95%CL [AUA
GIcNAc]
864 nd - 0.09 4.317 0.832 0.45 Y
885 nd - 0.23 8.927 0.588 0.57 Y
914 4.536 0.241 0.49 8.641 0.616 1.08 Y
949 nd - 0.11 nd - 0.35 Y
965 0.814 0.426 0.31 8.951 0.570 1.38 Y
905 3.802 0.257 0.36 9.039 0.054 1.44 Y
901 2.544 1.517 0.51 5.793 0.074 0.51 Y
880 2.461 0.790 0.37 4.733 0.110 0.41 Y
862 5.242 0.725 0.52 9.053 0.055 1.37 Y
872 2.738 0.578 0.15 4.391 0.085 0.60 Y
878 2.022 0.934 0.16 1.310 0.089 0.28 N
882 2.929 1.015 0.09 nd - 0.07 N
903 2.430 1.030 0.07 9.070 0.048 0.70 Y
869 1.292 0.465 0.29 0.219 0.151 0.23 N
865 nd - 0.06 7.378 0.039 0.58 Y
922 1.263 0.624 0.36 1.066 0.144 0.60 N
884 9.141 0.062 1.39 9.265 0.044 2.02 N(C)
902 9.252 0.073 1.22 9.239 0.043 1.34 N(C)
873 8.390 0.076 0.64 9.141 0.046 0.96 Y
877 7.216 0.190 0.60 9.222 0.039 1.35 Y
904 2.022 0.324 0.22 9.248 0.038 1.33 Y
956 8.382 0.115 0.68 9.193 0.042 1.11 Y
948 8.294 0.121 0.78 9.248 0.034 1.24 Y
945 nd - 0.10 8.966 0.437 0.73 Y
943 nd - 0.05 4.815 0.859 0.45 Y
867 8.894 0.109 1.05 8.974 0.393 1.32 N(C)
879 8.863 0.090 1.09 8.936 0.441 1.43 N(C)
923 nd - 0.08 8.931 0.455 1.33 Y
866 2.504 0.705 0.33 7.026 0.520 0.81 ' Y
919 nd - 0.06 0.665 1.026 0.17 N
921 nd - 0.06 1.468 0.915 0.21 Y
861 nd - 0.11 8.927 0.468 0.34 Y
947 nd - 0.07 2.524 0.624 0.35 Y
909 8.137 0.588 1.19 8.940 0.072 1.22 N(C)
908 0.664 1.260 0.12 8.858 0.119 0.98 Y
906 8.292 0.543 0.78 8.970 0.111 1.08 N(C)
917 2.535 0.634 0.26 8.974 0.105 1.25 Y
918 8.912 0.451 1.11 8.927 0.072 1.26 N(C)
967 1.088 1.369 0.13 6.386 0.168 0.62 Y
876 4.288 0.656 0.34 4.597 0.305 0.39 N
952 0.686 1.345 0.10 8.927 0.079 1.07 Y
913 0.111 1.521 0.05 nd - 0.05 N
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916 0.049 1.266 0.12 8.893 0.085 1.15 Y
863 3.894 0.547 0.45 8.884 0.116 1.14 Y
871 nd - 0.12 7.691 0.307 0.67 Y
875 0.044 2.074 0.07 1.871 0.693 0.26 Y
907 0.783 2.496 0.13 7.107 0.176 0.73 Y
910 1.584 1.212 0.11 1.871 0.975 0.19 N
911 1.150 0.690 0.09 3.009 0.658 0.22 Y
Av 3.004 0.36 6.379 0.79 34/49
Table 3.2.6 -  Hyaluronate lyase activities of strains isolated from asymptomatic 
carriers.
Lung Normal Induced Induction?
Strain Units
(SA)
95%CL [AUA
GlcNAcl
Units
(SA)
95%CL [AUA
GlcNAcl
3 nd - 0.05 1.233 0.674 0.19 Y
28 0.291 1.345 0.09 9.167 0.530 0.94 Y
162 nd - 0.03 nd - 0.03 N
166 0.029 0.774 0.09 nd - 0.01 N
167 nd - NA 0.011 0.193 NA N
307 0.459 1.007 0.07 0.552 1.181 0.11 Y
432 nd - 0.05 1.967 1.492 0.21 Y
304 7.328 0.144 0.03 8.972 0.181 1.18 Y
123 5.449 0.218 0.39 7.673 0.098 0.50 Y
154 5.859 0.230 0.44 9.113 0.056 1.22 Y
176 1.404 0.316 0.21 9.130 0.055 1.07 Y
301 6.632 0.489 0.51 8.870 0.069 1.07 Y
303 nd - 0.04 4.676 0.100 0.34 Y
308 2.969 0.536 0.27 9.141 0.058 1.22 Y
312 1.026 0.703 0.05 9.059 0.059 1.23 Y
315 0.078 0.547 0.09 2.666 0.072 0.18 Y
317 1.333 0.925 0.03 2.038 0.098 0.26 Y
339 nd - NA 8.831 0.052 NA Y
467 nd - 0.04 1.094 0.068 0.05 Y
468 0.403 0.759 0.05 0.232 0.169 0.03 N
26 9.315 0.047 0.09 9.379 0.384 0.70 N(C)
27 nd - NA nd - NA N
44 nd - 0.02 nd - 0.03 N
45 0.522 0.356 0.24 9.311 0.313 0.96 Y
46 0.753 1.256 0.03 nd - 0.03 N
103 0.504 1.738 0.03 0.477 1.106 0.02 N
106 0.771 0.857 0.02 nd - 0.01 N
139 0.298 1.078 0.03 nd - 0.07 N
163 0.265 1.512 NA nd - NA N
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1 Av I 1.575 I I 0.12 I 3.917 | | 0,46 | 17/29 |
Table 3.2.7 — Hyaluronate lyase activities of strains isolated from lower respiratory 
tract infections.
CSF Normal Induced Induction?
Strain Units
(SA)
95%CL [AUA
GIcNAcl
Units
(SA)
95%CL [AUA
GlcNAc]
1795 9.244 0.035 1.36 8.993 0.544 1.03 N(C)
1796 3.510 0.746 0.16 9.440 2.456 1.12 Y
1797 3.324 0.320 0.21 7.199 0.851 0.64 Y
1798 5.308 0.409 0.36 0.034 1.367 0.09 N
1799 1.722 0.288 0.15 7.913 0.777 0.61 Y
1800 6.110 0.502 0.83 9.450 1.758 0.62 Y
1801 2.487 0.684 0.36 8.916 0.555 1.01 Y
1802 2.344 0.127 0.10 8.318 0.757 0.53 Y
1803 0.253 0.532 0.09 8.903 0.608 1.01 Y
1804 4.912 0.226 0.20 8.959 0.585 0.95 Y
1805 nd - 0.05 8.924 0.469 0.98 Y
1806 2.192 1.234 0.19 8.933 0.589 1.05 Y
1807 2.636 0.424 0.14 8.924 0.654 1.06 Y
1808 2.539 1.702 0.18 8.924 0.607 1.25 Y
1809 2.477 0.557 0.08 5.968 0.799 0.40 Y
1810 nd - 0.02 nd - 0.09 N
1811 0.749 0.438 0.17 7.461 0.726 0.67 Y
1812 nd - 0.01 nd - 0.07 ^  N
1813 9.303 0.062 1.14 8.963 0.618 1.19 N(C)
1814 5.927 0.433 0.10 7.341 0.629 0.36 Y
1815 0.062 0.219 0.14 9.023 0.635 1.16 Y
1816 nd - 0.11 8.804 0.704 0.78 Y
1817 7.276 0.291 0.33 7.672 1.374 0.66 N(C)
1818 1.086 0.469 0.05 6.829 0.704 0.68 Y
1819 1.638 0.480 0.03 9.840 1.534 1.02 Y
1820 8.907 0.093 0.82 8.920 0.664 1.02 NIC)
1821 5.290 0.342 0.36 8.723 0.720 0.72 Y
1822 1.383 1.430 0.24 8.924 0.689 0.88 Y
1823 8.466 0.060 0.74 8.949 0.670 1.09 NIC)
1824 7.087 0.160 0.53 8.961 0.666 1.10 Y
1825 9.034 0.056 0.92 9.020 0.606 1.05 NIC)
1826 0.409 0.551 0.14 5.226 0.517 0.46 Y
1827 7.162 0.209 0.57 9.003 0.721 1.13 Y
1828 7.719 0.277 0.62 8.936 0.694 1.09 Y
1829 1.204 0.602 0.24 nd - 0.13 N
1830 2.576 0.404 0.28 2.835 1.235 0.39 N
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1831 7.532 0.150 0.58 9.038 0.591 1.10 Y
1832 6.807 0.266 0.30 9.170 0.498 1.26 Y
1833 7.279 0.453 0.51 8.405 0.640 0.65 Y
1834 5.888 0.165 0.26 9.119 0.573 1.25 Y
1835 1.472 0.821 0.11 9.140 0.540 0.78 Y
1836 6.869 0.202 0.49 9.071 0.580 0.90 Y
1837 8.301 0.271 1.06 9.056 0.637 1.25 N
1838 1.999 1.398 0.11 9.100 0.573 0.68 Y
1839 2.739 0.522 0.09 8.603 0.524 0.38 Y
1840 7.686 0.060 0.43 9.067 0.610 0.91 Y
1841 nd - 0.47 1.898 0.674 0.30 N
1842 1.985 0.643 0.06 3.770 0.898 0.26 Y
1843 nd - 0.08 5.256 0.677 0.41 Y
1844 nd - 0.16 8.774 0.652 0.98 Y
1845 nd - 0.11 8.765 0.672 1.04 Y
1846 nd - 0.15 7.283 0.766 0.53 Y
1847 nd - 0.04 nd - 0.05 N
1848 nd - 0.06 nd - 0.04 N
1849 nd - NA nd - NA N
1850 nd - 0.29 8.216 0.901 0.95 Y
1851 nd - 0.07 2.731 1.005 0.28 Y
1852 nd - 0.03 nd - 0.04 N
1853 nd - 0.35 8.788 0.671 1.00 Y
1854 nd - 0.11 6.958 1.063 1.19 Y
1856 8.887 0.072 0.63 9.383 0.337 0.90 Y
1857 2.251 1.025 0.50 3.589 0.611 0.80 Y
1860 3.763 1.068 0.90 3.511 0.905 1.00 N
1861 2.927 0.197 0.04 2.518 1.263 0.06 N
1862 3.685 0.569 0.06 3.865 0.419 0.05 N
1863 3.608 0.828 0.05 3.228 0.851 0.06 N
1864 3.967 0.225 NA 3.083 1.433 NA N
1865 4.646 0.598 NA 4.395 0.816 NA N
1866 5.387 0.169 NA 9.386 0.328 NA Y
1867 9.430 0.039 NA 9.400 0.298 NA N
1868 7.162 0.243 NA 9.412 0.298 NA Y
Av 3.501 0.31 6.701 0.73 47/71
Table 3.2.8 -  Hyaluronate lyase activities of strains isolated from CSF.
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Ear Normal Induced Induction?
Strain Units
(SA)
95%CL [AUA
GlcNAcl
Units
(SA)
95%CL [AUA
GlcNAc]
63 1.900 0.959 0.05 9.215 0.369 0.77 Y
59 3.705 0.695 0.09 3.658 0.409 0.17 N
197 4.388 0.523 0.14 9.321 0.380 1.10 Y
192 3.834 0.611 0.09 9.305 0.412 0.92 Y
10 3.693 0.557 0.10 9.297 0.403 0.96 Y
65 5.098 0.275 0.21 9.302 0.441 1.86 Y
55 3.780 0.269 0.04 3.343 1.015 0.10 N
347 5.207 0.243 0.17 8.892 0.378 0.52 Y
492 2.610 1.148 0.06 nd - 0.04 N
481 2.366 1.110 0.32 9.305 0.395 0.76 h Y
425 nd - 0.06 nd - 0.07 N
430 9.261 0.056 1.20 9.231 0.398 1.20 N(C)
428 9.285 0.099 1.20 9.288 0.399 1.40 N
213 nd - 0.23 6.367 0.571 0.52 Y
474 nd - 0.03 nd - 0.02 N
473 nd - 0.05 1.000 0.278 0.07 N
Av 3.445 0.25 6.095 0.65 8/16
Table 3.2.9 -  Hyaluronate lyase activities of strains isolated from the middle ear.
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3.3 -  Hyaluronate lyase negative mutants -  Natural and experimental
3.3.1 -  Introduction
The work described in this section concerns the functional deletion of hyl, and 
phenotypic characterisation of the resultant mutants. Two mutants are described. 
One is a naturally occurring deletion mutant and one has been generated by 
insertion-recombination mutagenesis. These are described in turn.
3.3.2 - Restriction mapping the deletion from strain 619 (ID 53)
As mentioned in section 3.1.3.3, one of the isolates (619 - strain ID 53) 
examined gave rise to a hyl PCR product that was approximately 400 bp smaller 
than the wild type product. This strain was a vaginal sepsis isolate. The small PCR 
product was either the result of spurious amplification of a non-specific product 
(deemed unlikely due to the relatively high annealing temperature used in the PCR 
reaction, and the absence of this sized product from any other strain), or the loss of 
part of the hyl gene. Data from the HRRA analysis described in section 3.1 were 
used to map this proposed deletion. Figure 3.3.1 is a representation of the various 
digests used in the HRRA procedure. The presence or absence of bands 
representing the respective digest products is indicated.
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0 2695
Ddel I I  | 1 | Ml
✓  ✓  ✓ ✓
0  2695
Msel □
V V V
0 2695
Rsal
✓  ✓  ✓  ✓  ✓
Figure 3.3.1 - Diagrammatic representation of the expected restriction sites on 
the database hyl sequence (approximate positions shown). Ticks below each 
fragment indicate that the particular band was seen with the deletion mutant allele 
19. Asterisks indicate that the band was expected but not seen. This was because 
the expected size of the band was too small or the quality of the stained gel was not 
good enough to visualise the fragment. The Hindlll pattern is not shown as the high 
numbers of restriction sites complicate the analysis, and do not substantially 
contribute to the definition of the deletion described below.
The most informative of the restriction patterns seen with this allele arose from 
HaeIII and Rsal digests. The absence of the expected bands between positions 1178 
bp to 1720 bp (with respect to the PCR product of the database gene sequence) with 
the Rsal digest, and positions 1283 bp to 1690 bp with the Hae III digest indicate 
that the deletion has occurred in this region.
Analysis of the MseI digest supports this conclusion; a band migrating at about 
470 bp is unique to allele 19. The presence of this band can be explained by 
looking at the Mse I sites in the 829 bp to 1698 bp region, shown in figure 3.3.2 
(below).
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1451 bp
829 bp 1404 bp 1503 bp 1698 bp
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<  0 0 = 0
575 bp 294 bp
Figure 3.3.2 - Representation of the region around 800-1700 bp of the hyl 
sequence. Arrows indicate Msel sites, with positions shown in base pairs with 
respect to the hyl PCR product.
The overall size of the deletion is estimated to be 400 bp, and the 3' end of the 
deletion is arbitrarily placed at the 3' most extremity of the estimated range of the 
deletion (ie; position 1697 bp on the hyl PCR product). It can be seen that we loose 
the 294 bp encompassing the three Msel sites 5' to this. We also effectively shorten 
the 575 bp fragment by 106 bp (= 400 bp -  294 bp). This would give rise to a 
fragment of 469 bp, which is in very close agreement with the 470 bp band 
observed.
The extent of variation in the 3' direction was not thought to be large, as if this 
were the case, the 176 bp HaeIII band (which is observed) would be noticeably 
smaller on the gel, due to the deletion encroaching on this region. The overall likely 
error in this approximation, taking into account estimating the size of the deletion, 
and variation of the 176 bp Hae III band was estimated to be not more than 20-30 
bp. Thus the site of the deletion was described as between nucleotides 1298 and 
1698 with respect to the hyl PCR product. These values correspond to nucleotides 
1513-1913 on L20670, the hyl sequence described by Berry et al. (Berry et a i, 
1994).
Subsequent sequence analysis showed this estimation to be accurate. Using the 
predicted site of the deletion described above, the appropriate sequencing primer 
(hsp.R2) was used to sequence over the junction of the deletion. This corresponded
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to 407bp, between nucleotides 1277 and 1684 of the hyl PCR product, or 1492 and 
1899 of L20670.
3.3.3 - Phenotypic analysis of the naturally occurring deletion mutant
Strain 619 was phenotypically Hyl' using both assays employed in this study. 
Also, this strain was unable to utilise HA as a sole source of carbon (see section 
3.4).
As mentioned in section 3.1.2, Southern analysis of PCR negative strains 
revealed that hyl is present in the chromosome as a single copy. This confirms the 
observation of Berry et al. (Berry et al., 1994) using a larger number of strains. 
However, this does not rule out functional degeneracy, where hyaluronic acid may 
be degraded by a factor genetically distinct from hyaluronate lyase.
The mutation seen in hyl from strain 53 was seen to arise from a sporadic 
deletion event. It is not known how long progenitors of this strain might have 
contained this deletion, nor what other mutations might have accumulated within 
its genome. With this in mind it was decided that strain 53 may not provide a 
reliable example of a hyl negative mutant. To address this, a defined hyl mutant was 
generated by the insertion of a chloramphenicol acetyl transferase (CAT) cassette 
into the hyl ORF.
3.3.4 -  Directed mutation of hyl by insertional inactivation
3.3.4.1 -  Generation of a WHP::CAT plasmid construct
As mentioned above, the phenotype of strain 53 was tentatively attributed to the 
loss of part of the hyl ORF. The potential for functional redundancy could not be 
reliably commented on, as the genetic background of this strain is unknown. In 
order to generate an isogenic knockout the hyl ORF was disrupted by the insertion 
of the chloramphenicol acetyl transferase (CAT) cassette.
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The molecular genetic approaches employed are outlined in chapter 2, and the 
rationale initially adopted is described in figure 3.3.3, below.
Step 1 involved cloning the WHP PCR product from strain R6 (ID 359) into a 
pUC18 derivative prepared for TA cloning (see chapter 2, section 2.2.1). This was 
analysed by restriction analysis to confirm the insertion and orientation of the WHP 
product within the vector. This is indicated below.
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EcoRI Ncol
3410 3947
2577 1146
894
Expected sizes of digest products based on the structure of pWHP.359 are given in 
the table. Results of screening 6 putative transformants by this restriction analysis 
are shown below.
3947bp
I146bp 
894bp
341Obp 
2577bp
EcoRI  Ncol
Figure 3.3.3 -  Screening minipreps of putative whp clones. Top: Diagramatic 
representation of the expected clone, with the whp product inserted in the ‘forward’ 
direction with respect to the vector sequence. Positions marked are given with 
respect to the vector (outside the circular portion) and the insert (inside the circular 
portion). Expected restriction sites are assigned according to the supplied vector 
sequence and the available hyl database sequence (accession no. L20670). Bottom: 
Restriction digests showing the products generated with the 6 putative 
recombinants screened. The markers used were kb ladder.
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As can be seen, 4 of the minipreps tested gave the expected sized products on 
digestion. One o f  these ( k ) was kept and named pWHP.359.
The central portion of the cloned WHP product was removed by digestion with 
fscoRI (see figure 3.3.3). The fragment containing the vector backbone, plus the 
whp 5’ and 3’ regions was purified from 1% agarose after electrophoresis. A 901 bp 
EcoRI CAT fragment (encoding the chloramphenicol acetyl transferase expression 
cassette - kindly donated by Sue Colby) was ligated to the pWHP.359 fragment. 
Transformations were carried out as described in chapter 2
Putative recombinants were isolated after expression and growth on the 
appropriate selective media. The WHP, CAT and TA primer pairs were used in 
various combinations in order to screen the putative recombinants and determine 
the orientation of CAT with respect to the WHP sequence. This is depicted in 
figure 3.3.4.
137
Chapter 3.3 -  h y l mutants
A
1 2  3 4 5 6  7 8
R
------------------- 1 (3)
\  ( 2)
----------------- 1 (4)
\ (5)
whp.for CAT.rev CAT.for whp.rev
whp 5' TAC whp 3'
190bp 901 bp 217bp
Figure 3.3.4 -  A: PCR confirmation of the location and orientation of the CAT 
cassette within the whp cloned hyaluronate lyase ORF. Lane designations; 1 - 
whp.for/CAT.rev, 2 -  whp.for/CAT.for, 3- whp.rev/CAT.rev, 4- whp.rev/CAT.for, 
5- CAT.for/rev control, 6- whp.for/rev control, 7- no DNA control with all primers, 
lane 8 - Kbl. B: Diagrammatic representation of the resultant recombinant, termed 
pWHP.359::CAT. The extent of the PCR products giving the bands seen on the gel 
are indicated by horizontal lines, with the respective lanes on the gel indicated in 
brackets.
This construct was used to transform of the lab strain R6. Selection was carried 
out on Blood-BHI agar plus chloramphenicol. Despite multiple rounds of 
transformation, no transformants were obtained with this construct. One possible
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explanation for this lies in the observation that the regions of homology between 
the construct and the chromosomal sequence are separated by approximately 2.5Kb 
with respect to the wild type sequence. The sites which mediate potential 
recombination are relatively small (around 200bp) with the overall size of the wild 
type hyaluronate lyase gene.
3.3.4.2 -  Generation of a second hyl::CAT construct
The next approach was slightly different. As there were no convenient staggered 
restriction sites in either pWHP.359 or the CAT EcoRI fragment a TA cloning 
approach was taken. This procedure exploits the terminal transferase activity of Taq 
polymerase, which preferentially adds dATP to the 3' hydroxyl end of a double 
stranded PCR product. In the absence of other nucleotides however, other residues 
can be added. The A-tagged CAT PCR product was obtained by simple PCR 
amplification of CAT from p683eCATl (a pneumolysin::CAT construct donated 
by Sue Colby), using the CATfor/rev primer pair. This was purified after agarose 
gel electrophoresis.
The vector was digested with /toil 1071 site (aka BstZ,\l\ - blunt cutting) which 
cleaves once at position 1833 bp with respect to the hyl numbering in figure 3.3.3. 
This was purified after agarose gel electrophoresis, and T-tagged as described in 
chapter 2, section 2.2.1. The PCR product using the CAT primers was ligated into 
this prepared vector, and transformed into E. coli.
7 putative transformants were found which were screened by PCR using the TA 
primers and hyl-2° primers. One particular putative transformant (yc) gave rise to 
products of the expected size using both primer pairs and was further characterised 
using the TA, hyl-2°, and CAT primers in various combinations. The results of this 
experiment are shown in figure 3.3.5.
139
Chapter 3.3 -  h y l  mutants
C A T  rev Hyl-2°for T A -3 ’
Figure 3.3.5 -  Generation of a second recombinant hyl::CAT construct. A; The
putative recombinant plasmid (yc) was screened using the TA, hyl-2° and CAT 
primers in various combinations. Lane designations; 1 - Kbl, lane 2 - TA-573', lane 
3 - CAT for/rev, lane 4 - hyl-2°for/rev, lane 5 - TA-5'/hyl-2° for, lane 6 - TA-3' hyl- 
2° rev, lane 7 - hyl-2° for/CAT rev, lane 8 - hyl-2° rev/CAT for, lane 9 - hyl-2° 
for/CAT for, lane 10 - hyl-2° rev/CAT rev, lane 11 - TA-57CAT for, lane 12 - TA- 
57CAT rev, lane 13 - TA-37CAT for, lane 14 - TA-37CAT rev, lane 15- no DNA 
control, all primers, lane 16 - Kbl.
B; The results of the PCR analysis are interpreted as shown. The diagram is not to 
scale, and the relative positions of the primer annealing sites have been omitted for 
simplicity. The extent of the PCR products giving the bands seen on the gel are 
indicated by horizontal lines, with the respective lanes on the gel indicated in 
brackets. The TA vector backbone is depicted as a single line, the cloned hyl and
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CAT sequences as boxes. The large arrows at the bottom of the diagram indicate the 
direction of the two ORF’s with respect to the 5'-3' orientation of the TA vector 
cloning site.
The structure depicted in figure 3.3.5B is supported on the basis of the 
theoretically calculated sizes of PCR products using the various primer 
combinations, and the estimated sizes of the products shown in figure 3.3.5 - A. 
This putative clone was kept and renamed pWHP::CAT2.
This was used to transform strain R6 using CSP1. After two rounds of 
transformation, followed by screening of putative crm resistant colonies by PCR 
using the CAT and hyl-2° primer pairs, a single putative recombinant, P41, was 
found. This was screened by PCR in a similar way to the plasmid construct, 
pWHP::CAT2, the results of which are shown in figure 3.3.6.
1 2  3 4 5 6 7 8  9 10 11 12
Figure 3.3.6 -  Photomontage showing the PCR analysis of the recombinant 
strain p41. Lane designations; 1 -  Kbl, 2 - R6 vs CAT for/rev, 3 - P41 vs CAT 
for/rev, 4 - R6 vs whp for/rev, 5 - P41 vs whp for/rev, 6 - R6 vs hyl-2° for/rev, 7 - 
p41 vs hyl-2° for/rev, 8 - P41 vs whp for/CAT for, 9 - P41 vs whp rev/CAT rev, 10 
- P41 vs hyl-2° for/CAT for, 11 - P41 vs hyl-2° rev/CAT rev, 12 - Kbl.
The original gel image has been rearranged for ease of presentation. Lanes 1 and 
12 contain kb ladder (kbl). The first 6 lanes between these (lanes 2-7) are arranged 
in pairwise groups, showing the results of PCR with the CAT, whp and hyl-2° 
primer pairs. Each pair is arranged as wild type (R6) then P41. As can be seen, the
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CAT element amplifies from P41, but not the parental wild type strain R6. There is 
an increase in the sizes of the products obtained using the whp and hyl-2° primer 
amplified from strain p41 relative to the parental strain R6.This size increase 
represents the additional 872bp of the CAT cassette.
The orientation of CAT within hyl was confirmed by the reactions shown in 
lanes 8-11. These reactions include one of the CAT primers with either the whp or 
hyl-2° primers used to confirm the orientation of the CAT insert in the plasmid 
pWHP359::CAT (see above). These confirm that the CAT insert is in the reverse 
orientation with respect to the hyl ORF. The reciprocal negative controls were also 
performed, which did not lead to the amplification of any products. In the interests 
of brevity, these reactions are omitted from figure 3.3.6.
The results of this experiment also reveal that the knockout has arisen as a result 
of a double crossover recombination event, not a single crossover. The latter event 
would lead to the incorporation of the entire length of the plasmid element into the 
chromosomal hyl sequence. This would also mean that in some of the CAT/whp or 
hyl-2° PCR’s, two products would be obtained. One arising from the CAT primer 
vs whp/hyl-2° anealing within the cloned hyl derived sequence, plus on from the 
CAT primer vs whp/hyl-2° anealing with the chromosomal copy of hyl. As can be 
seen from the gel image in figure 3.3.6, this is not the case.
A further confirmation of the structure of the hyl knockout was obtained by 
restriction analysis. The two CAT-hyl PCR products (those obtained with the whp 
primers) were digested with the restriction enzyme Styl. This enzyme was selected 
on the basis of the predicted cleavage sites shown from the available sequence data 
for hyl and cat (accession numbers L20670 and JO 1754 respectively). This 
experiment is described in figure 3.3.7.
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Products
Figure 3.3.7 -  Confirmation of the hyl interposon knockout structure by 
restriction analysis. A; Diagramatic depiction of the theoretical structure of the 
region, showing PCR products generated using the whp and CAT primers 
(described in the text above). Sfyl restriction sites are approximated. B; Separation
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of the digest products through 8% acrylamide, visualised using ethidium bromide. 
Markers = Kbl.
The sizes of the restriction digest products for the hyl 5' plus CAT PCR product 
are 909, 860, 600 and 336 bp. Those for the hyl 3' plus CAT PCR product are 929, 
821 and 272 bp. These were visualised by PAGE, shown in figure 3.3.7B. It was 
concluded that strain P41 was the desired hyaluronate lyase knockout strain. This 
was confirmed by sequencing across the junctions of the hyl::CAT insertion (data 
not shown).
3.3.5 -  Phenotypic characterisation of experimental hyl mutant P41
The aim of this mutagenesis was to address the question of functional 
degeneracy of hyaluronate lyase in S. pneumoniae. Put another way, can a 
structurally unrelated protein reproduce the depolymerisation of hyaluronic acid in 
the absence of a functional hyl product?
To answer this question, interposon mutagenesis was conducted with the hyT 
lab strain, R6, generating the hyt:crmR mutant, P41. The insertion site of the CAT 
cassette leads to the disruption of the hyl ORF. The inserted sequence (which lies in 
the reverse orientation with respect to the hyl ORF) results in stop codons in all 
three open reading frames. Thus read-through of the hyaluronate lyase transcript is 
blocked.
Strain P41 was used in hyaluronate lyase assays (described in chapter 3.2), along 
with the parental strain R6. Both the Stains-all and AUA-GlcNAc assays were used.
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A: Stains-all
R6 not R6 P41 not P41 Negative
induced induced induced induced control
2.5
B: AUA-GlcNAc
R6not R6 P41 not P41 Negative
induced induced induced induced control
Figure 33.8 -  Hyaluronate lyase assays using the hyaluronate lyase mutant
P41 and R6. A; Stains all assay. B; AUA-GlcNAc assay.
As can be seen, using both assays available, the mutant strain P41 is unable to 
degrade hyaluronic acid. This clearly shows that there is no functional redundancy 
with respect to hyaluronic acid degradation by the pneumococcus.
The next section describes the ability of some pneumococci to utilise hyaluronic 
acid as a sole carbon source, and the effect that this mutation has on growth.
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3.4 -  Pneumococcal growth on hyaluronate
3.4.1 -  Introduction
This section describes experiments conducted to demonstrate the ability of some 
pneumococcal strains to utilise hyaluronic acid as a sole carbon and energy source. 
Pneumococci cultured in vitro are supplied with readily metabolisable sources of 
carbon, in the form of complex carbohydrates and glucose in BHI medium, and 
glucose and sucrose in C-medium. The situation in vivo is quite different. For 
instance, in the case of pneumococcal carriage, strains have the ability to persist in 
the nasopharynx subsisting on the available sources of carbon.
As mentioned in section 1.7.1, hyaluronic acid is estimated to comprise as much 
as 50% of the human extracellular matrix (ECM) (Frost et al., 1996). It is 
suggested here that aside from the function of hyaluronate lyase as a means of 
tissue invasion, it may play a role in the acquisition of metabolisable carbon from 
host hyaluronic acid. In this manner, hyaluronate lyase may contribute to the ability 
of the pneumococcus to persist in the human host.
3.4.2 -  Formulation of defined media
The fist stage of these experiments was to generate media restrictive for 
pneumococcal growth, to which chosen carbon sources could be added. It was felt 
that BHI was by nature too complex to work with, in that the precise composition 
of the medium is unknown. The composition of pneumococcal C-medium on the 
other hand, is well defined. C-medium was formulated as described in chapter 2, 
section 2.1.1, omitting the C6 sugars glucose and sucrose. Experiments with a 
number of strains showed that this medium was unable to support pneumococcal 
growth, an example of which is shown in figure 3.1.1, using strain GM 108 (ID 
154), a Spanish serotype 3 strain isolated from the lower respiratory tract.
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Strain 154 Growth V-05
—-C-Nfcd+Cfc
—  C-Med-05
Figure 3.4.1 -  Growth of strain 154 in C-medium without glucose or sucrose, 
and with C-medium plus glucose at 890 pM. 890 pM was defined as the glucose 
concentration that supports limited growth of pneumococci as determined by R. 
Waite (unpublished data -  personal communication).
As can be seen, strain 154 was unable to grow on C-medium formulated 
without glucose or sucrose. This indicated that strain 154 was unable to subsist on 
other components of C-medium (such as amino acids or yeast extract). This 
observation was repeated with all strains studied. Thus a model system was defined 
which could be easily used to study the ability of pneumococci to grow on 
alternative carbon sources.
3 .43  -  Growth using HA as a sole source of carbon
The next series of experiments addressed the ability of hyaluronate to support 
growth of pneumococci. This experiment was performed with a large number of 
strains using C-medium that contained no added glucose or sucrose, to which 
aqueous HA at lOmg ml'1 had been added to give a final concentration of 2mg m l1. 
The results of such an experiment are shown in figure 3.4.2 below. The strains used 
are described in table 3.4.1.
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Strain Serotype Site of Isolation Year of Isolation
359 (R6) nc* n/k 1940’s
471 3 n/k 1955
1001 (D39) 3 n/k 1996
53 1 Vagina 1987 (Spain)
322 3 n/k 1991 (Kenya)
355 1 Blood 1995 (Uruguay)
312 7 Sputum 1989 (Kenya)
39 4 CSF/Blood 1988 (Spain)
393 4 n/k n/k
194 6B Eye 1989 (Spain)
169 6B Wound infection 1989 (Spain)
Table 3.4.1 -  Strains used in the growth experiment shown in figure 3.4.2. *nc
-  non-capsular. n/k -  not known.
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Figure 3.4.2 -  Growth of a range of strains on glucose and hyaluronate.
As can be seen, hyaluronate was able to support limited growth of some strains. 
Another feature of the experiment is the range of phenotypes seen with respect to 
growth on hyaluronate. Some strains were able to grow readily on HA with a short
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lag period (e.g.; strain 1001), whereas some did not begin to grow until 
significantly later (e.g.; strain 355, where O.D(620) began to increase 
approximately 11 hours after the start of the experiment). In all, 26 of the 36 strains 
studied (72%) showed some growth using HA as a sole carbon source. One 
possible suggestion for the occurrence of growth late in the time course is that 
components of dead and lysed cells are released, enabling the saprotrophic growth 
of a sub-population of cells. This is not thought to be the case, as experiments 
carried out using C-medium without added carbon failed to produce growth late in 
the time course with any strain.
This experiment is similar to one carried out using Streptococcus intermedius 
by Homer et al., which showed that a particular strain (UNS35) could also utilize 
hyaluronic acid (Homer et al., 1997). They were also able to identify an 
intracellular glycuronidase, responsible for cleavage of the hyaluronate lyase 
disaccharide product.
In the case of S. intermedius, growth on HA was shown to be catabolite 
repressed by glucose. Catabolite repression of hyaluronate lyase expression is not 
thought to occur in S. pneumoniae since ‘Stains-all’ assays of the culture 
supernatant showed that HA was still degraded when strains were cultured in C- 
medium plus HA that contained limiting amounts of glucose (890jiM) (R. Waite -  
personal communication).
3.4.4 -  Hyaluronate lyase is required for growth on HA
It was assumed that the first step in the process of hyaluronate utilization is the 
breakdown of the polymer into disaccharides by hyaluronate lyase. This suggestion 
is supported by the observation that strain 619 (ID 53 - the deletion mutant 
described in section 3.3.2) is unable to grow on hyaluronate (see figure 3.4.2, 
above). It was decided that this assumption would be more vigorously tested by 
looking at the growth phenotype of the lab mutant P41, described in section 3.3.4. 
The results of this experiment are shown in figure 3.4.3, below.
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R6/P41 growth on HA and glucose
----- R 6 - G
----- R 6 - HA
----- P41- G
----- P41 - HA
Figure 3.4.3 -  Growth of the hyaluronate lyase mutant P41, and its parental 
strain R6 on C-medium supplemented with glucose or HA.
As can be seen from figure 3.4.3, both R6 and P41 grow well on C-medium 
plus glucose, but only R6 is able to grow on C-medium plus HA. Thus it is 
concluded that functional hyaluronate lyase is required for the utilization of 
hyaluronic acid as a sole carbon and energy source. It is not known whether P41 is 
able to grow on disaccharide alone.
3.4.5 -  Further investigation of growth on HA derived metabolites
This section was concluded by a brief investigation of possible events in 
pneumococcal growth on HA downstream of hyaluronate lyase activity. It has been 
shown that growth requires hyaluronate lyase, which presumably performs the 
initial degradati ve reaction. It is further assumed that carbon utilization requires 
subsequent liberation of the N-acetylglucosamine and glucuronic acid derived 
moieties, from the AUA-GlcNAc disaccharide product. This step would involve
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another enzymatic cleavage. A further requirement is the uptake of either the 
disaccharide product of hyaluronate lyase, or its constituent monosaccharides 
described above.
C-medium without glucose or sucrose was supplemented with either N- 
acetylglucosamine or glucuronic acid (both at 8.7mM), and tested for the ability to 
support growth in the strains used in the experiment shown in figure 3.4.4.
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Growth on N-acetylglucosamine
---- 359
----- 1001
53
----322
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Figure 3.4.4 -  Growth of a range of strains on N-acetylglucosamine and 
glucuronic acid.
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The growth curves in figure 3.4.4 show that all strains grow well on N- 
acetylglucosamine as a sole carbon source, but not at all on glucuronic acid. Note also that 
strain 619 (ID S3), which was shown to be phenotypically Hyl'in section 3.3.2 was also 
able to grow on GIcNAc. Glucuronic acid failed to support growth with any strain.
3.4.6 -  Discussion
The data presented above indicate that S. pneumoniae is able to utilize hyaluronic acid 
as a sole carbon and energy source (supplemented with other growth factors in defined 
media which are unable to support growth themselves). Further, growth on hyaluronate has 
been shown to be dependent on hyaluronate lyase.
N-acetylglucosamine supported growth with all strains tested, including the hyl 
deletion mutant, strain 619 (ID 53). A suggested pathway for GIcNAc utilisation is offered 
in Chapter 4, section 4.4.
The case of glucuronic acid is complicated by the fact that the residue found in 
hyaluronate is the (3-4,5 unsaturated derivative. If the liberation of GIcNAc from AUA- 
GIcNAc (assumed to proceed via a glycuronidase activity as found by Homer et al.) results 
in the glucuronic acid derivative becoming fully saturated, then the experiment above is 
sufficient to demonstrate that glucuronic acid derived from hyaluronate is not a suitable 
substrate for pneumococcal growth. However, if the residue remains in the unsaturated 
form, it is not possible to speculate on its ability to contribute to carbon utilization in 
pneumococci on the basis of experimental evidence presented above. Another possibility is 
that the organism is not exposed to exogenous glucruronic acid as the disaccharide product 
of the hyaluronate lyase reaction is transported into the cell prior to cleavage by an 
intracellular glycuronidase. This is speculated upon in chapter 4, section 4.5.
These observations support the hypothesis that pneumococcal hyaluronate lyase 
contributes to virulence not only in its role as a spreading factor, but also enables the 
pneumococcus to persist in the host by metabolising host derived polysaccharides. The 
biochemical basis of HA metabolism is speculated upon in chapter 4.
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3. 5 -  The effect of the capsule on hyaluronate lyase phenotype
3.5.1 -  Introduction
The classic experiments of Avery, MacCleod and McCarty identified DNA as 
the genetic material responsible for mediating the transformation of S. pneumoniae 
between rough (acapsular) and smooth (capsular) (Avery et al., 1944). Since these 
early experiments, phase variation in pneumococci has been extensively studied.
The aim of the experiments described in this section was to assess the effect of 
the capsule on hyaluronate lyase phenotype.
The rationale behind the experiments described here is as follows; where the 
enzyme is cell associated (cell wall linked via LPXTG motif) and the strain 
produces a capsule, does the presence of the capsule occlude the enzyme from the 
surrounding environment? If this were to be the case, variation of capsule 
production may provide a means of in vivo regulation of hyaluronate lyase activity.
3.5.2 -  Generation of a capsule negative strain
This experiment required the direct comparison of a capsular strain and its 
acapsular variant. To achieve this, it was decided to attempt to knock out the 
capsule locus of a capsular strain of known phenotype.
The serotype three strain 154 was chosen from the phenotypic analysis described 
in section 3.2. This was a clinical isolate taken from a lower respiratory tract 
infection. It was proven to be inducibly positive for hyaluronate lyase, with cell 
associated activity. A serotype three strain was chosen for two reasons; the 
cellobiuronic acid capsule of this serotype is amongst the more extensive capsules. 
It was felt that this would be the strongest test for the occlusion hypothesis. 
Secondly, the phenotype of the serotype three strains is highly characteristic, 
forming large mucoid colonies on BHI-blood agar, thus facilitating the 
identification of capsule deficient mutants (looking for small colonies against a
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background of large, shiny colonies). First attempts at generating a capsule 
negative mutant were based on the allelic exchange mutagenesis rationale adopted 
in generating a Hyl' mutant.
The genes directing the synthesis of the serotype three capsular polysaccharide 
(and the other capsular loci studied in molecular detail) lie between two 
functionally unrelated genes, dexB and aliA.
Previous work in our lab (Victoria Barcus -  personal communication) was 
performed using a strain kindly donated by Francesco lannelli of Gianni Pozzi’s lab 
(PR201). In this strain the region between dexB and aliA had been replaced with a 
kanamycin resistance cassette. This had previously been used to transform the 
laboratory strain R6 to kanamycin resistance.
DNA from this derivative strain (R3) was used to amplify the region containing 
the kanamycin resistance cassette using dexB and aliA specific primers. This PCR 
product was approximately 3.5kb in size, and was used in transformation 
experiments using strain 154.
Despite repeated rounds of transformation using cspl, csp2 and growth phase 
dependent transformation protocols, no kanamycin resistant acapsular mutants were 
obtained. It has been observed by other groups that capsular pneumococci are less 
amenable to transformation by exogenous DNA than acapsular strains (Ravin,
1959, Weiser and Kapoor, 1999), although Watson and Musher were able to select 
transposon insertion capsular mutants after filter matings with E.faecalis (Watson 
and Musher, 1990). When pneumococci grow as a biofilm, capsular strains have a 
tendency to become acapsular (J.K. Struthers -  Personal communication). Loss of 
the capsule mediates pneumococcal adhesion to host epithelial cell receptors (see 
chapter 1, section 1.5.1).
Current work in our lab is addressing the question of variation in capsule 
production during biofilm growth (R.D. Waite -  unpublished data). This 
investigation employs the Sorbarod biofilm growth model described in chapter 2, 
section 2.2.5.
Strain ID 154 was passaged through the Sorbarod model, and a number of 
acapsular variants were obtained from the effluent, some of which reverted to the
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capsular phenotype after repeated passage on solid media, plus at least one stable 
acapsular variant. This stable variant was subsequently renamed AC 154.
3.5.3 -  Phenotypic characterisation of acapsular variant AC154
The phenotype of the acapsular strain described above was examined using the 
hyaluronate lyase assays (described in the preceding sections) under non-inducing 
and inducing conditions. Two induction methods were tested; growing the strain on 
BHI-blood agar overlaid with lOOpl hyaluronic acid [10 mg ml'1] or by inducing 
for 3 hours in liquid media (C-medium plus hyaluronic acid to a final concentration 
of [2 mg ml'1]). Figure 3.5.1 below shows the results from this experiment.
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A
Stains-all assay
a
c
3
154 154 AC 154 AC 154 Negative
(induced) (induced) control
B AUA GlcNAc assay
154 154 AC154 AC154 Negative
(induced) (induced) cortrol
Figure 3.5.1 -  Hyaluronate lyase assays of strain 154 and the acapsular 
derivative, AC154. A; Stains-all assay, B; AUA-GlcNAc assay
Both assays show that the activity of the parental (capsular) strain is higher than 
that of the acapsular derivative, and that induction of hyaluronate lyase activity can 
be seen with both the parental strain and its acapsular derivative.
3.5.4 -  Discussion
The hypothesis described in section 3.5.1 has been disproved on the basis of the 
results shown in section 3.5.3. Rather than the encapsulated strain having lower 
activity, it is the acapsular strain that produces less hyaluronate lyase. The fact that
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the activity of AC154 is noticeably lower than that of 154 (rather than being the 
same) is in itself an interesting observation. This will be returned to in section 
4.4.5.
The precise nature of the mutation that brought about the stable acapsular 
phenotype of strain AC 154 is not known, so it is not possible to conclude that the 
hyaluronate lyase phenotype observed is a direct result of the loss of the capsule 
alone.
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3.6 -  Characterisation of elements upstream from the published hyaluronate 
lyase sequence
3.6.1 -  Introduction
Analysis of the hyl sequence described by Berry et al. reveals that all of the 
codons 5’ to their suggested start codon also potentially encode amino acids (Berry 
et al., 1994). Furthermore, there is no satisfactory ribosome-binding site preceding 
the suggested start codon. One of the closest known homologues to the 
pneumococcal enzyme is that found in Streptococcus agalactiae. Alignment of 
their amino acid sequences reveals an additional 164 amino acids at the N terminus 
of the S. agalactiae protein, which includes a cleavable N-terminal signal sequence 
(Lin et al., 1997)(Gase et al., 1998). Taking these observations together, it seems 
likely that the available pneumococcal gene sequence is incomplete, and the true S' 
end of the gene and its promoter elements are yet to be described. In their paper 
Berry et al. note the questionable nature of the ascribed promoter in the sequence 
deposited under accession number L20670.
The available pneumococcal genome databank (http://www.wit.mcs.anl.gov) is not 
of use in this situation. The hyaluronate lyase ORF lies at the 5' extremity of one of 
the unassembled contigs (contig 4167) although an additional 54 bp 5' to the 
L20670 start point can be obtained from the contig sequence.
This chapter describes the attempts made to isolate and analyse this region from 
the laboratory strain R6.
3.6.2 -  Characterisation of the region S' to the known hyaluronate lyase gene 
by restriction analysis
Chapter 3.3 describes how the CAT cassette was introduced into the hyl ORF. 
The resultant pneumococcal transformant (P41) now contained a unique marker in 
the general region of the desired upstream region. The region 5' to the known
160
Chapter 3.6 -  Characterisation of the h y l promoter
hyaluronate lyase sequence was characterised at low resolution using a combination 
of restriction digestion and Southern analysis.
The strategy chosen was to use BsrBI, which cuts 119 bp 3’ to the end of the 
CAT insertion (position 1971 with respect to the L20670 sequence). This was used 
either on its own, or with a range of other enzymes known not to cleave either in 
CAT or the sequence 5’ to the BirBI site. These enzymes were Bst 11071, Hindi, 
Hpal, Pvull, Smal, SnaBl, and Swal. Genomic DNA from strain P41 was digested 
with these enzymes and separated through 1% agarose. The digest products were 
transferred to nitrocellulose and probed with Dig labelled CAT PCR product. 
Chemiluminescent detection of the resultant blot was performed the results of 
which are shown in figure 3.6.1.
Also a feint 
band at this 
position
Figure 3.6.1 -  Southern blot of P41 digests probed with Dig labeled CAT PCR 
product. Lanes; 1 = BsrBl only, 2 - BsrBVBstl 1071, 3 - BsrBVHincU, 4 - 
BsrBUHpal, 5 - flsrBl/Pvtdl, 6 - BsrBl/Smal, 7 - BsrBI/SnaBI, 8 =
- BsrBI/Swal, 9+11 - Dig Markers, 10 - Dig labeled CAT PCR product positive 
control.
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The banding pattern shown in figure 3.6.1 was interpreted thus;
PvuII H indi
f ls i l l071 SrniBI Hpal H indi
BsrBl BsrBl
I 1 l u  I____ i
-5 Kb
_l__
-4Kb 
_ | ___
-3 Kb 
_ |___
-2Kb
_J__
-I Kb
_l__
1851 bp
CAT
| 872bp |120bp|
Figure 3.6.2 -  Diagrammatic representation of the approximate positions of 
restriction sites 5' to the hyaluronate lyase start codon proposed by Berry et al.
Note that the positions indicated are approximate, within the degrees of accuracy 
afforded by agarose electrophoresis.
The Southern blot shows that there must be a second BsrBl site close to the 
known hyaluronate lyase start site since a CAT hybridizing band is seen in all 
digests. The presence of other bands of higher molecular weight indicate that those 
products were the result of partial digestion, with cleavage occurring at the BsrBl 
site y  to the CAT insertion site and at one (or in the case of HincU, two) positions 
5' to the known start point.
3.6.3 -  Attempts to clone the hyaluronate lyase promoter from P41
This approach takes advantage of the fact that a selectable marker has already 
been placed near the region of interest. The digests used for characterisation of the 
upstream region by Southern analysis were repeated. The resultant restriction 
products were then tagged with dATP, and cloned into a pre-prepared T-vector 
(both commercially available vectors and pUC18 prepared in this study were used). 
Ligation products were transformed into competent E. coli (JM109) and cultured 
on the appropriate selective media.
Despite repeated rounds of the steps described above, no chloramphenicol 
resistant transformants were obtained. A possible explanation for this is that high 
levels of transcription from a strong promoter may prove lethal to the E. coli host 
strain.
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3.6.4 -  iPCR using the pneumococcal transformant P41
As described above, the CAT marker in the R6 derivative P41 proved to be useful 
in mapping restriction sites 5' to the known hyl start point. It was decided that an 
inverse PCR (iPCR) approach, using the HIP5.out primer and CAT.rev primer (Cat 
having gone into the hyl gene in the reverse orientation).
Enzymes used in the experiment described above were selected on the basis of 
the predicted cleavage sites from the data available from the Southern analysis 
described above. Since B atB I was now known to cut in the region close to the 
known start point of the hyaluronate lyase gene, it was decided that this religated 
product would be easiest to obtain and its approximate size could be verified easily. 
For completeness, the other restriction enzyme combinations were also included in 
this experiment. The iPCR rationale is outlined in chapter 2, section 2.2.1.
The result of this experiment is shown in figure 3.6.3.
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1 2
1 2 3 4 5 6 7 8 9  10
| Band
Purified
tZ. 4~
A B
Figure 3.6.3 -  A; iPCR using P41 and the digests/primers outlined in the text 
above. Lanes; 1 - kb Ladder, 2 - BsrBl only, 3 - BsrBVBst\ 1071, 4 - BsrBl/HincU,
5 - BsrBVHpal, 6 - BsrBVPvull, 7 - BsrBUSmal, 8 - BsrBI/SnaBI, 9 - BsrBUSwal, 
10 - kb ladder. B; Purified band from lane 2 of part A. Lane 1 - Wizard® PCR Preps 
DNA Purification System, lane 2 - Qiagen QIAquick™ Gel Extraction Kit. l/20,h 
final recovery volume on gel.
The figure above shows that a single, strong iPCR product was obtained from 
the BsrBl digest reaction. This band migrates between 1 kb and 1632 bp on the gel 
(at approximately 1.3-1.4 kb). This was purified using two systems, as shown in 
part B. This was then used in direct sequencing using the HIP5.out primer.
The sequence obtained from this reaction is shown in figure 3.6.4.
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5 '  -  GAGCGGAAGAAACGACTACGAATACCATTCAGCAAAGCCAGAAGGA 
AGTTCAGTATCAGCAAAGGGATACAAAAAATTTAGTTGAAAATGGTGATT 
TTGGTCAGACGGAGGACGGAAGCAGTCCGTGGACAGGAAGCAAAGCTCAG 
GGGTGGTCAGCTTGGGTAGACCAGAAGAATAGTTiTGCAGATGCCTCAAC 
TTGAGTCATTGAGGATCTAAGGCATGGGGACTATCACTATTCTTCTCAAG 
CCCTGAGAAATTAAGGGCAGCGGTTCACCGTATGGTTCCCTAA - 3 '
Figure 3.6.4 -  Sequence derived from the iPCR product obtained from the 
fisrBI digested and ligated P41 genomic preparation described in the text 
above. Bases indicated in red represent previously unreported sequence. Black and 
grey bases represent those available from contig 4167 and L20670 respectively. 
The BsrBI site is underlined. Sequence 5' to this site returns to the L20670 
sequence at position 1971 (not shown).
Figure 3.6.4 indicates that an additional 126 bp of sequence has been obtained 
from this experiment. Although the total length of additional sequence is quite 
small (in agreement with die prediction made on the basis of the Southern analysis 
described above) these findings indicate that the experimental rationale adopted 
was a valid one.
Analysis of the extra sequence revealed indicate that there would be a stop 
codon 25 codons upstream from the transcriptional start point predicted by Berry et 
al. This is clearly erroneous, as the published sequence reveals 29 additional 
codons that encode amino acids. This discrepancy was put down to sequencing 
errors in the experiment described here.
3.6.5 -  Further iPCR experiments using P41
From the data presented above, it can be seen that the iPCR approach was 
successful in elucidating a further 126 bp upstream from the start of contig 4167 
(WIT database sequence). It was decided that this approach should be extended by 
selecting a different set of restriction digestion conditions and primer sets for the
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iPCR reaction. As has already been mentioned, the BatBI site lies relatively close 
to the known start-point of contig 4167. As such, this enzyme no longer proves 
useful in establishing a restriction digest protocol.
The next approach taken was to attempt to anchor the digestion point in the 5' 
direction. Once again, it proved possible to draw on the data generated in chapter 
3.6.2. The next predicted restriction point in the 5' direction was Hindi. A Hindi 
single digest was deemed to be unsuitable, as analysis of the sequence of contig 
4167 indicated that there was not another Hindi site for 6.2 kb. This would make 
any iPCR products obtained with the primers available unfavorably large.
In an attempt to resolve this problem, the 3' restriction point was defined by 
selecting known restriction sites of other available blunt cutting enzymes, which 
lies close to available primers used in the sequencing experiments described in 
Chapter 3.1.4. This approach is summarised in figure 3.6.5.
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H indi
(-1.8 kb)
Hae III Seal Sspl
(700bp) (1.5 kb) (1852bp)
1 i i i
H y l -  5’ CAT
t t
Rsal E coR \
(950bp) (1.6 kb)
Figure 3.6.5 -  Location of restriction sites used in the second round of iPCR 
described above.
Figure 3.6.5 shows the range of enzymes used in this round of iPCR, and their 
approximate positions with respect to the first nucleotide of the sequence described 
by Berry et al. (L20670).
An obvious drawback of this approach is that the enzymes cutting 3' to the start 
of the gene were not used in the experiment described in section 3.6.2 and as such 
their ability to cleave within the upstream sequence is unknown. It was decided to 
proceed with this in any case, as if cleavage were to occur between the proposed 
H indi site and the known upstream sequence, this would become apparent from 
sequence data obtained.
The experiment was carried out as described above, substituting the restriction 
enzymes appropriately. After ligation the iPCR reaction was performed using the 
HIP5’.out primer with one of three other enzymes; hyl.for, HSP.F1 and HSP.Flb 
(see Chapter 2, section 2.1.7, table 2.7 for annealing positions). Of the three primer 
combinations tried, only the HIP5’.out/HSP.Fl combination gave rise to 
amplification products. The results of this experiment are shown in figure 3.6.6.
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Figure 3.6.6 -  iPCR using anchored H indi digest and various other blunt 
cutting restriction enzymes. Primer pair used was HIP5.out/HSP.Fl. Lane 1 - kb 
ladder, lane 2 - HincUJEcoRV, lane 3 - HincWHaeTLl, lane 4 - HinclVRsal, lane 5 - 
Hincll/Scal, lane 6 - HinclVSspl, lane 7 - No DNA control, lane 8 - kb ladder.
As can be seen from the figure above, iPCR products were obtained from all 
reactions except the HincWSspl reaction. These products were purified after 
agarose gel electrophoresis using the QIAgen QIAquick™ Gel Extraction Kit, and 
sequencing reactions were performed using the ups.5 sequencing primer, which had 
been designed against the additional sequence derived previously. Only the 
HinclMHaeWl iPCR product gave rise to readable sequence, which is given in 
figure 3.6.7, below.
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5 ’ -  GGCCTCTTTTCTTTTTCTACATTGTAACAGTTTTTACTTTTTTCGTCGAGTC 
GGATGGAAGATATTGTTGAAGAATAAGCCCTCAATATGATAGAAACCGTTTACAA 
ATAACTTTAAAAATGGTATGATTTAATTAAACCGGTTTACTTTGTTGCTATAAAT 
CTCTAATTTGAGATTTAGTTCCTATTGATTTTACAATATGTTTATTGGAGTGTAT 
ACATGCAAACAAAAACAAAGAAGCTCATTGTGAGTTTGTCTTCACTTGTTTTATC 
AGGATTTTTATT AAACC ATTATATGAC AGTTG J A GC GG AAG AAAC GAC T AC G AAT 
ACCATTCAGCAAGCCAGAAGGAAGTTCAGTATCAGCAAAGGGATACAAAAA -  3 '
Figure 3.6.7 -  Sequence derived from the iPCR product obtained from 
HincII/Haelll digested and ligated P41 genomic DNA. The sequence data 
obtained in the previous iPCR experiment are shown in red, with the flsrBI site 
underlined. The additional data obtained in this experiment are indicted in blue, 
with the single HaeIII site underlined. Sequence 5' to this point reads back into 
L20670 at position 682.
As can be seen, this experiment has revealed a further 304 bp of unknown 
sequence. The known hyaluronate lyase sequence is regained at a Hae III site 
approximately 380 bp into the sequence. Thus, there is a Hae III site 431 bp 5’ to 
the first codon of contig 4167, indicating that the attempt to anchor the restriction 
point at 1.8 kb 5’ to the known sequence was unsuccessful due to the presence of 
this Hae HI site. Nevertheless, this was still a substantial amount of new sequence 
data. Sequencing of the other products shown in figure 3.6.6 proved to be 
unsuccessful.
Figure 3.6.8 places this additional sequence in the context of the known 
sequence, preliminary upstream sequence data, and the point at which the religated 
iPCR product runs back into the known hyaluronate lyase sequence. The translation 
products of the three open reading frames are shown, and the proposed likely ORF 
and control elements are also given.
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Hae III
I
GGCCTCTTTTCTTTTTCTACATTGTAACAGTTTTTACTTTTTTCGTCGAGTCGGATGGAA
1 ------------------+ ------------------+ ------------------ + ------------------ +------------------+------------------+ 60
CCGGAGAAAAGAAAAAGATGTAACATTGTCAAAAATGAAAAAAGCAGCTCAGCCTACCTT
G L F S F S T L * Q F L L F S S S R M E  
A S F L F L H C N S F Y F F R R V G W K -  
P L F F F Y  I V T V F T F F V E S D G R -
GATATTGTTG AAG AAT AAGCC C TC AAT ATG AT AG AAAC C GTTT AC AAAT AAC TTT AAAAA
6 1 ------- —  — —+ ----------------- + -------------------+ ------------------+------------------ +------------------+ 120
CTATAACAACTTCTTATTCGGGAGTTATACTATCTTTGGCAAATGTTTATTGAAATTTTT
D I V E E * A L N M I E T V Y K * L * K  
I L L K N K P S I  * * K P F T N N F K N -  
Y C  * R I  S P Q Y D R N R L Q I T L K M -
-35
I
t g g t a t g a t t t a a t t a a a c c g t t t a c t t t g t t g c t a t a a a t c t c t a a 'iB H B t t t a g t
1 2 1 ------------------+ ------------------ + ------------------ + ------------------ +------------------ +------------------+ 180
ACCATACTAAATTAATTTGGCAAATGAAACAACGATATTTAGAGATTAAACTCTAAATCA
W Y D L I K P F T L L L * I S N L R F S  
G M I  « L N R L L C C Y K S L I  * D L V -  
V * F N * T V Y F V A I N L * F E I * F -
Shine-
Dalgarno
Proposed 
new start
. sequence codon
TCCTATTGATT
▼ ▼ ▼
if^^BATGTTTATTGGAGTGTATACMaCAAACAAAAACAAAGAAGC
1 8 1 ------------------+ ------------------ ♦ ------------------ + ------------------ +------------------ +------------------+ 2 40
AGGATAACTAAAATGTTATACAAATAACCTCACATATGTACGTTTGTTTTTGTTTCTTCG
S Y 
P I  
L L
F Y N M F  I G V Y  
D F T I C L L E C I  
I L Q Y V Y W S V
T C K Q K Q R S  
H A N K N K E A - 
Y M Q T  K T  It K L -
TCATTGTGAGTTTGTCTTCACTTGTTTTATCAGGATTTTTATTAAACCATTATATGACAC
2 4 1  ------------------+------------------ + ------------------ + ------------------ +------------------ +------------------+ 300
AGTAACACTCAAACAGAAGTGAACAAAATAGTCCTAAAAATAATTTGGTAATATACTGTG
V C H L F Y Q D T I
1 il idilli il Melili “nil1' ; M " T J"
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BvrBI
i
TTCGAGCGGAAGAAACGACTACGAATACCATTCAGCAAAGCCAGAAGGAAGTTCAGTATC
3 0 1 --------------- - + ----------------- ■ + --------- --------+ ------------------+------------------+ ---------------- -  +
AACCTCGCCTTCTTTGCTGATGCTTATGGTAAGTCGTTTCGGTCTTCCTTCAAGTCATAG
L E R K K R L R I P F S K A R R K  F S I  
W S G R N D Y E Y H S A K P E G S  S V S  
I A E E T T T N T I Q Q S Q K E V Q Y Q
361  --- + - -  ----- - -    —-----+----------: -+---- - - - — -+
TCGTTTCCCTATGTTTTTTAAATCAACTTTTACCACTAAAACCAGTCTGCCTCCTGCCTT
S K G I Q K I  * L K M V I L V R R  R T E  
A K G Y K K F S * K W * F W S D G G  R K 
Q R D T K N L V E N G D F G Q T  E D G S
Position 1 on contig 
4167
1
GCAGTCCGTGGACAGGAAGCAAAQCTCAGGGGTQCTCAGCTTGGGTAGACCAGAAGAATA
--------------+-------------- +-------------- +-------------- +-------------- +-------------- +
CGTCAGGCACCTGTCCTTCGTTTCGAGTCCCCACCAGTCGAACCCATCTGGTCTTCTTAT
Position 1 on 
L20670
I
CAAGACGTCTACGGAGTTGAGCTCAGTAACTCCGATTCCTACCCCGATAGTGATAGAGTT
360
420
48 0
540
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1
541  ------------------+ ------------------+------------------ + ------------------ +------------------ +------------------+ 60 0
CGGGACTCTTTAATTCCCGTCGCCAAGTGGCATACCAAGGATAACTTCGATTCTTTTTCA
6 0 1 ------------------+ ------------------+------------------ + ------------------+------------------ +------------------♦ 660
TATTTG  AC GC AAAGTTCTAATTTTGTC T ATTATTTC AGC C CT AAC GGTTTC AAGC AT AGT
a
b
c
I N C V S R L K Q I
■ iU M M i
K S G L P K F V S
S R D C O S S Y H -
a a c t c c t t t c a c c a t t c c t g t t c g c t a a c a c c t t a a g a c g t t g c t g c a
a  L R K V V R T S D C G I L Q R R
b  * G K W * G Q A I V E F C N D
Figure 3.6.8 -  Upstream data obtained from the two iPCR experiments 
compiled and integrated with the known hyaluronate lyase sequence data 
from the sequence derived by Berry et al. (L20670) and on contig 4167 from 
the WIT database. Key elements are shown, including the ZfcrBI and HaeIII sites 
which limit the extent of information gained from each iPCR experiment. Colour 
keys are as follows; ■  Known sequence from L20670, □  Known sequence from 
contig 4167,0 sequence derived from the first round of iPCR, terminating in a 
ZfrrBI site, unboxed sequence represents data obtained from the second round of 
iPCR, terminating in a Hae III site. The predicted translation product is depicted in 
gray boxes; ■  ORF translation product predicted by Berry et al., □  ORF predicted 
from extended sequence data. -10, -35 and ribosome binding motifs of the 
predicted true promoter are also indicated.
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3.6.6 -  Discussion
The diagram above puts data of Berry et al., sequence from the unfinished 
pneumococcal genome and the data obtained here into context. There is good 
reason to believe that the true hyaluronate lyase promoter elements are further 
upstream than those presented in the sequence of Berry et al.. Comparison with the 
sequence of the S. agalactiae gene and the data shown here indicate that the 
hyaluronate lyase ORF proceeds for a further 131 codons before reaching a stop 
codon. It is reasoned that the true start codon cannot lie 5’ to this stop codon, and 
that the promoter must lie 3’ to this region (at around 180 bp on the sequence 
shown in the diagram above).
Analysis of the data obtained here reveals that there is an excellent candidate for 
a promoter on the basis of consensus -35, -10 RNA polymerase binding sequences, 
and their positions relative to one another. These are indicated as red boxes in the 
sequence shown in figure 3.6.8. The -35 sequence, TTGAGA correlates closely to 
the consensus sequence -  T82 Tg4 G78 A65 C54 A45, and is optimally separated from 
the -10 (Pribnow) box by 18bp. The -10 sequence (TACAAT) agrees closely with 
the consensus sequence of Tgo A95 T45 A«) A50 T%.
Similarly, there is a good translational consensus at the putative Shine-Dalgamo 
(or ribosome binding) site, shown in yellow in figure 3.6.8. The consensus 
sequence of this polypurine stretch is AGGAGG. The sequence presented here is 
GGAG, representing the core of this sequence. This is separated from the putative 
start codon by 7 bp.
Stop codons are encountered in all three reading frames in the region of the -35 
box, indicating that the start point of the hyaluronate lyase gene cannot lie 5’ to the 
proposed region. The proximity of the promoter elements described above to 
consensus provides tempting evidence that the promoter truly lies in the proposed 
region. If the promoter is a very strong one, as implied by the proximity to the 
consensus elements described, it may provide support for the hypothesis that it has 
not been possible to clone this element due to lethality caused by overtranscription 
in the E. coli host. Negative control of promoters by trans acting repressor
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molecules is common. However, no obvious centres of diad symmetry are evident 
in the region around the proposed hyaluronate lyase promoter elements.
Translation from the proposed start codon would produce 118 extra amino acids 
in the translation product. Gase and co-workers found that the S. agalactiae protein 
was 88 residues longer than had previously been described (Gase et al., 1998). The 
additional residues in the pneumococcal protein would bring the total number of 
amino acids in each protein into close agreement (1072 residues in the GBS 
enzyme, compared to 1067 residues in the pneumococcal protein), supporting the 
hypothesis of an evolutionary relationship between the enzymes.
Alignment of the first two kilobases of the two sequences reveals 51% identity 
(using the GAP program from the GCG Wisconsin Package), higher than would be 
expected to occur by chance. Comparison of the amino acid sequences reveals 50% 
identity and 65% similarity over the length of the whole proteins. Alignment of the 
N-terminal sequences is less certain, however the N-terminal 31 amino acids share 
58% similarity and 35% identity. This is shown in the alignment in figure 3.6.9, 
where the S. agalactiae sequence is the upper sequence, and the pneumococcal 
sequence is the lower.
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1 M EIK K K Y R IM L Y SA LILG TILV N N SY Q A K A E EL TK TT STSQ IR D T Q TN N I
• : I ■ I ■ • :
1 ...............................................................................................................................MQTKTKKL
5 1  EVLQTESTTVKETSTTTTQQDLSNPTASTATATATHSTM KQW DNQTQNK
. : | | : - | . * = . . - I  • • = - = I M
9 IA E E T T T N T IQ Q .............SQKEVQYQIVSLSSLVLSGFLLNHYM TVQRDTK
1 0 1  ELVKNGDFNQTNPVSGSW SHTSAREW SAWID. K EN TA D K SPIIQ R TEQ G Q
= I I • I I I I • I I = • • I = • I • • • I • = I I I I = I |:..|| I- = -- = 1-
5 4 NLVENGDFGQTEDGS S PWTGSKAQGWSAWVDQKNSSADASTRVIEAKDGA 
1 5 0  VSLSSDKGFRGAVTQKVNIDPTKKYEVKFDIETSNKAGQAFLRIM EKKDN
; • = I I • ■ = 1 = 11 --I I : : • I I I • : : I • I • I • I I • I I = I I ¡ I - - * -
1 0 4  IT ISS PE K L R A A V H R M V PIEA K K K Y K L R FK IK TD N K V G IA K V R IIEE SG K  
2 0 0  NTRLW LSEM TSGTTNKHTLTKIYNPKLNVSEVTLELYYEKGTGSATFDNI
: • I I I I- I I I I • : : I : • I • I • I = I • • = - I I I = I I • I I I • • • I • = I
1 5 4  DKRLW NSATTSGTKDW QTIEADYSPTLDVDKIKLELFYETGTGTVSFKDI 
2 5 0  SM KAKGPKDSEHPQPVTTQIEESVNTALNKNYVFNKADYQYTLTNPSLGK
. : . . . | | | | : I I • = = : = - I - - I I I I I  I - : - I I - = = -
2 0 4  E L V EV A D Q PSE D SQ T. DKQLEEKIDLPIGKKHVFPLADYTYKVENPDVAS 
3 0 0  IV G G IL Y PN A TG ST TV K ISD K SG K IIK EV PL SV TA ST ED K FT K LLD K W N D
: .||| I .|.|.| : | |.|| : | • : | | • : I I - - M I -  I M I  =
2 5 3  V K N G IL E PL K E G T T N V IV S . KDGKEVKKIPLKILASVKDTYTDRLDDWNG 
3 5 0  VTIGNHVYDTNDSNM QKINQKLDETNAKNIKTIKLDSNHTFLW KDLDNLN
= • 11= I I • - = • •  I • I = I I • I = = ■ l - .  = . - | .  I I - - = - I - -
3 0 2  IIAGNQYYDSKNDQM AKLNQELEGKVADSLSSISSQADRIYLW EKFSNYK 
4 0 0  NSAQLTATYRRLEDLAKQITNPHSTIYKNEKAIRTVKESLAW LHQNFYNV
- I I - I I I I I I = I I = = I I I = I I I I • I • = I • • = I I I = = I = • I = I • = • I I
3 5 2  TSANLTATYRKLEEMAKQVTNPSSRYYQDETWRTVRDSMEWMHKHVYNS 
4 5 0  N K D IEG SA N W W D FEIGV PRSITA TLA LM N N Y FTD A EIK TY TD PIEH FV PD
= 1-1 I I I I I = I I I • I I ■ I • • I I • I I • = I I • I • I I I • I I I • I I - I I I I
4 0 2  E K S IV G . . N W W DYEIGTPRAINNTLSLM KEYFSDEEIKKYTDVIEKFVPD 
5 0 0  A G Y FRK TLD N PFK ALG G N LV D M G RV K IIEG LLRK D N TIIEK TSH SLK N LF
= = - 1 1 1 1  l l l l l l l l l l l l l l l l l l = l - l l l l l l =  I - - I  = l = - - = l
4 5 0  PEHFRKTTDNPFKALGGNLVDM GRVKVIAGLLRKDDQEIS S T IR S IE Q V F  
5 5 0  TTA TK A EG FY A D G SY ID H TN VA Y TGA Y G N V LIDG LTQ LLPIIQ ETD Y K IS
- • • •  = I I I I • I I I  I I I I I I I I I I I I I I I I I I I I I • I I I I = I I • I - - I -
5 0 0  KLVDQGEGFYQDGSYIDHTNVAYTGAYGNVLIDGLSQLLPVIQKTKNPID 
6 0 0  NQELDM VYKW INQSFLPLIVKGELM DM SRGRSISREAASSHAAAVEVLRG
- = - = = = M I  = . | |  I I = I - I I I I I  I I I I i I I I I -  - - - = I - I I I I I I I I
5 5 0  KDKMQTMYHWIDKSFAPLLVNGELMDMSRGRSISRANSEGHVAAVEVLRG 
6 5 0  FLRLANM SNEERNLDLKSTIKTIITSNKFYNVFNNLKSYSDIANM NKM LN
: | : | : | | : : | . | . |  : | | | :  | = - = | = | | - I I I - I - I I - l - M -
6 0 0  IHRIADM SEGETK Q RLQ SLV K TIV Q SD SY Y D V FK N LK TY K D ISLM Q SLLS 
7 0 0  DSTVATKPLKSNLSTFNSM DRLAYYNAEKDFGFALSLHSKRTLNYEGM ND
I -  - I I -  I - I  1 1 - 1 1 - 1 1 =  I 1 1 1 1 1  = 111 = 111 I - 111 I I I  I l ­
e s o  DAGVASVPRTSYLSAFNKMDKTAMYNAEKGFGFGLSLFSSRTLNYEHMNK
7 5 0  ENTRGWYTGDGMFYLYNSDQSHYSNHFWPTVNPYKMAGTTEKDAKREDTT
I I- 11111 = 11111111 = 1 1111= =111111111 = 1111-1111-1- 
7 0 0  ENKRGWYTSDGMFYLYNGDLSHYSDGYWPTVNPYKMPGTTETDAKRADS .
5 0
8
100
53
1 4 9
1 0 3
1 9 9
1 5 3
2 4 9
2 0 3
2 9 9
2 5 2
3 4 9
3 0 1
3 9 9
3 5 1
4 4 9
4 0 1
4 9 9
4 4 9
5 4 9
4 9 9
5 9 9
5 4 9
6 4 9
5 9 9
6 9 9
6 4 9
7 4 9
6 9 9
7 9 9
7 4 8
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8 0 0  KEFMSKHSKDAKEKTGQVTGTSDFVGSVKLNDHFALAAMDFTNWDRTLTA 8 4 9
7 4 9 DTGKVL. PSAFVGTSKLDDANATATMDFTNWNQTLTA 7 8 4
8 5 0  QKGW VILNDKIVFLGSNIKNTNGIGNVSTTIDQRKDDSKTPYTTYVNGKT 8 9 9
7 8 5  H K SW FM LKDKIAFLGSNIQNT. STDTAATTIDQRKLESSNPYKVYVNDKE 8 3 3
9 0 0  ID LKQ A SSQ Q FTD T K SV FLE SK EPG RN IG Y IFFK N ST ID IER K EQ T G TW N  9 4 9
8 3 4  A S L T E Q . EKDYPETQSGFLESSDSKKNIGYFFFKKSSISM SKALQKGAW K 8 8 2
9 5 0  SINRTSK N TSIV SN PFITISQK H D N K G D SY G Y M M V PN ID RTSFD K LA N SK  9 9 9
8 8 3  D IN .E G Q S D K E V E N E F L T IS Q A H K Q N G D S Y G Y M L IP N V D R A T F N Q M IK E L  9 3 1
1 0 0 0  EVELLENSSKQQVIYDKNSQTWAVIKHDNQESLINNQFKMNKAGLYLVQK 1 0 4 9
1 0 7 2
1 0 3 1
Figure 3.6.9 -  Alignment of the extended pneumococcal hyaluronate lyase 
protein and that of S. agalactiae (GBS). The pneumococcal sequence is shown 
beneath the GBS sequence.
The transcribed protein sequences were analysed by the signal sequence and 
cleavage prediction methods of McGeoch (McGeoch, 1985), and also the 
prediction program of Nielsen et al. (Nielsen et al„ 1997) These facilities can be 
found at http://psort.nibb.ac.ip/form.html and
http://www.cbs.dtu.dk/services/SignalP/#submission respectively. The results of 
these independent analyses concur, and predict that the additional pneumococcal 
sequence reported here does indeed contain a cleavable N-terminal signal sequence, 
with cleavage occurring somewhere between residues 29 and 31. A signal sequence 
is also found in the GBS amino acid sequence. This is illustrated in figure 3.6.10.
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Predicted cleavage point
Predicted cleavage point
Figure 3.6.10 -  Signal sequence prediction by the method of Nielsen et al. The
desired profile of a signal sequence includes high S score (blue) before the cleavage 
point, low after and a high C score (green) immediately after the cleavage site. The 
GBS sequence is shown at the top, with the pneumococcal sequence at the bottom.
Analysis of the ORF ascribed by Berry et al. does not lead to the conclusion 
that the protein contains such a signal sequence. The presence of such a signal 
sequence in the extended protein is considered to provide a basis for the 
observation that hyaluronate lyase activity is high in the supernatant fraction of the 
protein encoded by the hyl allele in strain ID 922, with two stop codons occurring 
prior to the region encoding the cell wall anchor motif.
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This is also likely to account for the supernatant activity noted by Berry et al. 
although not by the LytA dependent mechanism, which they propose (Berry et al., 
1994).
3.6.7 -  Exploration of regions 5' to the hyaluronate lyase promoter
Genome sequencing efforts by another group have indicated that the 
pneumococcal hyl locus lies 3’ to the pneumococcal glutathione peroxidase gene 
(gpx) (unpublished - anonymous communication).
Analysis of the WIT database shows that the gpx gene lies at the 3’ end of 
contig 4154, with its ORF on the minus strand with respect to the majority of the 
genes on that contig. This arrangement is depicted in figure 3.6.11.
A
B
0 kb >  13 kb
Figure 3.6.11 -  Structure of contig 4154 and the proposed localisation of this 
contig with respect to contig 4167, bearing the hyl gene. A: Genes on contig 
4154; 1 = Hypothetical cytosolic protein, 2 = 6-phospho-P-glucosidase, 3 = PTS -  
cellobiose specific IIB component, 4 = putative cel operon regulator, 5 = PTS 
cellobiose specific IIA components = PTS cellobiose specific IIC component, 7 = 
a-glucosidase, 8 = glutathione peroxidase. B: Proposed localisation and orientation 
of contigs 4167 and 4154 with respect to one another.
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PCR primers were designed to read out from gpx in the 3’ to 5’ direction with 
respect to the open reading frame of the gene, and were used in conjunction with 
hyl specific primers, reading outwards with respect to the hyaluronate lyase ORF 
(note that the ORF’s of the two genes mentioned lie on the + and -  strands with 
respect to one another). The experiment was conducted with 11 strains of different 
hyaluronate lyase phenotypes (see chapter 3.2). The results of this PCR experiment 
are shown in figure 3.6.12.
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Ups5’.out
i gpx hyl
gpx.out
68 bp ? bp 416 bp
B 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 3.6.12 - Testing the hypothesis that gpx lies 5’ to hyl in the opposite 
orientation. A: The proposed location of the genes, the primers used and 
information known about the relative distances involved in bp. The unbroken line 
between the OFR’s (indicated by boxes) represents the known upstream sequence, 
described in section 3.6.5. The dashed line represents the putative, unknown 
sequence. B : Results of PCR using the gpx.out and ups5’.out primer pair. Lanes; 1 
- Kb ladder, 2 -  strain ID’s 213, 3 - 318, 4 - 39, 5 - 31, 6 - 91, 7 - 87, 8 - 324, 9 - 
329, 10 - 315, 11 - 30, 12 - 205, 13 - no DNA control, 14 - Kb ladder.
As can be seen, a product has been amplified from all strains tested, confirming 
the proposed location of the two genes with respect to one another. Size estimation 
from the ladder indicates that the product is approximately 700 bp in length. Given 
the information known about the primer binding sites this would mean that the 
unknown intervening sequence is approximately 200 bp in length. To confirm this, 
some of the products were selected for direct sequencing using the ups5'.out and 
gpx.out primers. The results of this experiment, shown in figure 3.6.13 below,
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confirm that contig 4154 does indeed lie 5' to contig 4167 with respect to the hyl 
ORF.
5' - CGTGGGATAAACTGATTGCAAGGGAAATCCAATATTTCGAAGCCCTGATCTTGTAACGT 
TCATAGAGTTCTTGAAGTCCCTGGTACTGGGGCGTTAAACCACATCCAGTAGCAGTGTT 
GACAATCAAGAGAACTTTGCCACGATAGCTATCCAAGGGAGTTGCTTGGTTGTTTTGGT 
TCAAAACGGAAAAATCATAAAGTGAAGTCATGAG£G££TCTTTTCTTTTTCTACATTGT 
AACAGTTTTTACTTTTTTCGTCGAGTCGGATGGAAGATATTGTTGAAGAATAAGCCTTC 
AATATGATAGAAACCGTTTACAAATAACTTTAAAAATGGTATGATTTAATTAAACCGGT 
TTACTTAGTTGCTCTAAATCTCTAATTTGAGATTTAGTTCCTATTGATTTTACAATATG 
TTTATTGGAGTGTATACATQCAAACAAAAACAAAGAAGCTCATTGTGAGTTTGTCTTCA 
CTTGTTTTATCAGGATTTTTATTAAACCATTATATGACAATTGGAGCGGAAGAAACGAC 
TACGAATACCATTCAGCAAAGCCAGAAGGAAGTTCAGTATCAGCAAAGGG .  3 '
Figure 3.6.13 -  Sequence reading into contig 4154 from upstream elements of 
hyaluronate lyase. Red sequence indicates the 5' end of contig 4154. Blue 
sequence indicates hyl upstream sequence data obtained as described in the 
preceding sections. Key restriction sites used in iPCR experiments are underlined 
with the proposed hyl start codon in bold.
The sequence data above show that we gain an additional 179 bp, in close 
agreement with the predicted size of the intervening region from the experiment 
outlined in figure 3.6.12. Analysis of this sequence does not reveal any further 
promoter like elements with respect to the hyl ORF. However, viewed in the 
opposite orientation, it seems as if the gpx gene had suffered the same fate as the 
hyl gene, in that the available sequence data proved to be truncated at the 5' end. 
Extension of this sequence yields further codons encoding amino acids, leading to a 
proposed promoter region. It is thought that this extension of the gpx sequence is 
valid on the basis of similarity of the pneumococcal glutathione peroxidase protein 
with homologues from S. pyogenes and B. suhtilis. These points are illustrated in 
figures 3.6.14 and 3.6.15.
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TTA TTCTTCA A CA A TA TC TTCCA TCCG A C|^^J^A A A A A G TA A A
------- +-------------- +--------------+---------------+-------------- +
AATAAGAAGTTGTTATAGAAGGTAGGCTGAGCTGCTTTTTTCATTT
AACTG'^HB3TAGAAAAAGAAAAGAGGCCCTCATaACTTCACTTTATGATTTTTCCG
1 ----------- +------------ +------------ +------------ +------------ +------------ +
TTGACAATGTTACATCTTTTTCTTTTCTCCGGGAGTACTGAAGTGAAATACTAAAAAGGC
L L Q C R K R K E A L  — I  H H R
TTTTGAACCAAAACAACCAAGCAACTCCCTTGGATAGCTATCGTGGCAAAGTTCTCTTGA
6 1 ----------------- + ------------------+------------------ +------------------+------------------ +------------------ +
AAAACTTGGTTTTGTTGGTTCGTTGAGGGAACCTATCGATAGCACCGTTTCAAGAGAACT
TTGTCAACACTGCTACTGGATGTGGTTTAACGCCCCAGTACCAGGGACTTCAAGAACTCT
1 21------------+------------ ♦------------ +------------ +------------ ♦------------ +
AACAGTTGTGACGATGACCTACACCAAATTGCGGGGTCATGGTCCCTGAAGTTCTTGAGA
ATGAACGCTATCAAGATCAGGGCTTTGAAATATTGGATTTCCCTTGCAATCAGTTTATGG
1 8 1 ----------------- + ------------------ + ------------------+------------------+------------------ +------------------ +
TAC TTGCGATAGTTC TAGTCC C GAAAC TT T ATAAC C T  AAAGGG AAC GTT AGTC AAATAC C
B R Y Q D Q G P  E I  WmummmMmmmm
GACAAGCACCCGGCAGCGCAGAGGAAATCAACGCCTTCTGTAGCCTACATTTTCAAACCA
2 4 1 ----------------- ♦ ------------------+ ------------------+------------------+------------------ +------------------ +
CTGTTCGTGGGCCGTCGCGTCTCCTTTAGTTGCGGAAGACATCGGATGTAAAAGTTTGGT
CCTTCCCACGTTTTGCCAAGATTAAGGTCAACGGTAAGGAAGCAGACCCTCTCTATGTCT
3 0 1 ----------------- + ------------------+------------------ +------------------+-------------------+------------------ +
GGAAGGGTGCAAAACGGTTCTAATTCCAGTTGCCATTCCTTCGTCTGGGAGAGATACAGA
GGTTACAAGACCAGAAATCCGGCCCACTAGGAAAACGAGTCGAATGGAATTTCGCTAAGT
3 6 1 --------- --------+ ------------------ +------------------ +------------------+-------------------+--------------— *
CCAATGTTCTGGTCTTTAGGCCGGGTGATCCTTTTGCTCAGCTTACCTTAAAGCGATTCA
TTCTCATCGGTCGAGATGGGCAAGTCTTTGAACGCTTTTCTTCAAAAACAGACCCAAAAC
4 2 1 ----------------- + ------------------ + ------------------+------------------+------------------ +------------------ +
AAGAGTAGCCAGCTCTACCCGTTCAGAAACTTGCGAAAAGAAGTTTTTGTCTGGGTTTTG
AAATTGAAGAGGCGATACAAACTCTACTATAA
4 8 1 ----------------- + ------------------ + ------------------+—  512
TTTAACTTCTCCGCTATGTTTGAGATGATATT
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Figure 3.6.14 -  Translation of the entire region encompassing the 
pneumococcal gpx O R F . |  -35 and -10 control regions, □  Shine-Dalgamo 
sequence, |  amino acid sequence described on contig 4154, □  additional amino 
acids obtained from sequence data presented here.
Figure 3.6.15 (below) shows the alignment of this extended pneumococcal Gpx 
protein with those of other organisms.
sp n
sp y
b s b
l a c
sp n
sp y
b s b
l a c
sp n
sp y
b s b
l a c
1 5 1  1 6 1
Figure 3.6.15 -  Alignment of the pneumococcal glutathioine peroxidase amino 
acid sequence with those of other bacteria. Only areas of amino acid identity are 
highlighted. The additional pneumococcal protein amino acids are undelined and in 
bold typeface, spn = S. pneumoniae, spy = S. pyogenes, bsb = B. subtilis, lac = L  
¡actis.
As can be seen, the additional pneumococcal sequence agrees closely with one 
or more of the related protein sequences. This strongly suggests that the proposed 
extension of the gpx gene is correct.
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In conclusion, it seems that it has been possible to describe the 5’ termini and 
promoter elements of the hyl and gpx genes, and evidence has shown that the 
contigs 4154 and 4167 are located next to one another in the pneumococcal 
genome.
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4.1. -  Variation at the locus encoding the pneumococcal hyaluronate lyase, hyl
Chapter 3, section 3.1 describes the analysis of genetic variation at the hyl locus 
by HRRA. PCR amplification of a 2709 bp fragment of this gene was successful 
from 115/122 (94.2%) strains tested. Those strains that were PCR negative were 
screened by Southern analysis, confirming the presence of the gene in these strains.
Berry et al. reported that hyl is present in the pneumococcal genome as a single 
copy (Berry et al., 1994). The Southern analysis performed here confirms this 
observation using a larger number of strains from diverse geographical locations 
(Spain, UK, Kenya) and different disease states (carried, septicaemia, pneumonia) 
over a time period ranging from 1988/89 until 1995.
The HRRA studies of hyl revealed that divergence at this locus was not notably 
higher than that of the housekeeping loci hexA and recP. Low nucleotide divergence 
was also observed with the pneumococcal lytA gene, although this example was 
complicated by evidence of recombination with loci encoding bacteriophage 
associated autolysins (Whatmore and Dowson, 1999). Direct sequence analysis of 
selected hyl loci revealed drawbacks associated with the HRRA technique. The 
prediction of nucleotide divergence estimated by the algorithm of Nei and Li is in 
some cases inaccurate, however comparisons between the loci studied are thought to 
be valid since they are likely to undergo variation in the same manner.
So, hyl, unlike other pneumococcal loci that are clearly under strong selective 
pressure (e.g.; the PBP’s) is not highly variable. This is an interesting observation; if 
the protein is cell associated (as the C-terminal cell wall anchor implies), low 
variation may indicate that the protein is not highly antigenic.
Paton et al. have reported that they were unable to demonstrate protection in a 
murine intra-peritoneal immunisation/challenge model, suggesting low antigenicity, 
although this was perhaps not the model of choice, since hyaluronate lyase may not 
be a virulence factor during intra-peritoneal challenge (Paton et al., 1997). Intra­
nasal challenge data has not been reported.
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4.2 -  Direct sequence analysis of selected alleles
Analysis of the translation products of the alleles sequenced show that non- 
synonymous alterations to the published sequence seem to be preferentially located 
in the a-domain of the molecule. There are two possible reasons for this, which are 
not mutually exclusive. The first is that variation of components of the P-domain is 
not tolerated due to steric restrictions on the topology of this domain. The second is 
that the a-domain, extending further into the extracellular environment, is subject to 
any antigenic recognition that may exist.
For a robust interpretation of the observed amino acid changes in terms of 
antigenic variation, a detailed map of the structure reported by Li et al. would be 
required in order to localise the changes observed to the respective structural 
elements. One tempting observation has been made on the basis of the structural 
information available in the Li paper. It is possible to determine the location of one 
of the more exposed loops (txL2) at the extremity of the a-domain to the region of 
amino acids 225-235 of the sequence of Berry et al. In this region there are 3 
different amino acid alterations seen, which affect up to 7/9 of the alleles sequenced. 
If antigenic selection were driving the limited amount of variation seen, it might be 
expected to manifest itself in clusters of alterations in surface exposed structures 
such as this.
Transformation mediated homologous recombination is a well-documented 
mechanism for genetic variation within Streptococcus pneumoniae. Maximum chi- 
squared analysis of the distribution of nucleotide alterations across the hyl alleles 
studied indicates that although the overall level of divergence between the alleles is 
low, there is statistically significant evidence for what appears to be recombination 
between hyl alleles. Molecular rearrangements of this nature would account for the 
higher number of hyl alleles found by HRRA compared to the housekeeping loci 
studied.
This does not exclude the possibility of inter-specific recombination, however a 
PCR based screen for hyl homologues in representatives of atypical pneumococci
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and related oral streptococci did not reveal any potential donors for divergent 
regions.
Taken together these findings indicate that recombination is restricted to the hyl 
alleles found in pneumococci. The inability to find hyl homologues in S. mitis, S. 
oralis or atypical pneumococci (which have previously been identified as ply and 
lytA positive (Whatmore et al., 2000)) is another example of the restriction of this 
gene to the ‘typical’ members of this group. Although other streptococci are 
phenotypically Hyl+, their hyl loci must be sufficiently divergent from the 
pneumococcal locus to render them negative in PCR and Southern based screens 
using probes based on the pneumococcal locus (this thesis and S. Widdison -  
unpublished data). Given the level of genetic promiscuity of the streptococci, it is 
perhaps surprising to find such restriction of this locus to species type, even to the 
extent of its absence from atypical isolates bearing other pneumococcal 
characteristics. Southern analysis is in progress within the group to address this 
question.
These observations have possible implications for the design of next generation 
conjugate vaccines. As mentioned in section 1.5.2, it is believed that conjugation of 
pneumococcal capsular polysaccharides to protein carriers will generate improved, 
thymus-dependent immune responses in key target populations.
The findings of this study suggest that hyaluronate lyase is a potential candidate 
for inclusion in such vaccines. It is a protein that appears to undergo limited variation 
at the amino acid level (notably in the P-domain).
4.3 -  Phenotypic analysis of hyaluronate lyase production
The publication of Kostoyukova et al. implied that hyaluronate lyase production 
was greater from pneumococci isolated from the CSF of meningitis patients than 
from carried isolates (Kostoyukova et al., 1995). The authors did not describe efforts 
to exclude large numbers of clonally related isolates from their study, or conduct a 
rigorous statistical interpretation of their results. The investigation was emulated 
using pneumococci isolated from a wider range of disease states, and which were
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varied on the basis of as many factors as possible to avoid the inclusion of multiple 
clonal isolates.
For statistical robustness, two independent assay systems were chosen on the 
basis that if one proved to be unreliable, then the other could serve as a backup. The 
assays approached the activity of hyaluronate lyase by measuring both the 
degradation of the HA substrate and the accumulation of reaction products.
The results of these assays (conducted on 185 strains) were compared using the 
model II anova technique, where isolates were grouped by their site of isolation. 
Pairwise post-hoc tests were performed to identify the source of variance identified 
in the Anova procedure. These tests showed that in some cases the mean titres of the 
isolates taken from the lower respiratory tract were lower than those of other groups 
of isolates. There was no evidence to support the findings of Kostoyukova et al. The 
variance from the means was found to be high within individual groups.
This heterogeneity reflects the findings of Reinholdt and Kilian, who examined 
the IgA protease phenotypes of a number of pneumococcal isolates and found 
considerable variability in activity (Reinholdt and Kilian, 1997).
There is the obvious notion that comparison of phenotype between strains studied 
in vivo and in vitro is complicated by the acceptance that pathogens regulate 
phenotype in response to their environment (as with competence induction, for 
example). It was felt that exposure of pneumococci to the hyaluronate lyase substrate 
might modulate the production of the enzyme.
In order to address this, all isolates were incubated in defined media containing 
HA prior to phenotypic analysis. It was found that in the majority of cases (65%) 
activity was higher after this treatment, that is, pneumococci are apparently inducible 
for hyaluronate lyase. This effect was shown to be statistically significant by the 
paired T-test.
The conclusion from this stage of the work described here is that care must be 
taken when ascribing phenotypic traits in vitro to behaviour in vivo. These 
experiments have endeavoured to obtain the ‘true’ hyaluronate lyase phenotype in 
the laboratory by induction of hyaluronate lyase by exposure of pneumococci to HA.
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4.4 -  Hyaluronate lyase mutants
The first hyl mutant encountered in this study was strain 619 (ID 53), found in 
the HRRA study. This strain has a 400bp deletion in the hyl gene, and was shown to 
be phenotypically Hyl . This strain was isolated from a Spanish patient suffering 
vaginal sepsis in 1987. The unusual site of isolation may imply trophic restriction 
placed upon this strain by its inability to degrade hyaluronic acid.
Since the genetic background of the Hyl mutant strain 619 was unknown, a 
defined Hyl' strain was constructed by interposon mutagenesis.
This mutant was also unable to degrade HA, thus confirming that there is no 
functional redundancy with respect to hyaluronate degradation by the 
pneumococcus.
No other mutants were found which were pnenotypically Hyf, although 2 
mutants that were Hyl+ were identified during the sequence analysis.
The first was from a Kenyan throat isolate (strain 86012 - ID 307), harbouring 
hyl allele 22. This allele contains a very unusual pair of inserted sequences that 
together restore the reading frame of the gene (see chapter 3, section 3.1.6). This 
strain was shown to be phenotypically Hyl+.
Either insertion alone would result in the introduction of variant amino acids, 
followed by a stop codon at a position N-terminal to that expected in the wild type.
Analysis of allele 2 also reveals a truncation N-terminal to either of those 
introduced by either of the insertion events found in allele 22.
This mutant was identified from the carried UK strain 12B-13E (ID 922). This 
allele contains two stop codons 3’ to the region encoding the cell wall anchor motif. 
Translation from this ORF results in the production of an enzyme lacking the C- 
terminal region containing the LPXTG cell wall anchor motif.
This has interesting implications for modulating the activity of the enzyme, 
especially in the light that the protein possesses an N-terminal signal sequence (see 
chapter 3, section 3.6 and this chapter, section 4.7).
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Hyaluronate lyase assays using this strain showed negligible activity associated 
with the cell-associated fraction, but high supernatant activity, indicating that the 
enzyme is indeed exported directly into the extracellular environment.
This representative of allele 2 (the most common allele found) was identified 
from a successful serotype 3 clone (designated clone C) described by Muller-Graf et 
al. (Muller-Graf et al., 1999). This allele was compared with other strains (of the 
same HRRA hyl genotype) identified as bearing from within the same clonal group, 
and strains which are unrelated to this clone. It was found that the truncation was 
restricted to the clonally related strains, with the clonally unrelated strains bearing 
the wild-type sequence at this point.
The interpretation of these findings is that the mutation has occurred at some 
point in the evolutionary history of the progenitor strain of clone C, which has been 
amplified with the clonal expansion of this group of isolates. Clone C is a large 
national clone whose expansion indicates that the loss of the hyaluronate lyase cell 
wall anchor is not detrimental to the success of the clone.
Returning to the insertions found in allele 22. It is not possible to say whether the 
insertions were introduced to this allele during the same, or independent mutation 
events. It is interesting to speculate that there has been a selective pressure to restore 
the cell-wall associated phenotype, hence the second duplication which restores the 
open reading frame required for the translation of a functional cell-wall anchor. Such 
restoration of phenotype by a duplication event has also been seen in the locus 
encoding photosystem II of Sytiechocystis, under nutrient limiting conditions (Kless 
and Vermass, 1995). Since allele 2 shows that hyaluronate lyase activity is not 
abolished by N-terminal truncation, we must assume that maintenance of hyaluronate 
lyase at the cell surface is a conditional, rather than absolute requirement.
4.5 -  Pneumococcal growth on hyaluronate
The nature of the host/pathogen relationship is, by necessity, exquisitely 
complex. While hyaluronate lyase activity is considered to be involved in penetration
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of the host tissues during invasive disease, there is also evidence that the enzyme 
contributes to pneumococcal persistence by utilising host hyaluronic acid as a carbon 
source (Chapter 3, section 3.4).
Various Gram negative organisms, including Staphylococcus epidermidis, 
Streptococcus pyogenes and S. intermedius have the ability to utilise hyaluronic acid 
as a sole carbon source (Costagliola et a i, 1996, Homer et al., 1997). The approach 
described in chapter 3, section 3.4 was successful in showing that HA was able to 
support growth as a sole carbon source with various strains of S. pneumoniae. 
Experiments with the isogenic hyl mutant and its parental strain indicated that this 
mode of growth was dependent on hyaluronate lyase.
In the case of S. intermedius, this mode of growth is catabolite repressed by 
glucose. This was not thought to operate in the pneumococcal system, as induction of 
hyaluronate lyase was unaffected using induction media containing glucose (data not 
shown), however it cannot be ruled out that other enzymes in the HA utilisation 
pathway are affected by the presence of glucose.
The reaction product of hyaluronate lyase is an unsaturated disaccharide that is 
likely to accumulate in the extracellular environment, given the proposed location of 
the enzyme on the cell surface. Events downstream of hyaluronate lyase function are 
proposed to include an exoglycosidase activity and a permease activity, the order of 
these is unknown in the pneumococcal system, but is speculated upon below.
Studies using other metabolites showed that exogenous GlcNAc, but not 
glucuronic acid supported growth with these strains. Growth on N- 
acetylglucosamine (GlcNAc) is proposed to proceed by the interconversions outlined 
in figure 4.1. Note; The following references to the pneumococcal genome sequence 
were made using the genome resource at http://www.wit.incs.anl.gov.
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Figure 4.1 -  N-acetylglucosamine catabolic pathway. Pneumococci are 
homofermentative, able to degrade glucose via the fructose intermediate. For brevity, 
only the steps leading to fructose-6-phosphate are shown in detail. Reactions 
downstream from this point are core metabolic activities, indicated by dashed lines. 
See text for details regarding uptake and proposed metabolic pathways.
The conversion of N-acetylglucosamine to fructose-6-phosphate involves 
internalisation, phosphorylation, deamination and deacetylation before an isomeric 
conversion step. This metabolic route was once perceived to be an exclusively Gram­
negative trait, however similar conversions are known to occur in Gram-positive 
organisms, see below. In E.coli the interconversions outlined in figure 4.1 are carried
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out by enzymes encoded by the nag operon. The first two steps are carried out by a 
multipass transmembrane protein of the sugar phosphotransferase class, encoded by 
nagE (Peri and Watgood, 1988). This enzyme was first described in E.coli and 
numerous homologues exist in S. pneumoniae (see http://www.wit.mcs.anl.gov)
A pneumococcal homologue of the glucose-6-phosphate isomerase (encoded by 
nagC in E.coli) has also been found.
While a homologue for the deacetylase encoding gene has not been found in S. 
pneumoniae. The available pneumococcal genome sequence is incomplete at the 
time of writing, so it is possible that the gene exists in a region of the pneumococcal 
chromosome that is not yet available in the public domain. Given the pneumococcal 
growth phenotype, this seems plausible.
Homer et al., have shown that both Streptococcus mutans and S. oralis utilise 
GlcNAc in the manner outlined above (Homer et al., 1993, Homer et al., 1996), 
leading to the suggestion that pneumococci share this metabolic trait.
A different hypothesis is that the conversion of GlcNAc to pyruvate proceeds via 
an alternative pathway, with glucosaminate as an intermediate (Michal, 1993).
This is not thought to be the case for two reasons; there is no homologue of the 
key enzyme, aminodeoxygluconate dehydratase in the available pneumococcal 
genome databank. Also, the production of hydrogen peroxide during the conversion 
of D-glucosamine to glucosaminate is unfavourable since pneumococci are catalase 
negative organisms.
Interestingly, two key enzymes in the glucosaminate pathway are found in the 
pneumococcal genome on the same contig (4167) as the hyaluronate lyase gene, 
namely 2-keto-3-deoxygluconokinase and 2-keto-3-deoxygluconate aldolase. The 
organisation of genes on contig 4167 is illustrated in figure 4.2.
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ORF assignments: 1 -  Hyaluronate lyase
2 - Transposase (putative assignment)
3 - 2-keto-3-deoxyphosphogluconate aldolase
4 - 2-keto-3-deoxy-D-glucokinase
5 -  Galactose-6-phosphate isomerase (LACB subunit)
6 -  Gluconate-5-dehydrogenase
Figure 4.2 -  ORF organisation of contig 4167.
The enzymes encoded by ORF’s 3 and 4 are required for uronic acid catabolism 
via the Entner-Doudoroff pathway. This is suggestive of a role in the utilisation of 
glucuronic acid.
Although the addition of exogenous GlcUA is unable to support growth, if the 
cell is able to transport the disaccharide product of hyaluronate lyase, these 
intracellular enzymes may enable the utilisation of both saccharide moieties of HA. 
The Entner-Doudoroff pathway is depicted in figure 4.3.
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Figure 4.3 -  Conversion of glucuronic acid to glyceraldehyde-3-phosphate and 
pyrvate via the Entner-Doudoroff pathway. Genes required for growth on 
glucuronic acid via the Entner-Doudoroff pathway have been reported in various 
organisms including E. coli, B. subtilis, H. influenzae and P. aeruginosa.
Of the five enzymatic stages in the pathway outlined in figure 4.3, two are 
notably absent from the currently available genome sequence data. These are 
gluconate isomerase and mannonate dehydratase. However, the pneumococcal 
genome does contain a homologue to the E. coli fructuronate reductase.
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The presence of the N-acetylglucosamine transmembrane transporter protein 
indicates that the pneumococcus possesses the necessary apparatus to take up this 
metabolite under the appropriate conditions. This may or may not be related to its 
mode of growth on hyaluronate however (for example, it may be required for 
pneumococcal survival in the bloodstream during bacteraemia). Cleavage of the 
hyaluronate lyase product during HA utilisation by S. intermedius is carried out by 
an intracellular enzyme (Homer et al., 1997), requiring the uptake of the disaccharide 
by the cell.
The results from Chapter 3, section 3.6 reveal that contig 4167, which contains 
hyl lies downstream of contig 4154. This contig contains loci encoding a cellobiose 
spceicfic PTS transporter (see chapter 3, section 3.6.7, figure 3.6.11).
The repeat unit of cellobiose is very similar to that of hyaluronic acid, and it is 
tempting to speculate that this transporter may actually be involved in the 
internalisation of the pneumococcal hyaluronate lyase reaction product.
The observation that HA can support growth of some pneumococcal strains 
provides compelling evidence to suggest that the status of this virulence factor 
should be broadened to encompass its contribution to persistence in the host, as well 
as its role as a spreading factor.
4.6 -  Effect of capsule on Hyl phenotype
The work described in chapter 3, section 3.5 was conducted in order to assess the 
effect of capsule loss on hyaluronate lyase phenotype. The starting hypothesis was 
that the presence of large amounts of capsular polysaccharide (as with the serotype 3 
capsule) might modulate the activity of cell associated hyaluronate lyase by 
occluding the enzyme from its substrate.
In fact the opposite effect was found. That is, the acapsular pneumococcal variant 
studied showed lower hyaluronate lyase activity than the parental strain.
Since the genetic background of this variant is unknown, and nature of the 
mutation which lead to its phenotype of this strain is undefined, it is not possible to 
infer too much from this observation.
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4.7 -  Completion of the gene encoding hyaluronate lyase and closure of two of 
the pneumococcal genome contigs
As mentioned in chapter 1, section 1.8.6, the hyl gene sequence presented by 
Berry et al. is inconclusive, and completion of the gene sequence of the related gene 
from S. agalactiae revealed the true promoter elements preceding an N-terminal 
signal sequence.
Various approaches were taken to characterise the upstream region of the 
pneumococcal gene, which resulted in the description of an excellent promoter 
candidate, expression from which results in a protein that contains a predicted N- 
terminal signal sequence.
This observation agrees well with the various findings of the preceding chapters, 
including the appearance of hyaluronate lyase in the culture supernatant of a strain 
which lacks the C terminal cell wall anchor and the ability of pneumococci to utilise 
exogenous HA as a sole carbon source.
The observation that hyl lies 3’ to the pneumococcal gpx gene enabled the 
linkage if two of the contigs of the unfinished pneumococcal genome at 
http://www.wit.mcs.anl.gov. This placed the locus encoding hyaluronate lyase in the 
context of several genes that may be involved in the utilisation of hyaluronate 
derived metabolites, described above. Also, it supports the proposed description of 
the hyl promoter on the basis of the lack of any other regions resembling promoter 
elements when reading into contig 4154.
This work also enabled the completion of the gpx open reading frame, as 
determined on the basis o f likely promoter elements and homology of the proposed 
translation product to homologous sequences from other bacteria.
4.8 -  Concluding remarks and ftiture directions
Work described in this thesis has shown that hyaluronate lyase undergoes 
restricted allelic polymorphism, and is a well conserved protein. This suggests that it
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is a possible candidate for trials involving the next generation of pneumococcal 
vaccines.
The broad range of phenotypes seen with a large group of isolates throws the 
broad association of hyaluronate lyase phenotype with disease-state into question, 
and the observation of induction of hyaluronate lyase stresses the need to observe 
such phenotypes under the appropriate experimental conditions.
Growth of pneumococci on HA indicates that the metabolic capability of the 
organism to persist on this substrate may form one pneumococcal survival strategy. 
The proposed role of the cellobiose-like transport system might be investigated 
following an interposon mutagenesis protocol of the type used in the generation of 
the Hyl strain described in Chapter 3, section 3.3.
Completion of the sequence encoding the protein reveals that it is likely to be 
transported to the cell surface as a result of a cleavable N-terminal signal sequence. 
The presence of a C-terminal anchor motif indicates that it remains associated with 
the cell for at least part of the time. In other streptococci (S. intermedius, for 
example) hyaluronate lyase activity is high in the cell supernatant fraction (Homer et 
al., 1994). As such, the question of subsequent cleavage at the C-terminal portion 
and release into the extracellular milieu represents an interesting line of enquiry.
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